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ABSTRACT  
The diagnosis of coeliac disease is made from a small-bowel mucosal biopsy 
specimen if villous atrophy with crypt hyperplasia is found on a gluten-containing 
diet and there is a response to a gluten-free diet. Positivity for serum coeliac 
antibodies supports the diagnosis. These autoantibodies are targeted to 
transglutaminase-2 (TG2) and produced in the small intestine. In coeliac disease, 
deposited autoantibodies have been found in the small-bowel mucosa. The 
diagnostics of coeliac disease is often problematic in that the quality of a small-
bowel biopsy sample is sometimes compromised and villous atrophy is occasionally 
patchy. Further villous atrophy can also appear in other diseases such as giardiasis, 
viral infections, food allergies and autoimmune enteropathy. In a minority of coeliac 
disease patients, small-intestinal damage does not recover on a gluten-free diet. 
Serum coeliac autoantibodies usually give no additional support in the diagnosis of 
non-responsive coeliac disease, as most non-responsive patients are serum 
autoantibody-negative. Gluten-induced small-bowel mucosal villous atrophy is the 
end stage of the disease and develops gradually from lymphocytic infiltration of the 
epithelium to crypt hyperplasia and further to villous atrophy. Small-bowel mucosal 
abnormalities caused by early-stage coeliac disease are unspecific and diagnosis 
cannot rely on them. The present aim was to assess the value of determinating 
small-bowel mucosal TG2-specific IgA autoantibody deposits in coeliac disease 
diagnostics and follow-up, especially in problematic cases. The occurrence of 
mucosal autoantibody deposits was compared to villous atrophy (I-IV), CD3+ and 
γδ+ intraepithelial lymphocyte (IEL) densities (I, III, IV) and serum autoantibodies 
(I-IV).  
In studies I-IV, a total of 261 patients had overt and 48 early-stage coeliac 
disease. In addition, 177 coeliac patients were examined after different periods on a 
gluten-free diet, and 27 patients evincing no histological response to the diet. 
Coeliac patients were compared to 86 non-coeliac controls. Small-bowel mucosal 
autoantibody deposits were found in all and serum autoantibodies in 91% of overt 
coeliac patients. Elevated densities of CD3+ and γδ+ IELs were present in 91% and 
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96% of overt coeliac patients, respectively (I). On a gluten-free diet, after recovery 
from villous atrophy, the densities of CD3+ IELs and the intensity of autoantibody 
deposits decreased, eventually also the density of γδ+ IELs, but remained constantly 
higher than in non-coeliac controls. None of the controls had serum autoantibodies, 
but 16% had weak autoantibody deposits in the small intestine. 
 In assessment of gluten dependence (II) ten patients underwent a gluten 
challenge with wheat, barley, rye and oats. Gluten caused villous atrophy and the 
appearance of small-intestinal autoantibody deposits and serum autoantibodies, in 
contrast to oats, which had no effect on any of the markers.  
Of the 27 non-responsive coeliac patients 21 were on a strict gluten-free diet 
(III). Of these, 95% evinced small-bowel mucosal autoantibody deposits, although 
serum autoantibodies were found in only 24%. Increased densities of CD3+ and γδ+ 
IELs were found in 76% and 71%, respectively. None of the ten controls with other 
enteropathies had coeliac disease autoantibodies in the serum or deposited in the 
small-bowel mucosa. Five of the controls had villous atrophy and one third 
increased densities of IELs.  
In early-stage coeliac disease (IV) small-bowel mucosal IgA deposit was found 
in 96%, serum autoantibodies in 73% and increased densities of CD3+ IELs in 62% 
and γδ+ IELs in 71%. In addition, twenty symptomatic early-stage patients with 
small-bowel mucosal TG2-specific IgA deposits started a gluten-free diet before 
villous atrophy developed. On a gluten-free diet the autoantibody deposits 
disappeared and symptoms were alleviated. 
The findings showed that determination of small-bowel mucosal TG2-specific 
IgA deposits is a sensitive tool in finding overt and early-stage coeliac disease. 
Morphological analysis or IEL densities do not suffice to identify early-stage 
disease or distinguish different causes of villous atrophy, whereas small-bowel 
mucosal autoantibodies are accurate in detecting coeliac disease even in 
seronegative patients. These results together give an opportunity to ascertain or 
exclude coeliac disease in patients with small-bowel mucosal lesions compatible 
with coeliac disease but without serum autoantibodies.  
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TIIVISTELMÄ 
Keliakian diagnoosiin vaaditaan ohutsuolen limakalvon villusatrofia ja 
kryptahyperplasia gluteenipitoisen ruokavalion aikana sekä vaste gluteenittomaan 
ruokavaliohoitoon. Positiiviset seerumin keliakiavasta-aineet tukevat diagnoosia. 
Nämä keliakia-autovasta-aineet kohdistuvat transglutaminaasi-2:ta (TG2) vastaan ja 
tuotetaan ohutsuolessa. Keliakiassa autovasta-aine kertymiä on löydetty ohutsuolen 
limakalvolta. Keliakian diagnostiikka on usein ongelmallista, sillä ohutsuolen 
koepalojen laatu on toisinaan puutteellinen ja joskus villusatrofia on läiskittäinen. 
Villusatrofiaa voi esiintyä myös muissa sairauksissa kuten giardiaasissa, 
virusinfektioissa, ruoka-allergioissa ja autoimmuunienteropatiassa. Pienellä osalla 
keliakiapotilaista ei vastetta gluteenittomaan ruokavalioon ole. Hoitoon 
reagoimatonta keliakiaa sairastavilla seerumin keliakia vasta-aineiden 
määrittämisestä ei ole apua, koska usein heillä ei ole vasta-aineita seerumissa. 
Gluteenin aiheuttama ohutsuolen villusatrofia on taudin myöhäisvaihe, joka kehittyy 
vähitellen lymfosyyttien kertymisestä epiteelille ja edelleen villusatrofiaan. Alkavan 
keliakian aiheuttamat ohutsuolen limakalvon muutokset ovat epäspesifisiä eikä 
niiden perusteella voi tautia diagnosoida. Tämän tutkimuksen tavoitteena oli tutkia 
ohutsuolen limakalvon TG2-spesifisten autovasta-ainekertymien määrittämisen 
hyötyä keliakian diagnostiikassa ja seurannassa, erityisesti ongelmatapauksissa. 
Autovasta-ainekertymien esiintymistä verrattiin villusatrofiaan (I-IV), CD3+ ja γδ+ 
epiteelinsisäisiin lymfosyyttitiheyksiin (IEL) (I, III, IV) sekä seerumin vasta-
aineisiin (I-IV).  
Osatöissä I-IV tutkittiin 261 hoitamatonta keliakiapotilasta sekä 48 potilasta, 
joilla oli alkava keliakia. Lisäksi tutkittiin 177 potilasta gluteenittoman ruokavalion 
aikana ja 27 potilasta, joiden suolivaurio ei parantunut gluteenittomalla 
ruokavaliolla. Keliakiapotilaita verrattiin 86 verrokkiin, joilla oli vatsavaivoja, 
muttei keliakiaa. Keliakia-autovasta-ainekertymiä löydettiin ohutsuolesta kaikilta ja 
vasta-aineita seerumista 91 %:lta hoitamattomista keliakiapotilaista. Kohonneet 
CD3+ ja γδ+ IEL-tiheydet löytyivät 91 %:lta ja 96 %:lta hoitamattomista 
keliakiapotilaista (I). Gluteenittomalla ruokavaliolla villusatrofian korjaantumisen 
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jälkeen laskivat sekä CD3+ IEL-tiheys että autovasta-ainekertymien intensiteetti ja 
lopulta myös γδ+ IEL-tiheys, joka kuitenkin jäi pysyvästi korkeammaksi kuin 
verrokeilla, joilla ei ollut keliakiaa. Kenelläkään verrokeista ei ollut seerumin 
keliakiavasta-aineita, mutta 16 %:lla oli heikot autovasta-ainekertymät ohutsuolessa.  
Tutkittaessa gluteeniriippuvuutta (II) kymmenen potilasta altistettiin gluteenille 
vehnällä, ohralla, rukiilla ja kauralla. Gluteeni aiheutti villusatrofian ja vasta-
aineiden ilmaantumisen sekä seerumiin, että kertymisen ohutsuoleen päinvastoin 
kuin kaura, jolla ei ollut mitään vaikutusta käytettyihin markkereihin.  
Hoitoon reagoimattomista 27 potilaasta, 21 noudatti tarkasti gluteenitonta 
ruokavaliota (III). Näistä 21 potilaasta 95 %:lla oli ohutsuolen limakalvolla 
autovasta-ainekertymiä vaikka seerumissa autovasta-aineita oli vain 24 %:lla. 
Kohonneet CD3+ ja γδ+ IEL-tiheydet löytyivät 76 %:lta ja 71 %:lta. Kenelläkään 
kymmenestä verrokista, joilla oli muu enteropatia, ei ollut autovasta-aineita 
ohutsuolen limakalvolla eikä seerumissa. Viidellä enteropatiapotilaista oli 
villusatrofia ja kolmanneksella kohonneet IEL-tiheydet.  
Alkavassa keliakiassa (IV) autovasta-aine kertymät löydettiin 96 %:lta ja 
seerumin vasta-aineet 73 %:lta sekä kohonneet CD3+ ja γδ+ IEL-tiheydet 62 %:lta 
ja 71 %:lta. Lisäksi kaksikymmentä oireista potilasta, joilla oli alkavaan keliakia ja 
TG2-spesifiset autovasta-ainekertymät ohutsuolen limakalvolla, aloitti 
gluteenittoman ruokavalion ennen villusatrofian kehittymistä. Gluteenittomalla 
ruokavaliolla autovasta-ainekertymät ja oireet hävisivät.  
Tämä tutkimus osoittaa, että TG2-spesifisten autovasta-ainekertymien 
määrittäminen ohutsuolen limakalvolta on herkkä menetelmä keliakian sekä alkavan 
keliakian löytämisessä. Morfologinen analyysi tai IEL-tiheyksien määrittäminen ei 
löydä alkavaa keliakiaa tai kykene erottamaan villusatrofian syytä. Ohutsuolen 
keliakia-autovasta-ainekertymät sitä vastoin löytävät myös seronegatiivisen 
keliakian. Nämä tulokset mahdollistavat keliakian varmistamisen tai poissulkemisen 
potilailla joilla ohutsuolen vaurio sopii keliakiaan, mutta joilla ei ole seerumin 
vasta-aineita.  
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ABBREVIATIONS 
AGA  anti-gliadin antibody 
AIDS   acquired immunodeficiency syndrome 
APC  antigen-presenting cell 
ARA  antireticulin antibody 
CTLA-4  cytotoxic T-lymphocyte-associated- 4 
DNA  deoxyribonucleic acid 
EATL   enteropathy-associated T-cell lymphoma 
ELISA  enzyme-linked immunosorbent assay 
EmA  endomysial antibody 
HLA  human leukocyte antigen 
IEL  intraepithelial lymphocyte 
Ig  immunoglobulin 
IL  interleukin 
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MMP  matrix metalloproteinase 
NK   natural killer 
NKG2D  natural killer group 2D, receptor of MICA 
NSAID  non-steroidal anti-inflammatory drug 
PCR  polymerase chain reaction 
p-value  is the probability of obtaining a test statistic at least as extreme as 
that actually observed, assuming that the null hypothesis holds. 
TCR  T- cell receptor 
TG  transglutaminase 
Th  T-helper cell 
Vh/CrD villous height-crypt depth ratio 
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INTRODUCTION 
Classically coeliac disease has been described as a severe malabsorbtion syndrome 
with diarrhoea, steatorrhea, weight loss, growth retardation and anaemia in infancy 
caused by intolerance to dietary gluten (Gee 1888, Dicke 1950). Currently patients 
with coeliac disease belong to all age-groups and may evince only mild 
gastrointestinal symptoms (Mäki et al. 1988, Collin et al. 1997) or extra-intestinal 
symptoms such as dermatitis herpetiformis (Collin and Reunala 2003) and 
neurological problems (Luostarinen et al. 1999). Coeliac disease appears in 
genetically predisposed patients and almost all have either the HLA-DQ2 or the 
DQ8 genotype, which are also present in 30% of the healthy population (Sollid et al. 
1989, Karell et al. 2003). 
The current diagnostic criteria for coeliac disease require small-bowel villous 
atrophy with crypt hyperplasia during a gluten-containing diet and clinical or 
histological recovery on a gluten-free diet (Walker-Smith et al. 1990, Catassi et al. 
2001). A typical feature of coeliac disease is the presence of serum autoantibodies, 
which can support diagnosis of coeliac disease (Walker-Smith et al. 1990, Catassi et 
al. 2001). These autoantibodies are targeted mainly towards transglutaminase-2 
(TG2) (Dieterich et al. 1997) and are produced at the small-intestinal level (Marzari 
et al. 2001). In coeliac disease, deposited autoantibodies have been found in the 
small-intestinal mucosa (Korponay-Szabo et al. 2004). In addition, small-intestinal 
TG2-specific IgA deposits have in some cases preceded villous atrophy (Korponay-
Szabo et al. 2004, Kaukinen et al. 2005, Salmi et al. 2006a). 
Gluten-induced small-bowel mucosal villous atrophy with crypt hyperplasia is the 
end stage of the disease process and develops gradually from lymphocytic 
infiltration of the epithelium to crypt hyperplasia and further to villous atrophy 
(Marsh 1992). It has previously been noted that serum autoantibody positivity 
(Collin et al. 1993), increased densities of either intraepithelial lymphocytes (IELs) 
(Salmi et al. 2006a) or T-cell receptor γδ−bearing IELs (Mäki et al. 1991a, Iltanen et 
al. 1999c, Salmi et al. 2006a) in patients with normal villous structure can predict 
forthcoming villous atrophy and coeliac disease. However, some patients are 
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seronegative during the early stages of the disease (Salmi et al. 2006a). In addition, 
increased densities of IELs are not specific for coeliac disease, as they are also 
encountered in other conditions (Salmi et al. 2006a). Patients with early-stage 
coeliac disease may show symptoms and even develop osteoporosis without 
evidence of small-bowel mucosal villous atrophy (Kaukinen et al. 2001, Kaukinen 
et al. 2005). There is thus a need for new tools to diagnose coeliac disease before the 
development of villous atrophy.  
The treatment of coeliac disease aims to eliminate symptoms and effect a 
complete recovery of the small-bowel mucosal villi. Currently, the only treatment 
for coeliac disease is a gluten-free diet, where wheat, rye and barley are forbidden 
(Walker-Smith et al. 1990). A strict gluten-free diet, though burdensome, improves 
the quality of life (Mustalahti et al. 2002a, Wagner et al. 2008). Patients with poor 
adherence to gluten-free diet often have small-bowel mucosal lesions leading to an 
increased risk of complications (Troncone et al. 1995, Kaukinen et al. 2007b).  
A minority of coeliac patients do not respond to a gluten-free diet; the condition 
is called refractory coeliac disease (Wahab et al. 2002, Leffler et al. 2007). 
Diagnosing refractory coeliac disease is challenging in that small-bowel mucosal 
villous atrophy does not respond as it should to a gluten-free diet and villous 
atrophy is known to appear in conjunction of other diseases such as giardiasis, viral 
infections, food allergies and autoimmune enteropathy (Green and Cellier 2007). 
Moreover, serum coeliac autoantibodies usually give no additional support in the 
diagnosis of coeliac disease, as most patients with refractory disease are serum 
autoantibody-negative on a gluten-free diet (Kaukinen et al. 2007b, de Mascarel et 
al. 2008, O'Shea et al. 2008, Verbeek et al. 2008b). 
The aim of the present study was to investigate the value of determining small-
bowel mucosal TG2-specific IgA autoantibody deposits in the diagnostic work-up 
and follow-up of coeliac disease. A further the purpose was to ascertain whether 
there are advantages in determining small-bowel mucosal IgA deposits compared to 
conventional methods in the diagnosis of coeliac disease in patients who do not 
completely fulfil the current criteria (Walker-Smith et al. 1990, Catassi et al. 2001) 
i.e. these with non-responsive and early-stage coeliac disease.  
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REVIEW OF THE LITERATURE 
1. COELIAC DISEASE 
Coeliac disease is a permanent intolerance to gluten appearing in genetically 
predisposed individuals. The condition was first described by Samuel Gee (1888) as 
a disease of all ages characterized by diarrhoea, cachexia and distended abdomen. 
After the harmful effect of wheat and rye was noted (Dicke 1950), a gluten-free diet 
was adopted as treatment for coeliac disease (van de Kamer et al. 1953). The current 
diagnostics of coeliac disease are based on the finding of small-bowel mucosal 
damage as described by J.W. Paulley (1954) more than fifty years ago. At present, 
coeliac disease is a common chronic disorder and patients with the severe symptoms 
described by Gee are in many countries rarely found (Mäki and Collin 1997). 
2. CLINICAL FEATURES 
2.1 Classical coeliac disease  
Classically coeliac disease has been described as a severe malabsorbtion 
syndrome with diarrhoea, steatorrhea, weight loss, growth retardation and anaemia 
in infancy (Young and Pringle 1971). In the past decades, the symptoms of the 
condition have become milder, severe malabsorbtion being nowadays rarely seen 
(Mäki et al. 1988, Collin et al. 1997). Patients may be overweight (Dickey and 
Kearney 2006) or have only mild abdominal symptoms (Mäki et al. 1988, Collin et 
al. 1997). Isolated malabsorbtion of iron or folic acid is a common finding in coeliac 
patients but does not necessarily lead to clinical manifestation (Tikkakoski et al. 
2007). Currently, coeliac disease is found in all age-groups and its prevalence 
increases with age (Mäki et al. 2003, Lohi et al. 2007, Vilppula et al. 2009). In the 
majority of patients symptoms are alleviated and the small-bowel mucosa recovers 
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on a gluten-free diet, but a small minority develop refractory coeliac disease, where 
there is no response to a withdrawal of gluten (O'Mahony et al. 1996, Collin et al. 
2004a). 
2.2 Extra-intestinal symptoms 
The symptoms of coeliac disease are not restricted to the intestine and the 
disorder can be regarded more as a disease of the whole organ system. The most 
common extra-intestinal symptom is dermatitis herpetiformis, an itching bullous 
dermatitis, typically situated in the extensor surfaces of the skin in the knees and 
elbows (Collin and Reunala 2003).These skin lesions disappear on a gluten-free diet 
(Reunala et al. 1984). Small-intestinal mucosal subtotal villous atrophy with crypt 
hyperplasia can be found in 60% of patients with dermatitis herpetiformis and the 
remainder have milder mucosal lesions in their small bowel (Reunala et al. 1984). 
In 7% of coeliac disease patients neurological symptoms lead to the diagnosis 
(Luostarinen et al. 1999). Common neurological symptoms related to the disease are 
neuropathy, gluten ataxia (Hadjivassiliou et al. 1996), cerebellar atrophy 
(Hadjivassiliou et al. 1998), epilepsy (Gobbi et al. 1992, Peltola et al. 2009), 
migraine (Gabrielli et al. 2003) and memory impairment (Luostarinen et al. 1999). 
Patients with gluten ataxia or epilepsy related to coeliac disease may benefit from a 
gluten-free diet (Hadjivassiliou et al. 2003, Gobbi 2005). 
Hypertransaminasaemia may be encountered in one third of coeliac patients 
(Farre et al. 2002). In contrast, about 9% of patients evincing unexplained 
hypertransaminasaemia also have coeliac disease (Volta et al. 2001a). Usually liver 
disease related to coeliac disease is mild and the liver enzymes normalize on a 
gluten-free diet. Severe liver failure which recovers on a gluten-free diet has also 
been described (Volta et al. 2001a, Kaukinen et al. 2002a). 
In the mouth, e.g. dental enamel defects (Aine et al. 1990) or aphtous stomatitis 
(Ferguson et al. 1976) can be the sole markers of coeliac disease. Arthritis related to 
coeliac disease has also been described (Bourne et al. 1985). Infertility (Collin et al. 
1996), abortions and foetal growth retardation during pregnancy (Martinelli et al. 
2000) can be caused by untreated coeliac disease, but on a gluten-free diet the 
problems of pregnancy are reduced. In children and adolescents coeliac disease may 
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cause growth retardation and delayed puberty (Mäki et al. 1988). On a gluten-free 
diet, however, catch-up growth is rapid (Damen et al. 1994) and the final height of 
coeliac patients diagnosed in childhood does not differ from that of the general 
population (Weiss et al. 2008).  
Osteoporosis is a common manifestation of coeliac disease; from 21% to 35% of 
untreated and 17% to 34% of treated adult coeliac disease patients have osteoporosis 
(Kemppainen et al. 1999a, Mustalahti et al. 1999, Meyer et al. 2001, Kaukinen et al. 
2007b). In addition, over one third of all coeliac patients manifest osteopenia 
(Meyer et al. 2001). Particularly, in patients not responding to a strict gluten-free 
diet and in non-adherent patients osteoporosis is even more frequent (Valdimarsson 
et al. 1994, Kemppainen et al. 1999a, Kaukinen et al. 2007b). Among coeliac 
patients, an increased risk of fractures has been reported by Vasquez and associates 
(2000) especially before initiation of a gluten-free diet or in non-compliant patients. 
Similar findings have since been reported in several studies (Olmos et al. 2008). 
Coeliac disease patients often have calcium malabsorbtion, leading to secondary 
hyperparathyroidism in almost one third of patients (Ciacci et al. 1995, Selby et al. 
1999). Secondary hyperparathyroidism is related to loss of bone mineral density and 
additional calcium is recommended in addition to the gluten-free diet, though 
calcium absorption has been described to normalize on a gluten-free diet (Corazza et 
al. 1995b, Selby et al. 1999). Furthermore, although bone mineral density improves 
during a gluten-free diet, it does not completely normalize in all patients 
(Kemppainen et al. 1999b, Meyer et al. 2001, Kaukinen et al. 2007b). 
 
2.3 Silent coeliac disease and autoimmunity 
In some patients, despite gluten-induced small-bowel mucosal lesions, coeliac 
disease is clinically asymptomatic and is often referred to as silent coeliac disease 
(Ferguson et al. 1993). This condition is usually found by serological screening in 
coeliac disease risk groups and in the general population (Volta et al. 2001a, Fasano 
et al. 2003, Mäki et al. 2003, Tommasini et al. 2004). One risk group consists of 
coeliac disease patients' family members and first-degree relatives. Here the 
prevalence of coeliac disease varies between 2.6% and 11% in different studies 
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(Mäki et al. 1991b, Mustalahti et al. 2002b, Fasano et al. 2003, Bonamico et al. 
2006, Rubio-Tapia et al. 2008). Another risk group comprises patients with selective 
IgA deficiency, whose risk of coeliac disease has been found to be increased ten-
fold (Collin et al. 1992). Furthermore, the prevalence of coeliac disease is increased 
in several autoimmune disorders or chromosomal anomalies (Table 1). 
Table 1. The prevalence of coeliac disease (CD) found by serological screening in certain 
coeliac disease risk groups. 
Associated condition Reference Prevalence of CD (%) 
Type 1 diabetes mellitus Mäki et al. 1984a 2.3% 
 Collin et al. 1989 4.1% 
 Not et al. 2001 5.7% 
 Hansen et al. 2006 12.3% 
 Mankai et al. 2007 5.3% 
 Remes-Troche et al. 2008 5.9% 
Autoimmune thyroid disease Collin et al. 1994b 4.8% 
 Meloni et al. 2001 4.4% 
 Volta et al. 2001b 3.2% 
Addison’s disease O'Leary et al. 2002 12.2% 
 
Myhre et al. 2003 7.9% 
 
Biagi et al. 2006 5.6% 
Primary Sjögren’s syndrome Iltanen et al. 1999a 14.7% 
 Luft et al. 2003 10.0% 
 
Szodoray et al. 2004 4.5% 
Primary biliary cirrhosis Bardella et al. 1997 0% 
 
Dickey et al. 1997 7.0% 
 
Volta et al. 2002 4.0% 
Autoimmune hepatitis Volta et al. 1998 2.8% 
 
Villalta et al. 2005 6.4% 
 
Diamanti et al. 2008 12.5% 
Down’s syndrome Bonamico et al. 2001a 4.6% 
 
Carnicer et al. 2001 6.3% 
 
Agardh et al. 2002 18.8% 
 
Nisihara et al. 2005 5.6% 
Turner’s syndrome Bonamico et al. 2002 6.4% 
 
Frost et al. 2009 4.7% 
Juvenile chronic/idiopathic arthritis Lepore et al. 1996 2.5% 
 
Stagi et al. 2005 6.6% 
IgA nephropathy Collin et al. 2002 3.6% 
Autoimmune myocarditis Frustaci et al. 2002 4.4% 
Alopecia areata Corazza et al. 1995a 1.2% 
 
In addition to the increased risk of coeliac disease in autoimmune disorders, patients 
with coeliac disease have an increased risk of developing other autoimmune 
disorder. In coeliac patients, the prevalence of type 1 diabetes mellitus varies 
between 3.8 and 5.4% (Collin et al. 1994a, Ventura et al. 1999, Sategna Guidetti et 
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al. 2001) and that of thyroid autoimmune disorders between 1.2 and 14% (Collin et 
al. 1994a, Ventura et al. 1999, Sategna Guidetti et al. 2001, Hadithi et al. 2007, 
Hakanen et al. 2001). Sjögren’s syndrome is present in 3.3% of coeliac disease 
patients (Collin et al. 1994a). Other autoimmune disorders associated with coeliac 
disease include autoimmune hepatitis, alopecia areata, Addison’s disease, pernicious 
anaemia, epilepsy with calcifications of brain and psoriasis (Ventura et al. 1999, 
Sategna Guidetti et al. 2001). In paediatric patients, the duration of gluten 
consumption seems to increase the risk of developing an autoimmune disorder later 
in life (Ventura et al. 1999), whereas studies in adults have not confirmed the 
protecting effect of a gluten-free diet in patients who have consumed gluten for 
decades before starting the diet (Sategna Guidetti et al. 2001, Viljamaa et al. 2005, 
Biagi et al. 2002). However, a contradictory finding in adults supporting the results 
of Ventura and colleagues (1999) in children has been published by Cosnes and 
associates (2008). 
3. DIAGNOSTIC CRITERIA 
The current European Society of Paediatric Gastroenterology, Hepatology and 
Nutrition criteria for coeliac disease from the year 1990 require small-bowel villous 
atrophy with crypt hyperplasia during a gluten-containing diet and either alleviation 
of symptoms or recovering of the small-bowel on a gluten-free diet. Positive serum 
antibody test results will support the diagnosis (Walker-Smith et al. 1990). For 
adults, the Amsterdam criteria entail similar demands for diagnosis (Catassi et al. 
2001). 
3.1 Differential diagnostics 
Although small-intestinal mucosal villous atrophy with crypt hyperplasia is 
characteristic of coeliac disease and required for diagnosing the condition (Walker-
Smith et al. 1990, Catassi et al. 2001), it is not a pathognomic finding only for 
coeliac disease. Similar lesions have been reported in patients with giardiasis, food 
allergies, tropical sprue, autoimmune-enteropathy, collagenous sprue, tuberculosis, 
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graft versus host reactions, idiopathic AIDS enteropathy and during viral 
gastrointestinal tract infections (Marsh 1992, Green and Cellier 2007, Cello and Day 
2009). 
Gluten challenge is not mandatory in the current diagnostic criteria. Nonetheless, 
it is recommended if the diagnosis of coeliac disease is obscure or in children 
diagnosed under the age of two years. In this age group, enteropathies such as cow’s 
milk sensitive enteropathy, post-enteritis syndrome and giardiasis often occur. 
Differentiation between other enteropathies and coeliac disease may prove difficult 
(Walker-Smith et al. 1990). Serum autoantibodies help the diagnosis in the majority 
of coeliac patients, but some patients are seronegative and thus challenging in the 
diagnostic process (Salmi et al. 2006b).  
4. SMALL-BOWEL MUCOSAL BIOPSY 
4.1 Morphology of small-bowel mucosa 
The diagnosis of coeliac disease is made from a small-bowel mucosal biopsy 
sample where villous atrophy and crypt hyperplasia are seen during a gluten-
containing diet (Walker-Smith et al. 1990). The diagnosis of coeliac disease should 
be made from well-oriented high-quality specimens, but in about 10% of specimens 
the quality is not adequate for diagnosis, mainly due to poor orientation (Collin et al. 
2005). The villous atrophy with crypt hyperplasia starts proximally and may be 
patchy and thus a single biopsy may miss it (Vogelsang et al. 2001, Bonamico et al. 
2004, Hopper et al. 2008). Furthermore, as mentioned in section 3.1., small-bowel 
mucosal villous atrophy with crypt hyperplasia is not pathognomonic only to coeliac 
disease. 
Gluten-induced small-bowel mucosal villous atrophy with crypt hyperplasia 
develops gradually (Figure 1) as Marsh has described. First, lymphocytes infiltrate 
the epithelium (Marsh I), whereafter the crypts become elongated (Marsh II) and 
finally villous atrophy develops (Marsh III) (Marsh 1992). 
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Figure 1. The development of coeliac small-bowel mucosal lesion and classification 
according to Marsh (1992). 
4.2 Inflammation in small-bowel mucosa 
The small-bowel mucosal epithelial cell layer contains not only epithelial cells, 
goblet cells, Paneth cells and enteroendocrine cells but also lymphocytes and 
occasionally other inflammatory cells. The majority of the intraepithelial 
lymphocytes (IELs) carry a certain type of surface molecule, CD3, on their surface 
and the density of CD3+ IELs has been shown to correlate well with total IEL 
density (Arranz et al. 1994). CD3+ IELs express T cell receptors (TCR) consisting 
of either α and β chains (αβ TCR) or γ and δ chains (γδ TCR) (Borst et al. 1988). 
Most CD3+ IELs express αβ TCR and CD8 (cytotoxic T-cells) or CD4 (helper T-
cells), but a minority of cells express γδ TCR but neither CD8 nor CD4 (Selby et al. 
1983, Borst et al. 1988, Verkasalo et al. 1990, Arato et al. 1998). The characteristics 
of CD3+ IELs in the small-bowel mucosa in coeliac disease patients and healthy 
controls are shown in Table 2.  
Table 2. Characteristics of CD3+ intraepithelial lymphocytes according to different studies 
(Selby et al. 1983, Verkasalo et al. 1990, Arato et al. 1998, Halstensen et al. 
1989, Jenkins et al. 1986) 
 Active coeliac disease Control 
CD8+ 59-93% 82-94% 
CD4+ <10% 5-16% 
CD8-CD4- 10-33% 0.4-9% 
αβ+ 50-80% > 90% 
γδ+ 20-50% < 10% 
 
In coeliac disease the density of intraepithelial lymphocytes is increased 
(Ferguson and Murray 1971). On a gluten-free diet, the densities of IELs decrease 
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towards normal, but in many patients still remain elevated (Ferguson and Murray 
1971, Iltanen et al. 1999b, Kaukinen et al. 1999). In detecting coeliac disease, it has 
been estimated that the sensitivity and specificity of CD3+ IELs are 93% and 73%, 
respectively (Järvinen et al. 2003). Nonetheless, there are also diseases other than 
coeliac disease, e.g. milk allergy, which could cause both small-bowel mucosal 
villous atrophy and an increased density of IELs (Kuitunen et al. 1982). The density 
of TCR αβ-bearing IELs is increased in active coeliac disease, but returns to normal 
levels after adoption of a gluten-free diet (Savilahti et al. 1990, Savilahti et al. 1992, 
Kutlu et al. 1993, Kaukinen et al. 1999). The sensitivity and specificity of increased 
density of αβ+ IELs have been is 83% and 66%, respectively, in detecting coeliac 
disease (Järvinen et al. 2003). TCR γδ-bearing lymphocytes in the small-bowel 
mucosal surface epithelium are increased in coeliac disease (Savilahti et al. 1990). 
The density of γδ+ IELs remains elevated during a gluten-free diet, although it 
decreases (Iltanen et al. 1999b, Kaukinen et al. 1999, Järvinen et al. 2003). The 
sensitivity and specificity of γδ+ IELs are 93% and 88%, respectively, in detecting 
coeliac disease (Järvinen et al. 2003).  
An abnormal IEL population can be found in some refractory coeliac disease 
patients. These aberrant cells usually lack TCR and some surface molecules, being 
either CD3+CD8- or CD3-CD8-phenotype. A few patients also have CD30+ IELs in 
their small-intestinal mucosa; these aberrant lymphocytes have been associated with 
poor prognosis in refractory coeliac disease (Farstad et al. 2002, Verbeek et al. 
2008b). It has been suggested that an abnormal IEL population could be an early 
manifestation of enteropathy-associated T-cell lymphoma (EATL) (Daum et al. 
2001) and patients yielding such findings are at an increased risk of death or 
developing EATL (O'Shea et al. 2008). Refractory coeliac disease and EATL are 
discussed in sections 11.1 and 11.2, respectively. 
In the lamina propria, situated under the epithelial cell layer of the small-bowel 
mucosa, T-cells constitute 50% of lymphocytes (Arato et al. 1998). In contrast to the 
epithelium, two thirds of T-lymphocytes are CD4+ and a smaller population are 
CD8+ in the lamina propria (Selby et al. 1983, Verkasalo et al. 1990). Almost all 
CD3+ lymphocytes in the lamina propria are αβ+, whereas γδ+ IELs are rare 
(Halstensen et al. 1989). In coeliac disease, changes in lamina propria lymphocyte 
22 
 
densities are relatively small and densities are similar to those in controls (Selby et 
al. 1983, Verkasalo et al. 1990). 
In addition to T-lymphocytes, other inflammatory cells, e.g. B-lymphocytes and 
plasma cells, are present in the lamina propria (Arato et al. 1998). The number of 
immunoglobulin (Ig)- containing cells is increased in the lamina propria of the small 
intestinal mucosa and during gluten consumption a majority of cells in the lamina 
propria are plasma cells, indicating that the immune system producing antibodies is 
activated in coeliac disease (Savilahti 1972, Shiner 1973, Lancaster-Smith et al. 
1976, Lancaster-Smith et al. 1977). The number of IgM-containing cells is 
constantly increased in patients with coeliac disease, whereas the number of IgA- 
and IgG- containing cells in the lamina propria returns to the same level as in non-
coeliac subjects during a gluten-free diet (Lancaster-Smith et al. 1976). Similarly to 
the increased numbers of immunoglobulin-containing cells, extracellular 
immunoglobulin has also been found in the small-intestinal mucosal lamina propria 
during a gluten containing diet in coeliac patients (Shiner and Ballard 1972, 
Lancaster-Smith et al. 1977); this topic is reviewed more specifically in section 5.2. 
5. COELIAC DISEASE ANTIBODIES 
5.1 Serological tests 
Serum autoantibodies targeted against transglutaminase-2 (TG2), as Dieterich 
and associates (1997) have shown, are a characteristic feature of coeliac disease; in 
the diagnostics serum antibodies have a supporting role (Walker-Smith et al. 1990, 
Catassi et al. 2001). These IgA class autoantibodies can be determined in the sera by 
indirect immunofluorescense using as antigen either rodent (R1-type antireticulin, 
ARA), primate or human tissues (anti-endomysium, EmA). In IgA-deficient coeliac 
patients IgG class autoantibodies against TG2 can be measured (Korponay-Szabo et 
al. 2003a). Levels of anti-TG2 antibodies can also be measured by enzyme-linked 
immunosorbent assay (ELISA) with human or guinea pig TG2 as antigen. These 
tests are highly sensitive and specific (Table 3). However, the EmA test is more 
accurate than anti-TG2 antibody tests and false-positive anti-TG2 tests have been 
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described in conjunction with chronic liver disease or Crohn’s disease (Carroccio et 
al. 2002b). The accuracy of anti-TG2 antibody tests is better with human TG2 as 
antigen than those with guinea pig TG2 (Carroccio et al. 2002b). Regardless of the 
good sensitivity and specificity of these tests, some coeliac disease patients with 
villous atrophy and adequate response to a gluten-free diet have no autoantibodies 
against TG2 in the sera at the time of diagnosis (Salmi et al. 2006b). These 
seronegative patients are often older and have a more severe condition than 
seropositive patients (Salmi et al. 2006b). According to some studies, another defect 
of these tests is their inability to recognize partial villous atrophy (Rostami et al. 
1999, Emami et al. 2008). 
On a gluten-free diet serum autoantibodies return rapidly to normal levels after 
gluten withdrawal, regardless of mucosal condition. The sensitivity of serum 
autoantibody tests to recognize villous atrophy on a gluten-free diet has been 
reported to be as low as 26-60%, specificity 77-93% (Kaukinen et al. 2002b, Dipper 
et al. 2009, Vecsei et al. 2009).  
In addition to anti-TG2 autoantibodies, many other autoantibodies have also been 
found in coeliac disease patients’ sera. Some of these autoantibodies are associated 
with a certain extra-intestinal manifestation. For example, autoantibodies targeted to 
TG3 are found in some dermatitis herpetiformis patients (Sardy et al. 2002) and 
autoantibodies against TG6 in gluten ataxia patients (Hadjivassiliou et al. 2008). 
Gluten-dependent serum anti-actin antibodies are associated with severe small-
bowel mucosal lesion (Clemente et al. 2000). Antibodies against desmin are present 
in some coeliac disease patients, but can be found in other diseases as well (Teesalu 
et al. 2001). 
Antibodies in coeliac disease are not restricted to antibodies against self-antigens; 
antibodies against gliadin, an alcohol-soluble part of wheat gluten, are also found. In 
untreated coeliac disease elevated levels of anti-gliadin antibodies (AGA) can be 
found in both IgA and IgG class (Troncone and Ferguson 1991). The sensitivity of 
serum AGA by ELISA test varies between 31% and 95% and the specificity 
between 46% and 97% (Mäki et al. 1991b, Sulkanen et al. 1998, Mankai et al. 2005, 
Kaukinen et al. 2007a). Furthermore, elevated AGA levels have also been found in  
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Table 3. Sensitivities and specificities of serological tests in untreated coeliac disease 
EmA endomysial antibody, ARA antireticulin antibody, TG transglutaminase, - no data 
 
References 
Coeliac disease 
 patients 
  EmA ARA Anti-TG2 
Controls Age group Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity 
Mäki et al. 1984b 29 245 children - - 97% 98% - - 
Hällström 1989 50 69 mixed 94% 100% 94% 100% - - 
Mäki et al. 1991b 13 109 mixed 92% 95% 92% 95% - - 
Ferreira et al. 1992 21 160 adults 100% 99% 90% 99% - - 
Kolho and Savilahti 1997 88 114 children 94% 100% - - - - 
Dieterich et al. 1998 106 114 mixed 100% 99% - - 98% 95% 
Sulkanen et al. 1998 92 95 mixed 85% 100% 78% 100% - - 
Rostami et al. 1999 85 16 mixed 60% 100% - - - - 
Bonamico et al. 2001b 62 56 children 95% - - - 90% 100% 
Fabiani et al. 2001 25 3516 mixed - - - - 90% 96% 
Carroccio et al. 2002b 24 183 adult 100% 100% - - 100% 97% 
Burgin-Wolff et al. 2002 208 157 mixed 96% 100% - - 96% 99% 
Fabiani et al. 2004 399 432 mixed - - - - 96% 100% 
Collin et al. 2005 126 106 mixed 89% 98% - - 94% 99% 
Mankai et al. 2005 143 74 mixed - - 87-94% 100% 86-87% 96% 
Bazzigaluppi et al. 2006 143 64 children 98% 97% - - 96% 96% 
Reeves et al. 2006 26 228 mixed 62-68% 80-98% - - 90-92% 81-83% 
Kaukinen et al. 2007a 44 46 adults 80% 100% - - 89% 98% 
Emami et al. 2008 21 329 mixed - - - - 38% 98% 
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conditions other than coeliac disease, for example in food allergies and in post-
infectious sprue (Lindberg et al. 1985). Moreover, increased levels of AGAs have 
been found even in healthy subjects without coeliac-disease-type genetics (Mäki et 
al. 1991b). Hence conventional AGA testing is not recommended in the diagnostics 
of coeliac disease (Hill et al. 2005). 
In contrast, antibodies against deamidated gliadin peptides, formed in the 
deamidation of gliadin by TG2, have a sensitivity between 84% and 91% and a 
specificity between 90% and 98% in detecting coeliac disease (Kaukinen et al. 
2007a, Volta et al. 2008). Antibodies against deamidated gliadin peptides are thus 
more promising than those against whole gliadin. 
5.2 Small-bowel mucosal antibodies 
Immunoglobulin-containing cells, especially those with IgA and IgM, are 
increased in coeliac disease patients’ small-bowel mucosa (Savilahti 1972). In the 
same way, the amount of immunoglobulins, which are produced in plasma cells of 
the lamina propria, is also elevated (Perkkiö et al. 1981). In addition to higher 
amounts of immunoglobulins in coeliac patients’ small-bowel mucosa, total 
immunoglobulin secretion to the small-intestinal lumen is also elevated in coeliac 
these patients (O'Mahony et al. 1991). 
Antibodies against gliadin (O'Mahony et al. 1990), reticulin (Mawhinney and 
Love 1975) and TG2 (Wahnschaffe et al. 2001) have been found in untreated 
coeliac disease patients’ small-intestinal secretions in vivo. In contrast to serum 
AGA, the amounts of anti-gliadin antibodies secreted to the small-intestinal lumen 
do not decrease during a gluten-free diet (O'Mahony et al. 1991). Similarly to the 
secretion of autoantibodies in the small bowel in vivo, autoantibodies can be found 
in supernatants of in vitro-cultured gliadin challenged small-bowel mucosal biopsy 
samples (Picarelli et al. 1996, Carroccio et al. 2002a, Stenman et al. 2008). 
Furthermore, Marzari and colleagues (2001) were able to isolate TG2 antibodies 
from intestinal lymphocyte libraries only, but not from peripheral lymphocyte 
libraries by a phage display library technique and identified the small-intestinal 
mucosa as the production site for coeliac disease autoantibodies. 
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In the 1970s, it was observed that treated coeliac disease patients develop 
extracellular depositions of IgA after hours of gluten challenge (Shiner and Ballard 
1972). Subsequently it was shown that there are strong depositions of extracellular 
IgA in untreated coeliac disease patients’ small-bowel mucosa (Jos and Labbe 1976, 
Lancaster-Smith et al. 1976, Jos et al. 1979). These depositions of IgA are situated 
under the basement membrane of epithelial cells in the surface and crypt epithelium 
and around vessels (Jos and Labbe 1976, Lancaster-Smith et al. 1976, Jos et al. 
1979). It was also noted that IgA deposits disappear on a gluten-free diet and rapidly 
reappear after gluten reintroduction, and that even a single dose of gluten is 
sufficient to induce their reappearance in coeliac patients (Lancaster-Smith et al. 
1976, Lancaster-Smith et al. 1977). In 1980s Karpati and associates (1988) also 
found these deposits in the small intestine of patients with dermatitis herpetiformis.  
After Dietrich and colleagues (1997) had identified TG2 as the main antigen of 
coeliac disease autoantibodies, Korponay-Szabo and associates (2004) showed that 
small-bowel mucosal IgA depositions target TG2. Extracellular IgA deposits 
disappeared from coeliac patients’ small-bowel biopsy samples when TG2 binding 
to fibronectin was disrupted by chloroacetic acid. In addition, IgA which was eluted 
from tissues by chloroacetic treatment directed towards purified TG2 both in ELISA 
and in western blot (Korponay-Szabo et al. 2004). Furthermore, it has been shown 
that IgA deposits in the small-bowel of active coeliac disease patients have the 
ability to bind external TG2 added to the tissue ex vivo (Salmi et al. 2006b). 
Determination of TG2-specific IgA deposits is made from frozen sections by 
double staining, a method developed by Korponay-Szabo and associates (2004). All 
IgA is stained by the direct immunofluorescense method and co-localization of IgA 
and TG2 is detected by double-staining both IgA and TG2. In coeliac disease, linear 
bands of subepithelial deposits are present along the villous and crypt epithelium 
and around vessels, whereas in non-coeliac samples endogenous IgA is found inside 
plasma cells and epithelial cells (Korponay-Szabo et al. 2004). 
In previous studies with small numbers of patients, results have been promising 
in detecting coeliac disease by determining small-bowel mucosal TG2-specific IgA 
deposits (Korponay-Szabo et al. 2004, Kaukinen et al. 2005, Salmi et al. 2006a). 
TG2-specific IgA deposits are present in untreated coeliac patients’ small-bowel 
mucosa also in a small minority of coeliac disease patients without serum antibodies 
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(Salmi et al. 2006b). TG2-specific IgA deposits have also been found in some 
coeliac patients with normal villi before the development of villous atrophy 
(Korponay-Szabo et al. 2004, Kaukinen et al. 2005, Salmi et al. 2006a). In contrast, 
IgA autoantibody deposits have been found neither in healthy persons nor in 
patients with other intestinal diseases (Salmi et al. 2006b).  
6. EARLY-STAGE AND LATENT COELIAC 
DISEASE 
Marsh pointed out that coeliac disease develops gradually (Marsh 1992). 
However, the diagnosis of coeliac disease requires a lesion which is the end-stage of 
the disease process (Walker-Smith et al. 1990, Marsh 1992). A patient is considered 
to have latent coeliac disease when evincing normal small-intestinal mucosal villous 
morphology while consuming a gluten-containing diet, but at some other time, 
previously or subsequently, may have a flat small-intestinal mucosal lesion which 
recovers on a gluten-free diet (Ferguson et al. 1993). Latent coeliac disease was first 
described by Weinstein (1974) in two patients with dermatitis herpetiformis who on 
a gluten-containing diet had normal mucosal architecture in their small bowel, but 
who during a gluten challenge developed villous atrophy and crypt hyperplasia.  
Diagnosis of latent coeliac disease is often retrospective, when patients with 
minor abnormalities in small-bowel inflammation markers, i.e. early-stage coeliac 
disease patients, are followed up on a gluten-containing diet and subsequently 
develop small-bowel mucosal villous atrophy with crypt hyperplasia compatible 
with coeliac disease (Salmi et al. 2006a). In the literature, patients with normal 
villous morphology and some abnormality in coeliac disease-related markers are 
also called potential coeliac disease patients (Arranz et al. 1994). Some patients, 
diagnosed in childhood, have developed tolerance to gluten after some years on a 
gluten-free diet. During this tolerance they have neither symptoms nor ongoing 
small-bowel mucosal damage despite long-term gluten consumption (Shmerling and 
Franckx 1986, Matysiak-Budnik et al. 2007, Kurppa et al. 2008). Of coeliac disease 
patients diagnosed in childhood 6.6% to 20% develop tolerance to gluten, but the 
latency may be transient or the patient may even change the disease phenotype and 
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develop dermatitis herpetiformis after decades of a gluten-containing diet 
(Shmerling and Franckx 1986, Matysiak-Budnik et al. 2007, Kurppa et al. 2008). 
Latent coeliac disease has also been described in a patient with giardiasis and active 
coeliac disease, which recovered to the latent stage without a gluten-free diet when 
giardiasis was treated (Carroccio et al. 2001). 
Patients having early-stage coeliac disease or latent coeliac disease may be 
symptomatic and even develop osteoporosis before they evidence small-bowel 
mucosal villous atrophy (Kaukinen et al. 2001, Kaukinen et al. 2005). Furthermore, 
it has also been recently observed that serum coeliac autoantibody-positive patients 
without villous atrophy benefit from a gluten-free diet similarly to those with villous 
atrophy and crypt hyperplasia compatible with coeliac disease (Kurppa et al. 2009). 
Even one case of malignancy associated with coeliac disease has been described as a 
first manifestation of early-stage coeliac disease (Freeman and Chiu 1986). For 
these reasons, developing coeliac disease would preferably be found earlier and 
several studies have been conducted to establish a diagnostic tool sufficiently 
sensitive and specific. Serum autoantibody positivity without villous atrophy may 
predict the development of coeliac disease, but some patients are initially 
seronegative with intact small-intestinal villous morphology, and autoantibodies 
appear later in the serum (Collin et al. 1993, Salmi et al. 2006a). 
An increase in IELs is an early phenomenon during coeliac disease development 
(Marsh 1992), although densities of IELs may remain within normal range in early-
stage coeliac disease (Iltanen et al. 1999b). Elevated densities of CD3+ IELs 
without villous atrophy may predict forthcoming coeliac disease, but they are not 
specific for this condition (Mahadeva et al. 2002, Salmi et al. 2006a). For example, 
Helicobacter pylori infection may increase IEL densities (Memeo et al. 2005). 
According to one recent study the sensitivity and specificity of an increased density 
of CD3+ IELs in predicting developing coeliac disease have been 59% and 57%, 
respectively (Salmi et al. 2006a). Elevated densities of γδ+ IELs can be regarded as 
a marker of coeliac disease without villous atrophy as they are also found in 
dermatitis herpetiformis patients with normal morphology in the small-bowel 
mucosa (Savilahti et al. 1992). High densities of γδ+ IELs have also been described 
in the early stage of coeliac disease (Mäki et al. 1991a, Iltanen et al. 1999c, Salmi et 
al. 2006a). Nonetheless, a raised density of γδ+ IELs is not specific for coeliac 
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disease– a similar increase has been observed in patients with small-intestinal 
bacterial overgrowth (Remes-Troche et al. 2008), cow milk-sensitive enteropathy, 
post-enteritis syndrome (Spencer et al. 1991) and other autoimmune disorders 
(Iltanen et al. 1999a). Furthermore, elevated densities of γδ+ IELs have shown no 
correlation with coeliac-type HLA-DQ genetics (Iltanen et al. 1999c). The 
sensitivity and specificity of increased densities of γδ+ IELs have been 76% and 
60%, respectively, in a recent study (Salmi et al. 2006a). 
In the normal small-bowel mucosa IELs are distributed in descrendo pattern, i.e. 
there are few scattered IELs in the upper third of the villi and the density of IELs 
increases downwards. In contrast, evenly distributed IELs are also to be found in 
coeliac disease. In addition, increased numbers of villous tip IELs have been 
reported to improve the accuracy of diagnostics in coeliac disease (Goldstein and 
Underhill 2001). Analysing villous tip IELs can also be used as a marker of 
forthcoming coeliac disease, its sensitivity and specificity being 84-88% and 71-
88%, respectively, in detecting coeliac disease without villous atrophy (Järvinen et 
al. 2004). 
In a small number of patients, determining small-bowel mucosal TG2-specific 
IgA deposits has proved a promising tool in detecting early-stage coeliac disease. 
The sensitivity and specificity of determining TG2-specific IgA autoantibody 
deposits have been 93% in patients with normal small-intestinal mucosal 
morphology who have subsequently developed villous atrophy with crypt 
hyperplasia (Korponay-Szabo et al. 2004, Kaukinen et al. 2005, Salmi et al. 2006a).  
7. EPIDEMIOLOGY 
During past decades coeliac disease was thought of as a rare condition with a 
prevalence varying from 1:600 (Mylotte et al. 1973) to 1:2000 (Logan et al. 1986). 
However, after population-based screening studies with serum autoantibodies 
became available, the biopsy proven prevalence of coeliac disease has risen to 1% in 
Europe, the Indian subcontinent and North America (Korponay-Szabo et al. 1999, 
Fasano et al. 2003, Mäki et al. 2003, Tommasini et al. 2004, Demirceken et al. 2008, 
Bhattacharya et al. 2009). Areas with lower prevalences (0.5-0.1%) of coeliac 
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disease have been reported in Brazil, Tunisia, Estonia, Russian Karelia and Greece 
(Akbari et al. 2006, Ben Hariz et al. 2007, Oliveira et al. 2007, Ress et al. 2007, 
Roka et al. 2007, Kondrashova et al. 2008). A higher prevalence of 3% has been 
reported in Swedish children (Myleus et al. 2009). The highest prevalence of coeliac 
disease has been found in Saharawi, where 5.6% of children are coeliac disease 
autoantibody-positive (Catassi et al. 1999). 
It has recently been shown that the prevalence of coeliac disease in the 
population in general is increasing over time, indicating that the phenomenon is not 
due merely to better diagnostics (Lohi et al. 2007, Rubio-Tapia et al. 2009b). 
Furthermore, coeliac disease is more common in the elderly population than in the 
younger and the prevalence of coeliac disease in older patients is at present over two 
per cent in Finland (Vilppula et al. 2009). 
8. GENETICS 
The genetic background of coeliac disease is strong which means an increased risk 
of the disorder in family members of coeliac patients. Concordance is 80% between 
monozygotic twins and 20% between dizygotic twins (Greco et al. 2002, Fasano et 
al. 2003, Nistico et al. 2006). The majority of coeliac disease patients express the 
HLA DQ2 molecule, encoded by the alleles DQA1*05 and DQB1*02 either in cis 
or trans position and almost all the remainder have HLA DQ8 (DQA1*03 and 
DQB1*0302) (Sollid et al. 1989, Spurkland et al. 1997). The majority of coeliac 
patients with neither HLA DQ2 nor HLA DQ8 express half of the DQ2 molecule 
encoded by either DQA1*05 or DQB1*02 (Karell et al. 2003). Patients carrying two 
copies of DQB1*02 are at a greater risk of disease than those with only one copy, 
but the effect of the gene dosage of HLA DQ2-encoding genes on the severity of 
coeliac disease is uncertain (Vader et al. 2003b, Karinen et al. 2006, Murray et al. 
2007). The HLA type (Celiac 1 locus) typical for coeliac disease is present in about 
30% of the general population (Sollid et al. 1989). It is thus not sufficient genetic 
factor alone and many studies have been carried out to explain other genetic risk 
factors (Greco et al. 2001). 
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Several regions are associated with coeliac disease. The Celiac 2 locus (5q31-33) 
encodes many cytokines (Greco et al. 2001, Liu et al. 2002), Celiac 3 (2q23-32) 
regulators of T-lymphocyte activation, CTLA-4, CD28 and ICOS (Holopainen et al. 
1999, Holopainen et al. 2004) and Celiac 4 (19p13) unconventional myosin 9B, 
which is involved in cellular permeability control (Van Belzen et al. 2003, Monsuur 
et al. 2005). It has recently been shown that certain alleles of myosin 9B together 
with HLA-DQ2 homozygosity may be involved in developing unresponsive coeliac 
disease (Wolters et al. 2007). 
9. PATHOGENESIS 
In the pathogenesis of coeliac disease both environmental factors and genetic 
factors exert a joint influence. The role of environmental factors other than gluten is 
uncertain, but it seems that some common viral infections such as adenovirus 12 and 
rotavirus infections in a genetically susceptible population might enter into coeliac 
disease development through molecular mimicry (Kagnoff et al. 1984, Stene et al. 
2006). Also hepatitis C virus has been studied as a possible cause of an autoimmune 
process (Fine et al. 2001). The importance of infections during the mother’s 
pregnancy and at the time of weaning is reflected in the variation of coeliac disease 
incidence according to birth season (Ivarsson et al. 2003). In addition to 
predisposing factors, protective factors such as breastfeeding during gluten 
introduction are also known (Ivarsson et al. 2002). 
Gluten, gliadin from wheat and the related storage proteins hordein from barley 
and secalin from rye, is rich in proline and thus resistant to degradation of proteases 
in the gastrointestinal tract (Vader et al. 2003a, Kagnoff 2007). In coeliac disease 
patients gluten peptides increase the permeability of the small-bowel epithelium by 
affecting zonulin in tight junctions (Drago et al. 2006). In untreated coeliac disease, 
gluten peptides also cross the epithelial barrier of the small-intestinal mucosa via 
transcytosis. (Heyman and Menard 2009, Zimmer et al. 2009). However, after 
entrance to the lamina propria, gluten activates mechanisms of both the innate and 
adaptive immune systems in coeliac disease patients, as presented in Figure 2. 
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Figure 2. Summary of mechanisms of the innate and adaptive immune systems involved in the pathogenesis of coeliac disease. Th, T helper cell; TNF, tumor 
necrosis factor; IFN, interferon; TG, transglutaminase; IEL, intraepithelial lymphocyte; MMP, matrix metalloproteinase; MICA, major 
histocompability complex I class molecule A; IL, interleukin NKG2D, natural killer group 2D (receptor of MICA). 
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The so-called toxic gliadin peptide p31-43 causes activation of innate immune 
system. This peptide induces increased interleukin (IL)-15 production in both 
epithelium and lamina propria (Maiuri et al. 2003, Hue et al. 2004), causing 
migration and activation of IEL to killer cells (Maiuri et al. 2001, Mention et al. 
2003, Meresse et al. 2004). IL-15 also induces expression of major histocompability 
complex class I molecule A (MICA) in enterocytes as well as expression of MICA 
receptor NKG2D in natural killer (NK) cells, αβ and γδ IELs (Roberts et al. 2001, 
Mention et al. 2003, Hue et al. 2004, Meresse et al. 2004). Activated IELs drive 
cells expressing MICA into apoptosis, causing intestinal damage (Hue et al. 2004). 
Gliadin peptide p56-89 activates the adaptive immune system after being 
deamidated by TG2. After deamidation of glutamine to glutamic acid, gliadin 
peptide fits into grooves in HLA DQ2 or DQ8 molecules of antigen presenting cells 
(APCs) (Molberg et al. 1998). Deamidation by TG2 is thus essential for gliadin 
peptide to become immunogenic. APCs present peptide to T-cells, causing 
activation of both T-helper cell (Th) 1 and Th2 pathways. In the Th1 pathway T-
cells produce proinflammatory cytokines such as TNF-α and IFN-γ   (Nilsen et al. 
1995), which activate fibroblasts and inflammatory cells to produce matrix 
metalloproteinases (MMP) responsible for matrix degradation and small-intestinal 
mucosal damage (Pender et al. 1997). In the Th2 pathway B-cells are activated to 
produce anti-TG2 antibodies (Sollid et al. 1997). 
The effect of coeliac disease autoantibodies on TG2 activity itself is debated. 
Esposito and colleagues (2002) showed the inhibitory effect of coeliac 
autoantibodies on TG2, whereas it was recently shown that coeliac autoantibodies 
increases the activity of TG2 (Kiraly et al. 2006, Myrsky et al. 2009). In vitro, 
coeliac autoantibodies interfere with the differentiation of epithelial cells (Halttunen 
and Mäki 1999), have effects on epithelial cell proliferation (Barone et al. 2007), 
increase epithelial cell permeability (Zanoni et al. 2006) and disturb angiogenesis 
(Myrsky et al. 2008).  
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10. TREATMENT 
Currently the only treatment for coeliac disease has been removal of the cause of 
the small intestinal lesion by omitting wheat, rye and barley from the daily diet 
(Walker-Smith et al. 1990, Catassi et al. 2001). A gluten-free diet is a lifelong 
treatment. Some patients diagnosed in childhood have, however, returned to gluten-
containing foods after years on a gluten-free diet and they may tolerate gluten for 
years or decades before symptoms reappear (Matysiak-Budnik et al. 2007, Hopman 
et al. 2008, Kurppa et al. 2008).  
A gluten-free diet may be difficult to adhere to; it may be restrictive, the 
availability of gluten-free products may be limited and these products may be 
expensive (Hall et al. 2009). A strict gluten-free diet, though it can be burdensome, 
nevertheless improves the quality of life of patients (Mustalahti et al. 2002a, 
Wagner et al. 2008). Furthermore, those patients with poor adherence to the diet 
have ongoing small-bowel mucosal lesions ranging from increased inflammation to 
villous atrophy (Troncone et al. 1995). In several studies adherence to a strict 
gluten-free diet has varied between 36% and 96% (Högberg et al. 2003, Viljamaa et 
al. 2005). Early onset and diagnosis of coeliac disease makes the diet easier to 
follow, whereas asymptomatic patients often show poor compliance (Fabiani et al. 
2000, Högberg et al. 2003, Wagner et al. 2008). 
In addition to relief of the classical symptoms of coeliac disease, a gluten-free 
diet increases bone mineral density (Kemppainen et al. 1999b) and reduces the risk 
of fractures (Olmos et al. 2008), reduces mortality (Corrao et al. 2001), and the risk 
of developing most cancers to the same level as in the population generally (Holmes 
et al. 1989) and lowers the incidence of amenorrhoea and abortions due to coeliac 
disease (Kotze 2004). The role of a gluten-free diet in preventing subsequent 
autoimmune disorders in coeliac disease patients remains controversial (Ventura et 
al. 1999, Sategna Guidetti et al. 2001, Biagi et al. 2002, Viljamaa et al. 2005, 
Cosnes et al. 2008).  
Monitoring of the response to a gluten-free diet is important in ensuring adequate 
strictness of the diet. However, complete recovery of the small-intestinal mucosa 
usually requires more than one year on a gluten-free diet (Collin et al. 2004a). 
Serum autoantibodies disappear soon after gluten withdrawal and they are used to 
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reveal dietary transgressions, although serum autoantibodies may also be absent 
despite persisting small-bowel mucosal damage (Troncone et al. 1995, Dickey et al. 
2000, Kaukinen et al. 2002b). Persistent villous atrophy despite diet increases the 
risks of complications, even in asymptomatic coeliac patients (Kaukinen et al. 
2007b). Examination of the morphology of the small-bowel mucosal biopsy is thus 
the best method to follow-up the response to a gluten-free diet. 
10.1 Oats in coeliac disease  
Among the cereals oats is distinct, belonging to different a tribe than wheat, rye 
and barley its storage protein, avenin, contains less prolines than gliadin, secalin or 
hordein (Jabri et al. 2005). Traditionally oats has been forbidden in coeliac patients’ 
gluten-free diet (Weijers and van de Kamer 1965).However, Janatuinen and 
associates (1995) showed that coeliac disease patients can tolerate oats. Since then 
several studies have found that ingested oats in coeliac patients in remission caused 
neither symptoms nor histological relapse (Srinivasan et al. 1996, Janatuinen et al. 
2000, Janatuinen et al. 2002, Storsrud et al. 2003c, Peräaho et al. 2004, Holm et al. 
2006). In addition, oats improves iron, fiber, thiamin and zinc intake in a gluten-free 
diet (Storsrud et al. 2003a). In newly diagnosed coeliac disease patients oats seems 
not to prevent improvement of the small-bowel mucosa (Janatuinen et al. 1995, 
Hoffenberg et al. 2000, Högberg et al. 2004). The suitability of oats has also been 
shown in dermatitis herpetiformis (Hardman et al. 1997, Reunala et al. 1998). Oats 
would not appear to evoke serum autoantibody formation or small-bowel mucosal 
damage in most coeliac patients (Picarelli et al. 2001, Kilmartin et al. 2003, Hollen 
et al. 2006, Srinivasan et al. 2006). Despite the tolerance to oats shown in a majority 
of studies, some patients develop symptoms and even small-bowel mucosal damage 
after ingestion of oats (Lundin et al. 2003, Arentz-Hansen et al. 2004, Peräaho et al. 
2004). Moreover, T-cells reactive to proline-rich areas of avenin have been found in 
some coeliac disease patients’ small-intestinal mucosa (Arentz-Hansen et al. 2004).  
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10.2 New treatments 
Currently the only treatment for coeliac disease is a strict gluten-free diet 
(Walker-Smith et al. 1990) but new therapeutic options have been widely studied. In 
vitro studies on blocking of HLA DQ2-mediated gluten presentation to T-cells (Xia 
et al. 2007), inhibition of TG2 activity by gluten peptide analogs (Siegel et al. 2007) 
or inhibition of paracellular permeability (Paterson et al. 2007) have been performed 
to obtain new treatment options for coeliac disease. Also germinating wheat 
(Stenman et al. 2009) and barley enzymes together with bacterial endopeptidases 
(Gass et al. 2007) have had promising effects on gluten degradation, thus 
diminishing gluten toxicity. Some of these treatments have been tested in humans 
(Paterson et al. 2007), but in future, when more new clinical drug trials will be 
conducted, sensitive and gluten-specific tools to detect immunoreactions caused by 
gluten will be needed.  
11. COMPLICATIONS 
11.1 Non-responsive coeliac disease and refractory sprue 
Among the criteria for coeliac disease, either a histological or a clinical response 
to a gluten-free diet is obligatory for diagnosis (Walker-Smith et al. 1990). 
However, about 1 to 8% of coeliac disease patients do not respond histologically to 
a gluten-free diet (O'Mahony et al. 1996, Kaukinen et al. 2007b). The main reason 
for an insufficient response is poor adherence to the diet or gluten contamination in 
the diet (Leffler et al. 2007). Gluten contamination can easily be suspected if serum 
autoantibodies are positive despite the gluten-free diet (Leffler et al. 2007). In 
addition, the diagnosis of coeliac disease may be incorrect, since small-bowel 
villous atrophy is not specific solely for coeliac disease (Green and Cellier 2007). 
Only 7-18% per cent of patients with non-responsive coeliac disease have 
symptomatic refractory coeliac disease (Wahab et al. 2002, Leffler et al. 2007). 
Diagnosis of both non-responsive and refractory coeliac disease is challenging in 
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that in these cases small-bowel mucosal villous atrophy does not respond to a 
gluten-free diet as it should. Moreover, serum coeliac autoantibodies usually give no 
additional support, as most patients with refractory coeliac disease are serum 
autoantibody-negative during a gluten-free diet in spite of the failure of small-bowel 
mucosa to recover (Kaukinen et al. 2007b, de Mascarel et al. 2008, O'Shea et al. 
2008, Verbeek et al. 2008b). The question thus arises as to whether these patients 
are really coeliac disease patients. 
Refractory coeliac disease patients can be divided into two types: refractory 
coeliac disease type I with a normal IEL population and type II with an aberrant IEL 
population in the small-intestinal mucosa. Usually, the lymphocytes in an abnormal 
IEL population lack TCR-γδ  (Verbeek et al. 2008b) and express neither CD3 nor 
CD8 molecules on their surface, but heterogeneity in the phenotypes of these cells is 
to be found (Farstad et al. 2002). In addition, expression of the CD30 molecule in 
IELs seems to be an indicator of poor prognosis (Farstad et al. 2002) as is lack of 
γδ+ IELs (Verbeek et al. 2008b). In consequence of the heterogeneity of IEL 
phenotypes, refractory coeliac disease patients cannot be straightforwardly divided 
into refractory coeliac disease types I and II only by expression of cell surface 
molecules. In addition, rearrangement of the TCR-γ gene is found in patients with 
refractory coeliac disease type II (de Mascarel et al. 2008).  
In refractory coeliac disease type I the prognosis of patients is good and the five 
year survival rate varies from 80% to 96% (Al-Toma et al. 2007, Rubio-Tapia et al. 
2009a). Patients with type II refractory disease, in contrast are at an increased risk of 
developing EATL; in a recent study 52% developed EATL during four to six years’ 
follow-up (Al-Toma et al. 2007) and the overall five-year survival rate is between 
45% and 58% in type II patients (Al-Toma et al. 2007, Rubio-Tapia et al. 2009a). It 
has in fact also been suggested that an abnormal IEL population in the small-
intestinal mucosa is an early manifestation of EATL (Cellier et al. 2000, Daum et al. 
2001). 
Refractory coeliac disease is treated with immunosuppressive drugs in 
conjunction with a strict gluten-free diet (Al-Toma et al. 2007, Rubio-Tapia et al. 
2009a). Refractory coeliac disease type I responds well to azathioprine after clinical 
remission is achieved by corticosteroids (Al-Toma et al. 2007). Case reports have 
also been published where patients have been treated with cyclosporine A, 
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infliximab or tacrolimus (Al-Toma et al. 2007). Refractory coeliac disease type II 
can be treated similarly to type I, but the response is often poor. Some cases have 
benefited from autologous stem cell transplantation (Al-Toma et al. 2007, Rubio-
Tapia et al. 2009a).  
11.2 Malignancies 
In studies published years ago, coeliac disease patients were at an increased risk of 
developing a number of malignancies; cancers of mouth, pharynx and oesophagus, 
small-bowel adenocarcinomas and lymphomas, particularly non-Hodgkin 
lymphomas (Swinson et al. 1983, Holmes et al. 1989). Current studies indicate that 
the total risk of malignancies is not elevated, but in certain types of malignancies, 
i.e. non-Hodgkin lymphomas, the risk is higher in coeliac disease patients than in 
the general population (West et al. 2004). On a gluten-free diet, the risk of 
malignancies is reduced and after five years the risks of most cancers, except non-
Hodgin lymphomas, have returned to the level of the population provided that the 
diet is strict (Holmes et al. 1989). 
EATL is a rare type of non-Hodgkin lymphomas with an incidence of 0.1 per 
100 000 (Verbeek et al. 2008a). It is situated usually in the proximal small-intestine 
and is found almost exclusively in coeliac disease patients (Brousse and Meijer 
2005, Verbeek et al. 2008a).The prognosis is poor. In a recent study the 5-year 
survival rate was 8% despite of chemotherapy (Al-Toma et al. 2007). Another type 
of non-Hodgkin lymphoma occurring in coeliac disease patients is B-cell 
lymphoma, which is usually located outside the small intestine and is more common 
than EATL (Sigurgeirsson et al. 1994, Hervonen et al. 2005). 
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THE PRESENT STUDY 
12. AIMS OF THE STUDY 
The aim of this study was to establish, whether determination of TG2-specific IgA 
deposits in the small-bowel mucosa is an accurate tool in the diagnostic work-up 
and follow-up of coeliac disease when compared to conventional histology and 
serology. 
Specific aims were to ascertain: 
1. The usefulness of small-bowel mucosal TG2-specific IgA autoantibody 
deposits in diagnosing overt coeliac disease (I) 
2. The effect of a gluten-free diet (I-IV) and oats (II) on small-bowel mucosal 
IgA deposits. 
3. The advantages of measurement of small-bowel mucosal IgA deposits in 
ascertaining the diagnosis of coeliac disease in patients who do not 
completely fulfil the current diagnostic criteria for coeliac disease i.e. non-
responsive (III) and early-stage coeliac disease (IV) 
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13. PATIENTS 
13.1 Coeliac disease patients (I-IV) 
This study was carried out mainly retrospectively and small-bowel biopsy 
specimens analyzed in this study were taken between the years 1993 and 2007. 
Small-bowel mucosal biopsy specimens from 379 IgA-competent coeliac disease 
patients were analyzed during this study (see Table 4). Specimens were taken from 
261 patients with overt coeliac disease either at the time of the diagnosis or during a 
gluten challenge (I, II, IV). Further, on a gluten-free diet of one year, a frozen 
follow-up biopsy was available from 72 of these 261 patients (I-IV). In addition, 
105 coeliac disease patients with a median of 8.0 (range 2.0-41.0) years on a gluten-
free diet were examined (I). The remaining patients recovered during the diet, but 
the use of frozen biopsy specimens is not routine practice in follow-up and thus 
these patients’ specimens were not available for analysis. Diagnosis of all these 
patients was based on the presence of villous atrophy and crypt hyperplasia in the 
small-bowel mucosa on a gluten-containing diet, thus fulfilling the current 
diagnostic criteria (Walker-Smith et al. 1990, Catassi et al. 2001).  
To reveal the gluten dependency of small-bowel mucosal TG2 specific IgA 
deposits, 23 children with coeliac disease in remission on a gluten-free diet were 
challenged with gluten-containing cereals in study II. Thirteen patients were 
randomized to add only oats to their otherwise gluten-free diet and ten patients also 
wheat, rye and barley (Figure 3). Follow-up biopsies were taken from these patients 
in the baseline situation, after six months and after 24 months of ingestion of oats. In 
addition, gluten-challenged patients were biopsied when relapse was suspected on 
the basis of symptoms or serology. 
Small-bowel mucosal biopsy specimens were taken from 27 patients with non-
responsive coeliac disease, including five with refractory sprue and six with 
enteropathy associated T-cell lymphoma (duration of gluten-free diet median of 6.0 
(range 0.1-24.0) years and six patients with poor adherence to diet (median time of 
diet 13.5, range 6.0-18.0 years) (III).  
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Table 4. Summary of patients and controls in studies I-IV 
Study Untreated CD Treated CD Long-term treated CD Challenged CD Complicated CD Early-stage CD Non CD 
I 261 72 105 - - - 78 
II  - - 23 - - - 
III 28* 28* - - 27 - 10 
IV 13* 13* - - - 48 42* 
* also included in study I; CD, coeliac disease 
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Figure 3. Study protocol of oat and gluten challenge study (II). Oats challenge= oats added 
to a gluten-free diet; gluten challenge= a diet containing wheat, rye, barley and 
oats. 
A total of 48 patients with clinical suspicion of coeliac disease and intact villous 
morphology were biopsied (IV). Of these 48, 28 continued on a gluten-containing 
diet (median 1.7, range 0.2-7.4 years), developed overt coeliac disease and started a 
gluten-free diet (follow-up time median 1.4 range 0.8-5.9 years). These 28 are 
referred to as early-stage coeliac disease patients (IV). The remaining 20 
symptomatic patients with small-bowel mucosal TG2-specific IgA autoantibody 
deposits started on a gluten-free diet prior to fulfilling the current criteria (Walker-
Smith et al. 1990, Catassi et al. 2001) to find evidence for gluten dependency. As 
clinical improvement was clear, they were considered as coeliac disease patients and 
referred to as the potential coeliac disease group; from these patients follow-up 
specimens were also taken after one year’s gluten withdrawal. 
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13.2 Controls (I, III, IV) 
 Small-bowel mucosal biopsy specimens were taken from 86 IgA-competent 
patients without coeliac disease (I, III, IV) (Table 4). Of these, 43 were initially 
suspected of having coeliac disease, but during follow-up on a normal, gluten 
containing-diet (median 6.0, range 0.8-10.0 years) they did not develop villous 
atrophy and coeliac disease was thus excluded. The final diagnoses of non-coeliac 
control patients were functional dyspepsia in 28, irritable bowel syndrome in 20, 
gastro-oesophageal reflux disease in 13, autoimmune enteropathy in 4, collagenous 
colitis in 3, inflammatory bowel disease in 3, lactose intolerance in 2 and aphtous 
stomatitis of unknown origin in 2. In the remaining 10 cases there were no special 
findings and during the follow-up their symptoms disappeared. They were 
considered healthy.  
13.3 Dietary intervention for coeliac disease patients (II) 
A total of 23 children in remission during a gluten-free diet, together with 
parents, were given instructions by a trained dietician on the oat-containing gluten-
free diet and gluten challenge (Holm et al. 2006). A detailed dietary analysis was 
assessed repeatedly by means of interview and 4-day record of food intake. At the 
outset, thirteen children were randomized to undergo oats challenge. The rolled, 
uncontaminated oats (Melia Ltd, Raisio, Finland) was given to the patients free of 
charge. During a two-year trial, the median daily consumption of oats was 45 g/day 
(range 13-81 g/day) in the oats challenge group. One patient this group had transient 
dietary lapses at the six-month time-point; all the rest adhered to a strict gluten-free 
diet throughout the study (Holm et al. 2006). 
A total of ten children were randomized to the gluten challenge group. In this 
group the median daily intake of gluten in the form of wheat-, rye-, barley- and oat-
containing normal bread was 14 g (range 7-19 g/day) and after adopting an oat-
containing gluten-free diet the median intake of oats was 41 g/day, range 24-59 
g/day.  
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14. METHODS 
14.1 Small-bowel biopsy (I-IV) 
Seven forceps biopsies were taken upon upper gastrointestinal endoscopy or one 
specimen by adult-size Watson capsule from the distal duodenum or proximal 
jejunum. Five forceps biopsies or one piece of capsule biopsy were formalin-fixed 
and embedded in paraffin. The remaining two forceps biopsies and one piece of 
capsule biopsy was embedded in optimal cutting temperature compound (OCT; 
Tissue-Tec, Miles Inc, Elkhart, IN, USA), snap-frozen and stored in -70°C. 
Determination of the Vh/CrD ratio and the percentage of CD3+CD8- IELs was 
carried out by two investigators, determination of small-bowel mucosal TG-2- 
specific IgA deposits and CD3+ and γδ+ IEL densities by several investigators. All 
specimens were evaluated without prior knowledge of disease history or laboratory 
findings. Intra- and interobserver variations are given in the context of each method 
if known. 
14.1.1 Morphometrical studies (I-IV) 
Haematoxylin-eosin staining was carried out on well-oriented 2µm thick 
paraffin-embedded sections. From these specimens villous height crypt depth ratio 
(Vh/CrD) was determined as Kuitunen and colleagues (1982) have previously 
described. A Vh/CrD ratio below two was considered compatible with untreated 
coeliac disease or inadequate response to a gluten-free diet. 
14.1.2 Detection of small-bowel mucosal TG2-specific IgA deposits (I-
IV) 
Frozen, unfixed, 5µm-thick sections were stained by direct immunofluorescence 
using fluorescein isothiocyanate-labelled rabbit antibody against human IgA (Dako 
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AS, Glostrup, Denmark). Sections were incubated in a humidified chamber for 30 
minutes at room temperature in the antibody at a dilution of 1:40 in phosphate 
buffered saline (PBS). To ascertain whether there is co-localization of IgA and TG2, 
sections from all specimens were double-stained with anti-IgA antibody as 
described above and using monoclonal mouse antibodies against TG2 at a dilution 
1:200 (CUB7402, NeoMarkers, Fremont, CA, USA), followed by rhodamine-
conjugated antimouse immunoglobulin antibodies (DAKO) diluted 1:120 in PBS. In 
coeliac disease subepithelial deposition can be found along the villous and crypt 
epithelium and around vessels, in contrast to non-coeliac samples where endogenous 
IgA is found inside plasma cells and epithelial cells (Korponay-Szabo et al. 2004, 
Kaukinen et al. 2005). The intensity of the IgA autoantibody deposits was classified 
either strong (+++), moderate (++), weak (+) or negative. In some specimens the 
intensity of depositions varied and in these cases the mean of these areas was 
regarded as intensity of the whole sample. The evaluation of samples was carried 
out in blinded fashion without knowledge of the patient's disease history. Intra- and 
interobserver variation has been 0.98 in earlier studies (Salmi et al. 2006b). 
Henceforward small-bowel mucosal TG2-specific IgA deposits are referred to with 
the term mucosal autoantibody deposits. 
 
Figure 4. Immunofluorescense staining of transglutaminase-2-specific IgA deposits from 
small-bowel mucosa. IgA is stained in green, transglutaminase-2 in red and co-
localization of them in yellow. In Figure A, strong (+++) transglutaminase-2-
specific IgA depositions (arrows) can be seen under both villous and crypt 
epithelium and around blood vessels in a coeliac disease patient. In Figure B no 
co-localization of IgA and transglutaminase is found in a non-coeliac control. 
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14.1.3 Intraepithelial lymphocytes (I, III, IV) 
Immunohistochemical staining of CD3+ and γδ+ IELs was carried out on frozen 
sections. CD3+ IELs were stained with monoclonal antibody Leu-4 (Becton 
Dickinson, San Jose, CA, USA) and γδ+ IELs with T-cell receptor -γ antibody 
(Endogen, Woburn, MA, USA) (I, III, IV). Positively stained CD3+ and γδ+ IELs 
were counted at a magnification x 100 throughout the surface epithelium. The result 
was expressed as IEL density/mm of epithelium and at least 30 fields were counted. 
Upper limits for normal values were set at 37 cells/mm of epithelium for CD3+ and 
4.3 cells/mm of epithelium for γδ+ IELs (Järvinen et al. 2003) (I, III, IV). Intra- and 
interobserver variation for CD3+ IELs has been 0.95 and 0.92, respectively, and for 
γδ+ IELs 0.98 (Salmi et al. 2006b). 
In addition, staining of CD3+, CD8+, CD30+ IELs was carried out on paraffin-
embedded sections, applying the standard immunoperoxidase method (Cellier et al. 
1998) with the following antibodies (all from Lab Vision Corporation, Fremont, 
CA, USA) CD3 (dilution 1:150), CD8 (1:50) and CD30 (1:60) (IV). Positively 
stained intraepithelial CD3+, CD8+, CD30+ lymphocytes were counted from 
randomly selected surface epithelium and expressed as IELs per 100 epithelial cells. 
The percentage of CD3+CD8- IELs was determined in patients with high numbers 
of IELs; a proportion above 52% was considered abnormal (Verkarre et al. 2003) 
(IV). 
 
14.2 Serology (I-IV) 
During the study period serum EmA (primate-type reticulin) replaced the ARA 
(rodent-type reticulin) test. Both of these antibody tests have been shown to measure 
anti-TG2 antibodies (Korponay-Szabo et al. 2000, Korponay-Szabo et al. 2003b), 
and the two tests have been shown to be virtually identical (Sulkanen et al. 1998). 
ARA and EmA were determined by an indirect immunofluorescence method, a 
serum dilution of 1:≥5 being considered positive (Sulkanen et al. 1998) (I, III, IV). 
In addition, serum IgA-class antibodies against TG2 were detected by enzyme-
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linked immunosorbent assay (ELISA) using human recombinant TG2 as antigen 
(Celikey, Phadia, GmbH, Freiburg, Germany). Concentrations over 5.0 U/ml were 
considered abnormal (I, II, III). Serum autoantibody positivity means that either 
ARA/EmA or anti-TG2 or both autoantibody tests are positive.  
 
14.3 HLA-typing (I, III, IV) 
A total of 165 patients were genotyped either for HLA-DQB1*02 and *0302 
alleles (corresponding to serological DQ2 and DQ8) using the DELFIA Celiac 
Disease Hybridization Assay (PerkinElmer Life and Analytical Sciences, Wallac 
Oy, Turku, Finland) according to the manufacturer's instructions, or based on 
polymerase chain reaction with allele-specific primers identifying HLA DQ2 and 
DQ8 and performed with a Dynal DQ low-resolution SSp kit (Dynal AS. Oslo, 
Norway), or for HLA DQB1* allele groups were determined using the Olerup SSP 
DQ low-resolution kit (Olerup SSP AB, Saltsjobaden, Sweden). This method 
determines the HLA DQ2, DQ4, DQ5, DQ6, DQ7, DQ8 and DQ9 allele groups.  
14.4 Deoxyribonucleic acid (DNA) extraction and 
analysis of T-cell clonality (IV) 
DNA was extracted from paraffin-embedded biopsy samples with the Illustra DNA 
extraction nucleon HT kit (GE Healthcare, Buchinghamshire, UK) according to 
manufacturer’s instructions. One hundred nanograms of DNA were used as a 
template in two separate polymerase chain reactions (PCR) to detect the clonality of 
the TCR-γ gene as described elsewhere (Diss et al. 1995). DNA from T-cell line 
Jurkatt was used as a positive control for monoclonality. All PCRs were performed 
in duplicate. 
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14.5 Ethical considerations (I-IV) 
The study protocols were approved by the Ethical Committee of Tampere 
University Hospital. All adult subjects and all children and their parents gave their 
written informed consent. 
14.6 Statistical analysis (I-IV) 
Sensitivities were calculated from the equation a/(a+c)*100, specificities 
d/(b+d)*100. In the equations, ‘‘a’’ denotes the number of biopsy-proven coeliac 
disease patients recognized by the test, ‘‘b’’ is the number of biopsy-proven non-
coeliac disease controls with a positive test result, ‘‘c’’ denotes the number of 
coeliac disease patients misclassified by the test and ‘‘d’’ represents the non-coeliac 
disease controls negative for the test. The efficiency of test was calculated by 
dividing the number of patients correctly classified by the test as diseased and non-
diseased by the number of all tested patients. 
Quantitative data were expressed as medians and ranges. Statistical differences 
were evaluated using Mann-Whitney U test and Wilcoxon signed-rank test as 
appropriate and all testing was two-sided. Correlations were tested by Spearman’s 
correlation test. P- values < 0.05 were considered statistically significant. All 
statistical testing was performed using Statistical Package for the Social Sciences 
version 17 (SPSS Inc. Chicago, IL, USA). 
49 
 
15. RESULTS 
15.1 Diagnosing overt coeliac disease (I) 
A total of 261 (I-IV) small-bowel mucosal specimens from patients with overt 
coeliac disease were analyzed and compared to 86 specimens from controls without 
coeliac disease (I, IV). Demographic data and main symptoms leading to endoscopy 
in both groups are presented in Table 5. All patients with active coeliac disease had 
a Vh/CrD ratio under 2 by definition; in contrast, only five (6%) patients, with 
autoimmune enteropathy or Crohn’s disease, out of 86 non-coeliac patients had 
villous atrophy. The Vh/CrD ratio was within normal limits in all the remaining 
non-coeliac controls (Table 7, Figure 6A). 
Table 5. Demographic data on untreated coeliac patients and controls 
 Coeliac disease 
n=261 
Controls 
n=86 
Age, median (range), years 47 (4-79) 49 (29-76) 
Female, n (%) 167 (64) 54 (63) 
Main symptom, n (%)   
   Abdominal complaints 97 (37) 73 (85) 
   Malabsorbtion 21 (8) 7 (8) 
   Extra-intestinal symptoms* 38 (15) 6 (7) 
   Screening† 96 (37) 0 
   Other‡ 9 (3) 0 
* aphtous stomatitis, arthralgia, collagenosis, growth retardation, infertility, depression, 
memory disorders, ataxia, extra-pyramidal symptoms, renal failure, alopecia  
†
 screening in risk groups (family members, autoimmune thyroid diseases, Sjögren’s 
syndrome, IgA nephropathy, epilepsy, type 1 diabetes mellitus) and population screening  
‡
 after gluten challenge 
 
Small-bowel mucosal TG2-specific IgA deposits were present in all active 
coeliac disease patients, being strong or moderate in 235 (90%) out of 261 cases. Of 
non-coeliac control subjects 14 (16%) out of 86 had weak IgA deposits in the small-
bowel mucosa, giving a sensitivity and specificity of 100% and 84%, respectively 
for small-bowel mucosal IgA deposits in finding overt coeliac disease (Figure 5 and 
Table 14). Although all patients with overt coeliac disease had small-bowel mucosal 
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autoantibody deposits, serum EmA was negative in 24 (9%) out of the 261 cases. In 
all non-coeliac patients serum autoantibodies were negative. 
Densities of CD3+ IELs were increased in 91% of coeliac disease patients with 
active disease and in 31% of the non-coeliac controls. Similarly, an increased 
density of γδ+ IELs was found in 96% of patients with active disease and in 27% of 
the non-coeliac controls. Medians and distribution of Vh/CrD and IELs are 
presented in Table 7 and Figure 6. Measuring the densities of IELs had lower 
sensitivity and specificity than determination of mucosal autoantibody deposits 
(Table 14).  
 
15.2 Follow-up on a gluten-free diet (I) 
At baseline, patients with available follow-up biopsies did not differ from those 
without in degree of small-bowel mucosal villous atrophy (p=0.982). During a 
gluten-free diet, clinical symptoms were alleviated and small-bowel mucosal 
atrophy completely recovered in 70% of the short-term treated and in 98% of the 
long-term treated patients. Demographic data on treated patients are shown in Table 
6. 
Table 6. Demographic data on coeliac disease patients examined during gluten-free diet. 
 Short-term treated Long-term treated 
Age, median (range), years 47 (16-72) 54 (7-81) 
Female, n(%) 48 (68) 70 (67) 
Duration of gluten-free diet, 
median (range), years 
1* 8 (2-41) 
*duration of gluten-free diet was one year in all 
 
The intensity of mucosal autoantibody deposits decreased statistically significantly 
(p<0.001) during a gluten-free diet; deposits were still present in 58 (82%) out of 71 
short-term and in 59 (56%) of the 105 long-term treated patients (Figure 5). Serum 
autoantibodies normalized faster than mucosal autoantibody deposits, being positive 
in 15% of short-term treated patients and negative in all long-term treated patients, 
despite villous atrophy in two patients. After gluten withdrawal the small-bowel 
villous atrophy normalized more slowly than serum autoantibody levels, but faster  
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Figure 5. Intensity of small-bowel mucosal transglutaminase-2 specific IgA deposits in different study groups (I, III, IV)  All coeliac groups differed 
statistically significantly from non-coeliac controls (p<0.001 in all). CD, coeliac disease; GFD, gluten-free diet. 
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Figure 6. Villous height crypt depth ratio (A) densities of CD3+ (B) and γδ+ (C) IELs in different study groups; medians, quartiles and minimum and 
maximum values are shown. The dash line represents upper limit of normal range. Outliers, below or above more than 1.5x interquartile range are 
not shown. All statistically significant (p<0.05) p-values compared to either untreated coeliac disease (CD) or non-coeliac controls are given as 
follows * p< 0.05 compared to untreated CD and † p< 0. 01 compared to non-coeliac controls.  
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than mucosal autoantibody deposits and the densities of CD3+ and γδ+ IELs. After 
long-term treatment, the increased density of γδ+ IELs persisted longer than other 
markers of coeliac disease. Medians and distribution of Vh/CrD and IELs are 
presented in Table 7 and Figure 6. 
Table 7. Villous height crypt depth ratio, median (range) and densities of IELs per mm of 
epithelium, median (range) in coeliac patients with and without gluten in diet and 
in non-coeliac control patients. 
 Vh/CrD CD3+ IELs γδ+ IELs 
Active CD , n=261 0.3 (0.0-1.9) ‡ 70 (18-170) ‡ 18.7 (0-76.5) ‡ 
Treated CD    
Short GFD, n=71 2.5 (0.3-4.0)* ‡ 37 (12-133)* ‡ 13.1 (0-56.3)* ‡ 
Long GFD, n=105 3.3 (1.2-5.9)*† 38 (6-91)* ‡ 12.1 (0-39.6)* †‡ 
Non CD controls, n=86 3.2 (0.1-4.9)* 31 (3-62)* 2.0 (0.7-24.8)* 
* p<0.001 compared to active coeliac disease group, 
† p< 0.001 compared to short-term gluten-free diet group 
‡ p <0.001 compared to non-CD group 
CD coeliac disease, GFD gluten-free diet, IEL intraepithelial lymphocyte, Vh/CrD villous 
height crypt depth ratio  
15.3 Exposure to gluten and oats (II) 
At baseline in this study, all treated coeliac disease children were in clinical 
remission and had normal villous architecture. Demographic data on the children are 
shown in Table 8. The Small-bowel mucosal median Vh/CrD ratio was 4.1 (range 
3.0-5.1) in the oat challenge group and 4.4 (range 3.2-5.9) in the gluten challenge 
group (p=0.351). At baseline, weak to moderate TG2-specific IgA autoantibody 
deposits were present in the small-bowel mucosa in four out of 13 (31%) in the oat 
challenge group and in three out of 10 (30%) (p=0.544) in the gluten challenge 
group, although serum coeliac disease autoantibodies were negative in all patients.  
Table 8. Demographic data on treated children in remission in oat and gluten challenge 
groups. 
 Oats group 
n=13 
Gluten group 
n=10 
Age, median (range), years 11 (9-18) 13 (7-18) 
Female, n (%) 6 (46) 9 (90) 
Duration of gluten-free diet, 
median (range), years 
7 (2-17) 5 (2-10) 
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In the oat challenge group there was no significant change in the intensity of 
mucosal IgA deposits during the two-year trial (p=0.276) (Figure 1B in original 
article II). In contrast, in the gluten challenge group all children developed moderate 
to strong mucosal IgA deposits in parallel to mucosa relapse (Figure 1A in original 
article II). Two patients were biopsied because of positive serum autoantibody tests 
before they developed small-intestinal mucosal villous atrophy during a gluten-
containing diet, and both had clear mucosal TG2-specific IgA depositions despite 
intact small-intestinal mucosal morphology. When an oat-containing gluten-free diet 
was adopted after relapse of the disease, the intensity of the small-bowel mucosal 
IgA deposits decreased significantly within six months (p=0.01). After two years 
with oats only one out of seven (14%) had minor depositions left in the mucosa, this 
not differing significantly from the baseline situation (p=0.257). At the end of the 
two-year trial with oats all patients were again negative for serum autoantibodies 
and had a normal Vh/CrD ratio (Table 9). 
Table 9. Villous height crypt depth ratio (Vh/CrD), median (range), presence of mucosal 
IgA deposits, n (%), and serum autoantibodies, median (range) in children 
challenged with cereals. All statistically significant p-values (p<0.05) are given.  
 Vh/CrD Mucosal autoantibody deposit Serum autoantibody 
Oat group n=13 
Baseline 4.1 (3.0-5.1) 4 (31%) 0.3 (0-1.0) 
Oats 24 months  4.0 (2.9-5.2) 3 (23%) 0.5 (0-0.9) 
Gluten* group n=10 
Baseline 4.3 (3.2-5.9) 3 (30%) 0.4 (0-1.3) 
During gluten 0.6 (0.1-2.0)† 10 (100%)† 96.5 (9.5-100)† 
Oats 6 months 4.0 (1.3-5.2) ‡ 6 (75%)‡ 1.9 (0.6-10.5) ‡ 
Oats 24 months 4.9 (3.3-5.2) 1 (14%) 1.3 (0.1-1.6) 
Reference value >2.0  <5.0 
*Gluten means wheat, rye and barley, †p= 0.05 compared to baseline situation, ‡ p<0.05 
compared to diet containing gluten  
 
One child in the oat challenge group admitted passing dietary transgressions at 
six months. At that time, his serum anti-TG2 antibody titre increased from 0.4 to 3.1 
U/ml, but still remained below the cut-off level of 5 U/ml. The intensity of small-
bowel mucosal IgA deposits was slightly increased. After continuing with a strict 
oat-containing gluten-free diet both serum and mucosal autoantibodies decreased.  
Two coeliac disease children experienced abdominal pain and vomiting 
immediately after intake of oats and within one month both withdrew prematurely 
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from the study. At the time of follow-up biopsies taken upon withdrawal, the small-
bowel mucosal villous morphology was normal. Furthermore, serum anti-TG2 
antibodies and small-bowel mucosal autoantibody deposits remained negative in 
both patients (Figure 4 in original article II).  
15.4 Differentiating non-responsive coeliac disease from 
other enteropathies (III) 
Non-responsive coeliac disease was found in 27 patients during a gluten-free 
diet. Demographic data are presented in Table 10. In six of these cases the reason 
for poor histological recovery was clearly dietary transgressions. All these non-
adherent patients were asymptomatic, but one later died of malabsorption. In the 
remaining 21 patients adherence to the diet was strict; EATL was found in six and 
five had symptomatic refractory disease. The remaining ten were asymptomatic 
regardless of persistent villous atrophy. During follow-up, six of these non-
responsive coeliac disease patients who adhered to the gluten-free diet died of 
coeliac disease complications; one with EATL is alive and the remaining fourteen 
are in remission with or without immunosuppressive drugs. As controls, ten patients 
with other enteropathies were examined. Of these, five had villous atrophy (four 
with autoimmune enteropathy and one with Crohn’s disease) but not the HLA DQ2 
or HLA DQ8 genotypes compatible with coeliac disease. During the follow-up 
control patients were all in remission with or without immunosuppressive 
medication. 
Table 10. Demographic data on non-responsive coeliac disease patients and controls with 
other enteropathies 
 Non-responsive coeliac disease  
 poor adherence good adherence Other enteropathies 
Age, median (range), years 49 (30-77) 52 (21-76) 52 (23-64) 
Female, n(%) 6 (100 %) 10 (48 %) 6 (60 %) 
Duration of gluten-free diet, 
 median (range), years 
14 (6-18) * 5 (0.3-24) 0 
* gluten contaminations repeatedly 
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Coeliac disease autoantibodies were both present in sera and deposited in the 
small bowel in all six coeliac disease patients with poor adherence to the gluten-free 
diet. In contrast, only four (19%) out of the 21 non-responsive coeliac disease 
patients with good adherence to the diet had autoantibodies in their sera while 20 
(95%) of these 21 patients had TG2-specific IgA class autoantibodies deposited in 
the small-intestinal mucosa (Figure 5). There was no difference in the intensity of 
small-bowel mucosal TG2-specific IgA deposits in patients with EATL, refractory 
sprue, asymptomatic non-responsive coeliac disease or untreated coeliac disease 
patients with subsequent response to the diet. In contrast to clear IgA depositions in 
almost all non-responsive coeliac patients, none of the ten patients with other 
enteropathies had autoantibodies either in sera or deposited in their small-intestinal 
mucosa.  
Increased densities of CD3+ and γδ+ IELs were present in 76% and 71% of 
patients with villous atrophy despite strict gluten-free diet and in 83% and 67% of 
patients with poor adherence to diet, respectively. As many as 30% of patients with 
other enteropathies had also elevated densities of IELs. Medians and distributions of 
markers are shown in Table 11 and Figure 6. 
 
Table 11. Villous height crypt depth ratio (Vh/CrD) and densities of intraepithelial 
lymphocytes (IELs) and presence of abnormal IEL population in non-responsive 
coeliac disease patients and in patients with enteropathies of other type. 
Statistically significant p-values compared to other enteropathies are shown. 
Between coeliac disease patient groups there were no statistically significant 
differences. 
 Non-responsive coeliac disease 
patients Other 
 Poor 
Adherence 
n=6 
Good adherence 
n=21 
enteropathies 
n=10 
Vh/CrD 0.1 (0.1-1.5)* 0.1 (0.1-1.8)** 2.3 (0.1-4.6) 
CD3+IELs /mm of epithelium 55 (30-132)** 55 (11-109)** 28 (15-40) 
γδ+ IELs /mm of epithelium 13.3 (3.2-17.2)* 11.9 (0-37.8)** 1.0 (0-14.0) 
CD30+ IELs /100 epithelial cells 0 (0-4.6) 0 (0-14.4) 0 (0-28.3) 
Abnormal IEL population, n (%) 0 6 (29%) 0 
*  p< 0.05 
**p< 0.01 
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Densities of CD30+ IELs and CD8-/CD3+ IEL ratio were determined in all non-
responsive coeliac patients on a strict gluten-free diet, in six coeliac disease patients 
with dietary transgressions and in four controls suffering from autoimmune 
enteropathy. An abnormal proportion of CD8-/CD3+ IELs was found in all coeliac 
patients with EATL, but not in coeliac patients without lymphoma or in controls. An 
increased density of CD30+ IELs was found in six (28%) out of 21 non-responsive 
but adherent coeliac disease patients and in one patient with dietary transgressions 
and one in the control group. Of these six adherent but non-responsive patients with 
CD30+ IELs four had EATL, one had refractory coeliac disease and one was 
asymptomatic. The TCR-γ gene rearrangement was found to be polyclonal in three 
patients, of whom two had EATL and one had symptomatic refractory sprue. 
15.5 Finding early-stage coeliac disease (IV) 
Specimens from 26 out of 28 early-stage coeliac disease patients were available 
for determination of TG2-specific IgA deposits from small-intestinal mucosa when 
villous atrophy was not present. Demographic data on these patients are presented in 
Table 12. Of these 26 patients 25 (96%) had small-bowel mucosal TG2-specific IgA 
deposits. Increased densities of CD3+ and γδ+ IELs were found in 13 (62%) and 15 
(71%) out of 21 patients before villous atrophy developed. Medians and 
distributions of Vh/CrD and IELs are shown in Table 13 and Figure 6. Serum 
coeliac disease autoantibodies were present in 19 out of the 26 patients (73%). The 
sensitivity of mucosal IgA deposit was 96% in finding coeliac disease prior to the 
development of villous atrophy.  
In parallel with the progression of small-bowel lesion, the intensity of mucosal 
IgA deposits and densities of intraepithelial cells increased (Figures 5 and 6). At the 
time of diagnosis of coeliac disease, when villous atrophy was evident, all coeliac 
disease patients evinced mucosal autoantibody deposits. All patients showed clinical 
and histological response to a gluten-free diet and the intensity of IgA deposits 
decreased. A total of seven patients in the early-stage coeliac disease group were 
initially serum autoantibody-negative; six of them still had positive small-bowel 
mucosal IgA deposits, two had a family history of coeliac disease and all (six) cases 
tested had coeliac-type HLA. 
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Table 12. Demographic data on mild enteropathy coeliac disease patients divided into 
early-stage coeliac disease (CD) with subsequent villous atrophy on a gluten-
containing diet and the potential CD group who started a gluten-free diet without 
villous atrophy. 
 Early stage CD 
n=28 
Potential CD 
n=20 
Age, years 37 (2-69) 46 (21-74) 
Female, n (%) 21 (75) 16 (80) 
Main symptom, n (%)   
Abdominal complaints 17 (61) 17 (85) 
Malabsorbtion 2 (7) 1(5) 
Extra-intestinal symptoms* 5 (18) 2 (10) 
Screening† 4 (14) 0 
HLA-DQ2 or DQ8 present 12/12 16/16 
*aphtous stomatitis, growth retardation, epilepsy, atopic dermatitis, polyneuropathy, 
arthralgia 
 
†
 type I diabetes mellitus, family history, autoimmune thyroid disorders, Sjögren’s 
syndrome, and osteoporosis 
 
 
Table 13. Villous height crypt depth (Vh/CrD) ratio, median (range) and densities of 
intraepithelial lymphocytes (IELs) per mm of epithelium, median (range) in 
early-stage and in potential coeliac disease. Statistically significant p-values are 
shown. Between early-stage and potential coeliac disease groups there were no 
statistically significant differences at the time of the first biopsies. 
 Vh/CrD CD3+ IEL γδ+ IELs 
Early-stage CD, n=28    
early-stage situation 2.8 (2.0-4.5) † 46 (12-185) †† 8.8 (0-34.8) †† 
at diagnosis‡ 1.0 (0.3-2.0)* † 68 23-138)** † 16.8 (1.4-58.7)** † 
after GFD 2.9 (2.1-3.5)***  †† 36 (21-82)*** 7.8 (1.4-56.3)*** † 
Potential CD, n=20    
early-stage situation 2.6 (2.2-3.6)  † 52(22-118) † 13.4 (4.2-34.8) † 
after GFD 2.9 (2.1-3.8) †† 29 (19- 66) 8.6 (3.2-25.5) †  
Controls n=76 3.3 (2.1-4.9) 30 (3.2-62) 2.0 (0-24.8) 
‡
 villous atrophy with crypt hyperplasia present in all  
* p<0.001 compared to first biopsy specimens 
** p<0.05 compared to first biopsy specimens 
*** p <0.01 compared to biopsy specimen at diagnosis  
†
 p<0.001 compared to control group 
 
††
 p<0.05 compared to control group 
 
In the remaining twenty patients (Table 12) with small-intestinal mucosal TG2-
specific IgA deposits but intact villous morphology, serum autoantibodies were 
found in 14 (74%) out of 19 tested patients before starting a gluten-free diet. 
Intraepithelial CD3+ and γδ+ lymphocyte densities were increased in 15 (75%) and 
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in 18 (90%) out of the twenty patients prior to commencing the diet, respectively. 
Sixteen out of the 20 patients having TG2-specific small-bowel mucosal IgA 
deposits in intact villi (potential coeliac disease) consented to a follow-up biopsy 
after one year on a gluten-free diet. The intensity of the deposits decreased in all but 
one during the diet. Parallel to these changes, abdominal symptoms and signs of 
malabsorption were resolved in 13 (65%) and improved in five (25%) of the patients 
during the gluten-free diet. Two patients with extra-intestinal symptoms experienced 
no change in their condition during the diet. 
 
15.6 Comparison of coeliac disease-related markers 
Small-bowel mucosal TG2- specific IgA deposits were proved to be the most 
efficient of the coeliac disease-related markers investigated in this study (Table 14). 
In overt coeliac disease its sensitivity was 100%, whereas serum autoantibodies, 
which have the highest specificity, were not present in 9% of patients with overt 
coeliac disease. Small-bowel mucosal densities of IELs had both lower sensitivities 
and specificities compared to mucosal autoantibody deposits in detecting overt 
coeliac disease (Table 14). In differentiating coeliac disease patients without 
response to a gluten-free diet from non-coeliac disease subjects only small 
intestinal-mucosal TG2-specific IgA deposits showed high sensitivity, whereas 
increased densities of IELs and in particularly serum autoantibodies failed to find 
non-responsive coeliac disease patients (Table 14). In detecting early-stage coeliac 
disease, before villous atrophy developed, small-bowel mucosal autoantibody 
deposits turned out to be superior in predicting forthcoming coeliac disease and had 
the highest sensitivity, 96%, while the sensitivities of increased densities of IELs 
and serology were between 62% and 73% (Table 14). 
In overt coeliac disease, there was a weak inverse correlation (r=-0.149, p=0.016, 
Spearman’s correlation test) between small-bowel mucosal TG2-specific IgA 
deposits and Vh/CrD ratio, whereas the intensity of mucosal autoantibody deposits 
and serum coeliac autoantibodies did not correlate (r=0.061, p=0.324, Spearman’s 
correlation test) in patients with overt coeliac disease. Similarly, mucosal 
autoantibody deposits were also found in seronegative patients on a gluten-free diet 
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with both good and poor response and even in early-stage coeliac disease patients 
without villous atrophy but subsequently developing coeliac disease on a gluten-
containing diet. It is of note that irrespective of diet, all serum autoantibody-positive 
patients also had TG2-specific IgA deposits present in the small-bowel mucosa.  
 
Table 14. Sensitivities and specificities of coeliac disease-related markers in differentiating 
active, non-responsive (during gluten-free diet) and early-stage coeliac disease 
(CD) from non-coeliac patients, including patients with enteropathies of other 
cause than coeliac disease 
 Villous 
atrophy 
Mucosal auto-
antibody deposits 
CD3+ 
IELs 
γδ+ IELs Serum auto-
antibodies 
Sensitivity  
Overt CD 100%* 100% 91% 96% 91% 
Non-responsive CD  100%* 95% 76% 71% 24% 
Early-stage CD 0%* 96% 62% 71% 73% 
Specificity 94% 84% 69% 73% 100% 
Efficiency of test ** 91% 96% 85% 90% 92% 
*by definition 
** calculated on coeliac disease patients before starting a gluten-free diet and all non-
coeliac controls 
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16. DISCUSSION 
16.1 Diagnosing overt coeliac disease 
The current criteria for coeliac disease require villous atrophy with crypt 
hyperplasia during a gluten-containing diet and recovery of the small-bowel mucosa 
on a gluten-free diet, while positive serum antibodies have a supporting role 
(Walker-Smith et al. 1990, Catassi et al. 2001). In addition, gluten challenge is 
recommended in special cases (Walker-Smith et al. 1990). Although villous atrophy 
is a diagnostic criterion for coeliac disease, it is not exclusively pathognomic for this 
condition (Marsh 1992, Green and Cellier 2007, Cello and Day 2009) as also seen in 
this patient material, where villous atrophy was encountered in five control patients 
without coeliac disease. Serum autoantibodies are highly sensitive and specific 
(Table 3) in detecting coeliac disease. However, in some patients fulfilling the 
current criteria serum autoantibodies are never found (Salmi et al. 2006b), which 
makes the diagnostics of coeliac disease even more challenging.  
In this study, all coeliac disease patients evincing villous atrophy during a gluten-
containing diet had TG2-specific IgA deposits in their small-bowel mucosa, this 
including 26 seronegative coeliac patients, similarly to the situation recently 
described in adults by Salmi and colleagues (2006b). In contrast to the present 
findings, in a recent study 27% of children with untreated coeliac disease below the 
age of two years had no autoantibody deposits in their small-bowel mucosa (Maglio 
et al. 2010). During the disease process the avidity of autoantibodies increases 
(Westerlund et al. 2007). Thus the lower sensitivity of mucosal autoantibody 
deposits in detecting coeliac disease in the youngest age groups may be due to the 
lower avidity of autoantibodies, which would promote autoantibody spillover into 
circulation rather than depositing in the small-intestinal mucosa. 
TG2-specific IgA deposits were as sensitive as villous atrophy in detecting overt 
coeliac disease, but their specificity was lower. This may be due to the fact that 
patients in the control group were symptomatic patients. They were all negative for 
coeliac disease serum autoantibodies, but elevated densities of IELs were seen in 
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approximately 30% of them. Whether these “false-positive” TG2-specific mucosal 
autoantibody deposits in 16% of the control patients predict forthcoming coeliac 
disease and the lower specificity turns out to be a consequence of the higher 
sensitivity of IgA deposits than villous atrophy, remains to be seen. Nonetheless, 
this group with symptoms is a relevant control group in that in clinical work it has to 
be determined whether symptomatic patients have coeliac disease or not.  
16.2 Gluten dependency of markers 
On a gluten-free diet symptoms should disappear and the small-bowel mucosal 
villi should recover (Walker-Smith et al. 1990). In this study changes in small-
bowel mucosal markers during a gluten-free diet as well as gluten and oat challenge 
were investigated and compared to coeliac serology and the clinical picture. The 
current findings indicate that the coeliac disease markers disappear in a sequential 
order during a gluten-free diet. Serum autoantibodies normalize rapidly after gluten 
withdrawal and disappear completely after strict long-term treatment. This seems to 
be followed by the recovery of the small-bowel mucosal villous morphology, as also 
previously reported (Dickey et al. 2000, Kaukinen et al. 2002b). Thereafter, the 
densities of CD3+ IELs decline, although considerably more slowly, being still 
elevated in half of the patients even after a long-term gluten-free diet (Figure 6b). 
Subsequently, TG2-specific IgA deposits begin to disappear, but remnants of 
deposits persist for a fairly long time after commencement of a gluten-free diet 
(Figure 5). Eventually, the last marker, which remains abnormal, is the density of 
TCR γδ+ IELs, which does decrease but does not reach normal values (Figure 6c), 
as has been described previously (Savilahti et al. 1990, Iltanen et al. 1999b, 
Kaukinen et al. 1999). 
In the present study, ingestion of oats during two years had no any adverse 
effects in most patients, as also shown in numerous previous studies (Janatuinen et 
al. 1995, Srinivasan et al. 1996, Janatuinen et al. 2000, Janatuinen et al. 2002, 
Storsrud et al. 2003c, Peräaho et al. 2004, Holm et al. 2006). Only two patients 
discontinued eating oats due to symptoms and returned to a gluten-free diet. During 
an oat-containing diet there was no change in coeliac disease markers, including 
small-bowel mucosal TG2-specific IgA deposits, not even in those two patients who 
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discontinued the diet. These results are compatible with those in many studies, 
where oats has had no immunogenic effect on coeliac disease patients (Picarelli et 
al. 2001, Kilmartin et al. 2003, Hollen et al. 2006, Srinivasan et al. 2006). In 
contrast to oats in a gluten-free diet, when wheat, rye and barley were added to the 
diet together with oats, villous atrophy developed in all patients, densities of IELs 
increased and autoantibodies were deposited in the small-bowel mucosa and 
reappeared in the serum. During an oat-containing gluten-free diet their small-bowel 
mucosa healed completely in two years.  
The disappearance of small-bowel mucosal TG2-specific IgA deposits during a 
gluten-free diet and reappearance during gluten challenge but not during oat 
ingestion shows that small-bowel mucosal IgA deposits are gluten-dependent as 
well as independent of oat consumption. These promising results on gluten 
dependency and the gluten restricted appearance of small-bowel mucosal TG2-
specific IgA deposits would imply that mucosal IgA deposits can be used to help in 
diagnostics. For example, in those cases where patients have started a gluten-free 
diet on their own and the villous architecture in the small-intestine has normalized 
before the intestinal biopsy, small-bowel mucosal autoantibody deposits allow 
reliable confirmation of the diagnosis. 
16.3 Differentiating non-responsive coeliac disease from 
other enteropathies 
A strict gluten-free diet improves the quality of life, even though keeping the diet 
strictly gluten-free may be burdensome (Mustalahti et al. 2002a, Wagner et al. 
2008). In contrast, patients with poor adherence to a gluten-free diet have persisting 
small-bowel mucosal lesions leading from an increased density of IELs to villous 
atrophy (Troncone et al. 1995). Persistent villous atrophy, even asymptomatic, 
increases the risks of complications in coeliac disease patients (Kaukinen et al. 
2007b). Follow-up of mucosal healing is thus particularly important.  
Dietary transgressions are a common reason for non-responsive coeliac disease 
(Leffler et al. 2007). As also previously shown these patients can be differentiated 
from other non-responsive patients by serum autoantibody titres (Leffler et al. 
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2007). Similarly to the situation in gluten-challenged patients these poorly adherent 
patients have high serum autoantibody titres, while most non-responsive patients 
with a strict diet are seronegative (Kaukinen et al. 2007b, de Mascarel et al. 2008, 
O'Shea et al. 2008, Verbeek et al. 2008b). This renders the diagnostics of non-
responsive coeliac disease challenging and obscure.  
A major finding in studying non-responsive coeliac disease was the high 
sensitivity and specificity of small-bowel mucosal TG2-specific IgA deposits in 
detecting coeliac disease among seronegative enteropathies; autoantibody deposits 
in the small-intestinal mucosa were present in 95% of all non-responsive coeliac 
disease patients during a strict gluten-free diet, also in patients with EATL, 
compared to none among patients with other enteropathies (i.e. autoimmune 
enteropathy and Crohn’s disease). Determination of small-bowel mucosal TG2-
specific IgA deposits is thus of assistance in diagnosing serum coeliac disease 
autoantibody-negative enteropathies in that it detects coeliac disease with high 
sensitivity and thus excludes coeliac disease in patients with no coeliac autoantibody 
deposits in the small-bowel mucosa. Nonetheless, determination of small-bowel 
mucosal IgA deposits is not able to distinguish patients with good or poor adherence 
to a gluten-free diet, whereas serum autoantibodies are.  
Why do TG2-specific IgA deposits remain in the small-bowel mucosa during a 
strict gluten-free diet? One explanation is local production of autoantibodies due to 
traces of gluten in gluten-free products (Storsrud et al. 2003b, Collin et al. 2004b). 
A case has been described where a minimal amount of gluten sufficed to maintain 
autoantibody production and small-bowel mucosal lesion (Biagi et al. 2004). 
Another reason might be that during the disease process avidity of coeliac 
autoantibodies increases (Westerlund et al. 2007), leading to stronger antibody-
antigen binding, so that the autoantibodies remain in the gut over a long period 
(Salmi et al. 2006b). 
The monoclonal TCR-gamma gene is often found in EATL; the monoclonality of 
TCR-γ gene has been found in the duodenal mucosa in 38% of EATL patients and 
in 17% of refractory coeliac disease patients (Daum et al. 2001). In the present 
study, similar TCR-gamma gene monoclonality was observed; 33% of EATL 
patients and 25% of refractory coeliac disease patients without EATL evinced a 
monoclonal TCR-gamma gene rearrangement. In this study, the best marker to 
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differentiate patients with EATL from those without was an abnormal proportion of 
CD3+CD8- IELs; this abnormal IEL population was found in all EATL patients, but 
in none without EATL. Similarly to these results, a previous study also found 
immunophenotyping of IELs to be a more accurate method to find patients with 
EATL than determination of TCR-γ gene clonality (Daum et al. 2001). 
The present results indicate that the typical markers of abnormal IEL phenotype 
distinguish the most severe conditions of coeliac disease from the less severe, while 
determination of small-bowel mucosal IgA deposits distinguishes all coeliac disease 
patients. To detect the reason for non-responsive coeliac disease these tests should 
thus be used together to confirm the diagnosis of coeliac disease and to reveal 
abnormal immunophenotypes of IELs. It is important to find an abnormal IEL 
population early so that treatment can be initiated before EATL develops, as the 
prognosis of EATL is poor, only 8% to 20% surviving for 5 years, (Gale et al. 2000, 
Al-Toma et al. 2007). In the present study, five EATL patients died within a few 
years after diagnosis and only one (17%) patient out of six with EATL is still alive. 
16.4 Finding early-stage coeliac disease 
Coeliac disease without small-bowel mucosal villous atrophy does not fulfil the 
current criteria for coeliac disease (Walker-Smith et al. 1990), but the fact is that 
patients may be symptomatic and even develop osteoporosis without evidence of 
small-bowel mucosal villous atrophy (Kaukinen et al. 2001, Kaukinen et al. 2005). 
Furthermore, it has also recently been observed that coeliac patients benefit from a 
gluten-free diet regardless of the stage of villous atrophy (Kurppa et al. 2009). For 
these reasons, several studies have been made to establish a diagnostic tool sensitive 
and specific enough to detect early-stage coeliac disease before villous atrophy 
develops. 
Serum autoantibody positivity without villous atrophy may predict the 
development of coeliac disease (Collin et al. 1993, Salmi et al. 2006a), but serum 
autoantibodies are not sensitive enough to reveal early-stage coeliac disease. In the 
current study only 73% of early stage coeliac disease patients without villous 
atrophy had serum autoantibodies as has previously been reported (Goldstein and 
Underhill 2001, Tursi and Brandimarte 2003). However, TG2-specific IgA 
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autoantibodies were deposited in the small-bowel mucosa in 96% of patients before 
the emergence of villous atrophy. Similar high accuracy has been reported by 
Korponay-Szabo and associates (2004), Kaukinen and associates (2005) and Salmi 
and colleagues (2006a). A slightly lower sensitivity of 79% of IgA autoantibody 
deposits was recently reported by Tosco and associates (2008) in children. Similarly 
to early-stage coeliac disease patients without villous atrophy, small-bowel mucosal 
autoantibody deposits have also been found in patients with gluten ataxia even 
without symptoms of gastrointestinal tract or villous atrophy (Hadjivassiliou et al. 
2006).  
In the present study, patients who were positive for serum autoantibodies also 
had deposited antibodies in the small-bowel mucosa, regardless of the diet. This is 
in contrast to the findings of Tosco and colleagues (2008) on children with early-
stage coeliac disease, where fifteen percent of seropositive coeliac patients did not 
have autoantibodies deposited in the small-intestinal mucosa. In another study on 
small-bowel mucosal IgA deposits in diabetes mellitus type I patients with normal 
small-bowel mucosal morphology, the results showed that 21% of patients having 
coeliac disease autoantibodies in their sera evinced no deposits in the small-bowel 
mucosa (Maglio et al. 2009). In addition to the reasons discussed in section 16.1 the 
discrepancy may also be dependent on technical issues involved in visualizing the 
IgA deposits in histological specimens. 
Despite the good accuracy of IEL densities in detecting early-stage coeliac 
disease (Iltanen et al. 1999c, Salmi et al. 2006a), their sensitivity was lower than 
that of mucosal autoantibody deposits in this study; before the development of 
villous atrophy CD3+ and γδ+ IEL densities were elevated in 62% and 71%, 
respectively. 
Small-bowel mucosal TG2-specific IgA deposits are more sensitive than other 
markers tested in predicting forthcoming coeliac disease, but this prompt the 
question, whether these patients should be placed on a gluten-free diet before 
diagnostic criteria are fulfilled. Kurppa and associates (2009) showed that patients 
with positive coeliac disease serology benefit on gluten-free diet, regardless of the 
degree of villous atrophy. In this current study, twenty symptomatic patients with 
small-bowel mucosal IgA autoantibodies voluntarily started a gluten-free diet before 
villous atrophy developed and the clinical response was clear – at the same time IgA 
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deposits disappeared from the gut mucosa. These results together would imply that 
symptomatic patients with autoantibodies either in the sera or deposited in the 
small-intestinal mucosa would benefit from treatment, but further randomized 
controlled studies are required. 
16.5 Strengths and shortcomings of the present study 
The results of the present study show the high sensitivity of small-bowel mucosal 
TG2-specific IgA deposits in the diagnosis of coeliac disease in a large group of 
untreated coeliac disease patients. The specificity of determining small-bowel 
mucosal autoantibody deposits was, however, lower, 86%. The non-coeliac control 
group, where 16% were found to have deposits, consisted of symptomatic patients. 
For ethical reasons it was not possible to recruit completely healthy persons to 
undergo upper gastrointestinal endoscopy. Symptomatic patients may not be the 
ideal non-coeliac control group, since they may develop coeliac disease later in life, 
especially those proving positive for deposits. 
 This study was carried out mainly retrospectively on stored biopsy specimens and 
for example HLA DQ-typing was thus not available for all patients. Nonetheless a 
strength of the study was the opportunity to evaluate a series of biopsies from the 
same patients at different time-points and on different diets. This makes for the 
possibility to draw conclusions as to what happens during disease development and 
treatment. However, biopsy specimens during a gluten-free diet were not available 
from all untreated patients, as the use of frozen biopsy specimens is not routine in 
clinical practice. The frozen biopsy specimens were available from patients who 
participated in scientific studies. The remainder recovered during gluten-free diet.  
This study showed for the first time that TG2-specific IgA autoantibody deposits 
are dependent on gluten consumption, but that consumption of pure oats has no 
effect on the intensity of autoantibody deposits in the small-bowel mucosa. This 
study also showed the presence of coeliac disease autoantibody deposits in six 
EATL patients, supporting the findings of Salmi and associates (2006b). Taking into 
account that refractory coeliac disease and especially EATL are rare conditions, 
with a prevalence of 0.1 per 100 000 (Verbeek et al. 2008a), several patients with 
these conditions were encountered in this study. However, such patients are 
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recognized later, not at the time of diagnosis of coeliac disease, and for this reason 
their first biopsies or serum samples were not available, though it would be both 
interesting and of scientific value to establish whether there are some differences in 
these patients already at the time when coeliac disease is diagnosed as compared to 
patients with responsive coeliac disease. The number of patients with other 
enteropathies is small and conclusions regarding the prevalence of TG2-specific IgA 
autoantibodies in for example Crohn’s disease or ulcerative colitis patients’ small-
bowel mucosa cannot be drawn based on this study; further investigations among 
these patient groups are called for.  
The wide variation in patients’ ages is a further strength of this study. Here 
small-bowel mucosal TG2-specific IgA deposits were studied in both adults and 
children over two years of age. One shortcoming of the study is absence of children 
below the age of two. In that youngest age group, food allergies are more common 
causes of small-bowel mucosal villous atrophy than in older children and adults, and 
this could lead to wrong diagnoses of coeliac disease (Walker-Smith et al. 1990). In 
a recent study by Maglio and associates (2010), the authors showed that in the group 
of children under two years only 73% of coeliac disease patients had small-bowel 
mucosal autoantibody deposits present, while 88% of them had serum 
autoantibodies. 
In the current study, only patients and controls with normal levels of serum IgA 
were included. However, coeliac disease is common in selective IgA deficiency 
(Korponay-Szabo et al. 2003a) and it is clear that small-bowel mucosal TG2-
specific IgA deposits are not able to detect these patients, while autoantibody 
depositions can be determined with IgG and IgM immunoglobulin classes 
(Korponay-Szabo et al. 2004, Borrelli et al. 2009).  
16.6 Re-evaluation of diagnostic criteria for coeliac 
disease 
The current diagnostic criteria for coeliac disease do not take into account forms 
of the disease without villous atrophy with minor inflammatory changes in the 
small-bowel mucosa (Walker-Smith et al. 1990, Catassi et al. 2001); likewise 
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refractory coeliac disease without response to a gluten-free diet does not fulfil these 
criteria. It has been reported that positivity for serum autoantibodies predicts the 
development of coeliac disease (Collin et al. 1993). Such patients with early-stage 
coeliac disease often have symptoms and risks of osteoporosis (Kaukinen et al. 
2005) and a recent study has shown that all symptomatic serum autoantibody-
positive patients, despite the degree of villous atrophy, benefit from a gluten-free 
diet (Kurppa et al. 2009). It seems that a gluten-free diet should be considered for 
serum autoantibody-positive patients even in the absence of villous atrophy. Some 
coeliac patients with either early-stage or more severe disease are seronegative 
(Salmi et al. 2006a) and thus subjects with a clinical suspicion of coeliac disease 
should undergo gastroscopy and duodenal biopsies should be taken for routine and 
if necessary specialized histological examinations. 
 According to the present findings, IgA deposits should be determined in 
seronegative patients suspected of having coeliac disease. If villous atrophy and 
small-bowel mucosal TG2-specific IgA deposits are present the subject can be 
regarded as a coeliac disease patient and placed on a gluten-free diet. Equally in the 
situation where deposits are present without manifest mucosal lesion and the 
patients are symptomatic, a gluten-free diet should be prescribed. In patients without 
small-intestinal TG2-specific IgA deposits other causes of symptoms and possible 
small-intestinal lesion should be taken into consideration.  
Altogether, there is clearly call for new diagnostic criteria which on the one hand 
specify the role of positive autoantibody findings in both sera and small-intestinal 
mucosa even without villous atrophy, and on the other hand give a diagnosis of 
refractory coeliac disease even without dietary response.  
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17. CONCLUSIONS AND FUTURE ASPECTS 
This study showed that determination of small-bowel mucosal TG2-specific IgA 
deposit is as sensitive a tool in finding overt coeliac disease as the conventional 
villous morphological analysis. Morphological analysis fails to distinguish between 
different causes of villous atrophy, whereas small-bowel mucosal autoantibodies are 
accurate in detecting coeliac disease even in seronegative and EATL patients. 
Coeliac patients on a gluten-containing diet had small-bowel mucosal autoantibody 
deposits irrespective of their serological finding, in contrast to patients with other 
enteropathies, of whom none had autoantibody deposits in the small-intestinal 
mucosa. These results together give an opportunity to ascertain or exclude coeliac 
disease in patients with small-bowel mucosal lesions compatible for coeliac disease 
but without serum autoantibodies. Furthermore, TG2-specific IgA deposits remain 
in the small-intestinal mucosa for a fairly long time, even years, after gluten 
withdrawal and thus can be used as an instrument to diagnose coeliac disease in 
patients who have by themselves started a gluten-reduced diet without proper 
diagnosis. 
In addition, TG2-specific IgA deposits in the small-intestinal mucosa were a 
more sensitive marker than determination of serum autoantibodies or densities of 
CD3+ or γδ+ IELs in detecting early-stage coeliac disease. Densities of IELs 
seemed to be unspecific and indicate rather inflammation in the small intestine than 
coeliac disease. These findings also indicated that determining autoantibodies from 
the small-intestinal mucosa is more sensitive than determining them from sera. In 
seronegative, potential coeliac patients with small-bowel mucosal autoantibody 
deposits, symptoms were alleviated during a gluten-free diet. Thus, in future, 
prospective controlled studies are warranted to establish whether subjects with 
small-bowel mucosal IgA deposits will benefit from a gluten-free diet regardless of 
serum autoantibodies or stage of mucosal lesion.  
In clinical practice, determination of small-bowel mucosal TG2-specific IgA 
deposits could be available in a centralized framework as a special tool used in 
problematic cases but not in routine diagnostics, because the procedure requires 
71 
 
frozen sections and interpretation needs practice even if the staining itself is easy to 
perform. In research, determination of small-bowel mucosal autoantibody deposits 
offers a sensitive tool to detect the harmfulness of gluten in clinical studies where 
new treatments for coeliac disease are being developed. 
72 
 
ACKNOWLEDGEMENTS 
This study was carried out at the Medical School, University of Tampere, the 
Department of Gastroenterology and Alimentary Tract Surgery and the Department 
of Paediatrics, Tampere University Hospital and the National Graduate School of 
Clinical Investigation. 
 
First I wish to express my deep gratitude to my supervisors Professor Markku 
Mäki, M.D. and Docent Katri Kaukinen, M.D. for all the support they have given 
me. They both encouraged and inspired me to continue this study from advanced 
studies to a dissertation project. Markku has always had time to explain the 
background to issues and has enthusiastically drawn many pictures to clarify this 
project when we have met and discussed on my work. I admire Katri’s positive 
attitude and patience in teaching and the fact that she has always been available, 
even during holidays, when I have needed help.   
 
I am grateful to Professor Jukka Mustonen, M.D. from the Medical School and 
the Head of the Department of Gastroenterology and Alimentary Tract Surgery 
Docent Juhani Sand, M.D. for providing me with working facilities.  Deepest thanks 
are also due to the Head of the Department of Gastroenterology and Alimentary 
Tract Surgery Docent Pekka Collin, M.D. providing me with working facilities and 
for collaboration as a co-author during this study. 
 
I am indebted to the Professor Matti Korppi, M.D. from the Medical School and 
the Heads of the Department of Paediatrics Docent Matti Salo, M.D. and  Anna-
Leena Kuusela, M.D. for providing working facilities in the Paediatric Research 
Centre. I am thankful to Professor Per Ashorn, M.D. for initiating the Tampere 
Research Training Program for Medical Students, in which I was able to participate.  
I also thank Professor Ilkka Pörsti, M.D. and Docent Merja Ashorn, M.D. for 
consenting to be members of the follow-up group for the thesis. 
 
73 
 
The contribution of the external reviewers of this thesis Docent Juhani Grönlund, 
M.D. and Docent Seppo Niemelä, M.D. is acknowledged in valuable comments and 
constructive criticism to improve the quality of this work. 
 
I wish to thank my co-authors Katri Lindfors, Ph.D, Teea Salmi, M.D., Docent 
Jukka Partanen, M.D., Niina Woolley, M.Sc, Katri Haimila, Ph.D., Kaija Laurila, 
M.Sc., Markku Peräaho, M.D., Mikko Villanen, M.D. and Sari Iltanen, M.D. for 
smooth collaboration. Especially I wish to thank Ilma Korponay-Szabo, M.D. for all 
her help and for instructing me in the analysis and photographing of specimens. 
 
I am thankful to Mr. Robert MacGilleon, M.A. for revising the language of this 
thesis and the original publications. 
 
My warmest thanks go to all members of the Coeliac Disease Study Group. 
Especially, I am thankful to Tiina Raivio, M.D., Sini Lohi, M.D.,  Kalle Kurppa, 
M.D. and Essi Myrsky, M.Sc. for peer support and lively discussions. I also thank 
Tiina Rauhavirta, M.Sc., Laura Airaksinen M.Sc., Heidi Kontro M.Sc and Suvi 
Kalliokoski M.Sc. for aid and company in the lab. The Coeliac Disease Service 
Laboratory and technicians Mrs. Anne Heimonen, Mrs. Mervi Himanka and Mrs. 
Soili Peltomäki deserve special thanks for helping me with hundreds of specimens 
and many questions. I am thankful to Mrs. Marja-Leena Koskinen for teaching me 
immunohistohemistical staining of specimens. I deeply appreciate the work of Mrs. 
Kaija Kaskela and Mrs. Zoe Virmaa. 
  
I wish to thank all my friends for showing me that there is world outside the lab. 
Especially, I thank Mrs. Annika Laaksonen for dragging me out into the fresh air 
every now and then, as well as Riikka Leppänen, M.D. and Johanna Repo, M.D. 
who have been available when needed for long discussions.  
 
Lämpimät kiitokset vanhemmilleni Tuula ja Matti Järviselle tuesta ja 
rohkaisevasta asenteesta läpi koko koulu- ja opiskeluajan sekä avusta Tiilan 
hoidossa. Sisartani Satu Kopposta kiitän sekä avusta Tiilan hoidossa, että yhteisistä 
keskusteluista, joissa olen oppinut puolustamaan kantaani. 
74 
 
 
 
My heartfelt thanks belong to my dear husband Tero Koskinen for his love and 
for sharing everyday life and also for supporting with this project and rescuing my 
files from broken computers. Finally I thank my little sunbeam Tiila for cheering up 
my days. 
 
This study project and the Coeliac Disease Study Group were financially 
supported by the Research Council for Health, the Academy of Finland, the Sigrid 
Juselius Foundation, the Paediatric Research Foundation, the Mary and Georg C. 
Ehrnrooth Foundation, the Competitive Research Funding of the Pirkanmaa 
Hospital District, the Research Fund of the Finnish Coeliac Society, the Yrjö 
Jahnsson Foundation, European Union Marie Curie Mobility Grant MRTN-CT-
2006-036032 (TRACKS), The National Graduate School of Clinical Investigation, 
the Finnish Foundation of Gastroenterological Research and the Finnish Medical 
Society Duodecim.  
 
Permission from the copy-right owners of the original articles to reproduce the 
publications is acknowledged. 
 
 
Tampere, April 2010 
 
Outi Koskinen 
75 
 
REFERENCES 
Agardh D, Nilsson A, Carlsson A, Kockum I, Lernmark A and Ivarsson SA. (2002) Tissue 
transglutaminase autoantibodies and human leucocyte antigen in Down's syndrome patients with 
coeliac disease. Acta Paediatr. 91:34-38. 
Aine L, Mäki M, Collin P and Keyriläinen O. (1990) Dental enamel defects in celiac disease. J Oral 
Pathol Med. 19:241-245. 
Akbari MR, Mohammadkhani A, Fakheri H, Javad Zahedi M, Shahbazkhani B, Nouraie M, 
Sotoudeh M, Shakeri R and Malekzadeh R. (2006) Screening of the adult population in Iran for 
coeliac disease: comparison of the tissue-transglutaminase antibody and anti-endomysial antibody 
tests. Eur J Gastroenterol Hepatol. 18:1181-1186. 
Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM and Mulder CJ. (2007) Survival in 
refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation 
of single-centre experience. Gut. 56:1373-1378. 
Arato A, Hacsek G and Savilahti E. (1998) Immunohistochemical findings in the jejunal mucosa of 
patients with coeliac disease. Scand J Gastroenterol Suppl. 228:3-10. 
Arentz-Hansen H, Fleckenstein B, Molberg O, Scott H, Koning F, Jung G, Roepstorff P, Lundin KE 
and Sollid LM. (2004) The molecular basis for oat intolerance in patients with celiac disease. 
PLoS Med. 1:e1. 
Arranz E, Bode J, Kingstone K and Ferguson A. (1994) Intestinal antibody pattern of coeliac disease: 
association with gamma/delta T cell receptor expression by intraepithelial lymphocytes, and other 
indices of potential coeliac disease. Gut. 35:476-482. 
Bardella MT, Quatrini M, Zuin M, Podda M, Cesarini L, Velio P, Bianchi P and Conte D. (1997) 
Screening patients with celiac disease for primary biliary cirrhosis and vice versa. Am J 
Gastroenterol. 92:1524-1526. 
Barone MV, Caputo I, Ribecco MT, Maglio M, Marzari R, Sblattero D, Troncone R, Auricchio S and 
Esposito C. (2007) Humoral immune response to tissue transglutaminase is related to epithelial 
cell proliferation in celiac disease. Gastroenterology. 132:1245-1253. 
Bazzigaluppi E, Roggero P, Parma B, Brambillasca MF, Meroni F, Mora S, Bosi E and Barera G. 
(2006) Antibodies to recombinant human tissue-transglutaminase in coeliac disease: diagnostic 
effectiveness and decline pattern after gluten-free diet. Dig Liver Dis. 38:98-102. 
Ben Hariz M, Kallel-Sellami M, Kallel L, Lahmer A, Halioui S, Bouraoui S, Laater A, Sliti A, 
Mahjoub A, Zouari B, Makni S and Maherzi A. (2007) Prevalence of celiac disease in Tunisia: 
mass-screening study in schoolchildren. Eur J Gastroenterol Hepatol. 19:687-694. 
Bhattacharya M, Dubey AP and Mathur NB. (2009) Prevalence of Celiac Disease in North Indian 
Children. Indian Pediatr. 46:415-417. 
Biagi F, Pezzimenti D, Campanella J and Corazza GR. (2002) Gluten exposure and risk of 
autoimmune disorders. Gut. 51:140-141. 
Biagi F, Campanella J, Martucci S, Pezzimenti D, Ciclitira PJ, Ellis HJ and Corazza GR. (2004) A 
milligram of gluten a day keeps the mucosal recovery away: a case report. Nutr Rev. 62:360-363. 
Biagi F, Campanella J, Soriani A, Vailati A and Corazza GR. (2006) Prevalence of coeliac disease in 
Italian patients affected by Addison's disease. Scand J Gastroenterol. 41:302-305. 
Bonamico M, Mariani P, Danesi HM, Crisogianni M, Failla P, Gemme G, Quartino AR, Giannotti A, 
Castro M, Balli F, Lecora M, Andria G, Guariso G, Gabrielli O, Catassi C, Lazzari R, Balocco 
NA, De Virgiliis S, Culasso F, Romano C and SIGEP (Italian Society of Pediatric 
Gastroenterology and Hepatology) and Medical Genetic Group. (2001a) Prevalence and clinical 
picture of celiac disease in italian down syndrome patients: a multicenter study. J Pediatr 
Gastroenterol Nutr. 33:139-143. 
Bonamico M, Tiberti C, Picarelli A, Mariani P, Rossi D, Cipolletta E, Greco M, Tola MD, Sabbatella 
L, Carabba B, Magliocca FM, Strisciuglio P and Di Mario U. (2001b) Radioimmunoassay to 
detect antitransglutaminase autoantibodies is the most sensitive and specific screening method for 
celiac disease. Am J Gastroenterol. 96:1536-1540. 
Bonamico M, Pasquino AM, Mariani P, Danesi HM, Culasso F, Mazzanti L, Petri A, Bona G, Italian 
Society Of Pediatric Gastroenterology Hepatology (SIGEP) and Italian Study Group for Turner 
76 
 
Syndrom (ISGTS). (2002) Prevalence and clinical picture of celiac disease in Turner syndrome. J 
Clin Endocrinol Metab. 87:5495-5498. 
Bonamico M, Mariani P, Thanasi E, Ferri M, Nenna R, Tiberti C, Mora B, Mazzilli MC and 
Magliocca FM. (2004) Patchy villous atrophy of the duodenum in childhood celiac disease. J 
Pediatr Gastroenterol Nutr. 38:204-207. 
Bonamico M, Ferri M, Mariani P, Nenna R, Thanasi E, Luparia RP, Picarelli A, Magliocca FM, 
Mora B, Bardella MT, Verrienti A, Fiore B, Uccini S, Megiorni F, Mazzilli MC and Tiberti C. 
(2006) Serologic and genetic markers of celiac disease: a sequential study in the screening of first 
degree relatives. J Pediatr Gastroenterol Nutr. 42:150-154. 
Borrelli M, Maglio M, Agnese M, Paparo F, Gentile S, Colicchio B, Tosco A, Auricchio R and 
Troncone R. (2009) High density of intraepithelial gammadelta lymphocytes and deposits of 
immunoglobulin (Ig)M anti-tissue transglutaminase antibodies in the jejunum of coeliac patients 
with IgA deficiency. Clin Exp Immunol. DOI:10.1111/j.1365-2249.2009.04077.x: 
Borst J, van Dongen JJ, Bolhuis RL, Peters PJ, Hafler DA, de Vries E and van de Griend RJ. (1988) 
Distinct molecular forms of human T cell receptor gamma/delta detected on viable T cells by a 
monoclonal antibody. J Exp Med. 167:1625-1644. 
Bourne JT, Kumar P, Huskisson EC, Mageed R, Unsworth DJ and Wojtulewski JA. (1985) Arthritis 
and coeliac disease. Ann Rheum Dis. 44:592-598. 
Brousse N and Meijer JW. (2005) Malignant complications of coeliac disease. Best Pract Res Clin 
Gastroenterol. 19:401-412. 
Burgin-Wolff A, Dahlbom I, Hadziselimovic F and Petersson CJ. (2002) Antibodies against human 
tissue transglutaminase and endomysium in diagnosing and monitoring coeliac disease. Scand J 
Gastroenterol. 37:685-691. 
Carnicer J, Farre C, Varea V, Vilar P, Moreno J and Artigas J. (2001) Prevalence of coeliac disease 
in Down's syndrome. Eur J Gastroenterol Hepatol. 13:263-267. 
Carroccio A, Cavataio F, Montalto G, Paparo F, Troncone R and Iacono G. (2001) Treatment of 
giardiasis reverses "active" coeliac disease to "latent" coeliac disease. Eur J Gastroenterol 
Hepatol. 13:1101-1105. 
Carroccio A, Iacono G, D'Amico D, Cavataio F, Teresi S, Caruso C, Di PL, Colombo A, D'Arpa F, 
Florena A, Notarbartolo A and Montalto G. (2002a) Production of anti-endomysial antibodies in 
cultured duodenal mucosa: usefulness in coeliac disease diagnosis. Scand J Gastroenterol. 37:32-
38. 
Carroccio A, Vitale G, Di Prima L, Chifari N, Napoli S, La Russa C, Gulotta G, Averna MR, 
Montalto G, Mansueto S and Notarbartolo A. (2002b) Comparison of anti-transglutaminase 
ELISAs and an anti-endomysial antibody assay in the diagnosis of celiac disease: a prospective 
study. Clin Chem. 48:1546-1550. 
Catassi C, Ratsch IM, Gandolfi L, Pratesi R, Fabiani E, El Asmar R, Frijia M, Bearzi I and Vizzoni 
L. (1999) Why is coeliac disease endemic in the people of the Sahara? Lancet. 354:647-648. 
Catassi C, Cellier C, Cerf-Bensussan N, Ciclitira PJ, Collin P, Corazza GR, Dickey W, Fasano A, 
Holmes GK, Klincewicz P, Mearin ML, Mulder CJS, Murray JA, Pena AS, Schuppan D, Sollid 
LM, Uil JJ, Wahab PJ, Walker-Smith JA and Watson P. (2001) When is a coeliac a coeliac? 
Report of a working group of the United European Gastroenterology Week in Amsterdam, 2001. 
Eur J Gastroenterol Hepatol. 13:1123-1128. 
Cellier C, Patey N, Mauvieux L, Jabri B, Delabesse E, Cervoni JP, Burtin ML, Guy-Grand D, 
Bouhnik Y, Modigliani R, Barbier JP, Macintyre E, Brousse N and Cerf-Bensussan N. (1998) 
Abnormal intestinal intraepithelial lymphocytes in refractory sprue. Gastroenterology. 114:471-
481. 
Cellier C, Delabesse E, Helmer C, Patey N, Matuchansky C, Jabri B, Macintyre E, Cerf-Bensussan N 
and Brousse N. (2000) Refractory sprue, coeliac disease, and enteropathy-associated T-cell 
lymphoma. French Coeliac Disease Study Group. Lancet. 356:203-208. 
Cello JP and Day LW. (2009) Idiopathic AIDS enteropathy and treatment of gastrointestinal 
opportunistic pathogens. Gastroenterology. 136:1952-1965. 
Ciacci C, Cirillo M, Mellone M, Basile F, Mazzacca G and De Santo NG. (1995) Hypocalciuria in 
overt and subclinical celiac disease. Am J Gastroenterol. 90:1480-1484. 
Clemente MG, Musu MP, Frau F, Brusco G, Sole G, Corazza GR and De Virgiliis S. (2000) Immune 
reaction against the cytoskeleton in coeliac disease. Gut. 47:520-526. 
Collin P and Reunala T. (2003) Recognition and management of the cutaneous manifestations of 
celiac disease: a guide for dermatologists. Am J Clin Dermatol. 4:13-20 
77 
 
Collin P, Salmi J, Hällström O, Oksa H, Oksala H, Mäki M and Reunala T. (1989) High frequency of 
coeliac disease in adult patients with type-I diabetes. Scand J Gastroenterol. 24:81-84. 
Collin P, Mäki M, Keyriläinen O, Hällström O, Reunala T and Pasternack A. (1992) Selective IgA 
deficiency and coeliac disease. Scand J Gastroenterol. 27:367-371. 
Collin P, Helin H, Mäki M, Hällström O and Karvonen AL. (1993) Follow-up of patients positive in 
reticulin and gliadin antibody tests with normal small-bowel biopsy findings. Scand J 
Gastroenterol. 28:595-598. 
Collin P, Reunala T, Pukkala E, Laippala P, Keyriläinen O and Pasternack A. (1994a) Coeliac 
disease--associated disorders and survival. Gut. 35:1215-1218. 
Collin P, Salmi J, Hällström O, Reunala T and Pasternack A. (1994b) Autoimmune thyroid disorders 
and coeliac disease. Eur J Endocrinol. 130:137-140. 
Collin P, Vilska S, Heinonen PK, Hällström O and Pikkarainen P. (1996) Infertility and coeliac 
disease. Gut. 39:382-384. 
Collin P, Reunala T, Rasmussen M, Kyrönpalo S, Pehkonen E, Laippala P and Mäki M. (1997) High 
incidence and prevalence of adult coeliac disease. Augmented diagnostic approach. Scand J 
Gastroenterol. 32:1129-1133. 
Collin P, Syrjänen J, Partanen J, Pasternack A, Kaukinen K and Mustonen J. (2002) Celiac disease 
and HLA DQ in patients with IgA nephropathy. Am J Gastroenterol. 97:2572-2576.. 
Collin P, Mäki M and Kaukinen K. (2004a) Complete small intestine mucosal recovery is obtainable 
in the treatment of celiac disease. Gastrointest Endosc. 59:158-9; author reply 159-60. 
Collin P, Thorell L, Kaukinen K and Mäki M. (2004b) The safe threshold for gluten contamination in 
gluten-free products. Can trace amounts be accepted in the treatment of coeliac disease? Aliment 
Pharmacol Ther. 19:1277-1283. 
Collin P, Kaukinen K, Vogelsang H, Korponay-Szabo I, Sommer R, Schreier E, Volta U, Granito A, 
Veronesi L, Mascart F, Ocmant A, Ivarsson A, Lagerqvist C, Burgin-Wolff A, Hadziselimovic F, 
Furlano RI, Sidler MA, Mulder CJ, Goerres MS, Mearin ML, Ninaber MK, Gudmand-Hoyer E, 
Fabiani E, Catassi C, Tidlund H, Alainentalo L and Mäki M. (2005) Antiendomysial and 
antihuman recombinant tissue transglutaminase antibodies in the diagnosis of coeliac disease: a 
biopsy-proven European multicentre study. Eur J Gastroenterol Hepatol. 17:85-91. 
Corazza GR, Andreani ML, Venturo N, Bernardi M, Tosti A and Gasbarrini G. (1995a) Celiac 
disease and alopecia areata: report of a new association. Gastroenterology. 109:1333-1337. 
Corazza GR, Di Sario A, Cecchetti L, Tarozzi C, Corrao G, Bernardi M and Gasbarrini G. (1995b) 
Bone mass and metabolism in patients with celiac disease. Gastroenterology. 109:122-128. 
Corrao G, Corazza GR, Bagnardi V, Brusco G, Ciacci C, Cottone M, Sategna Guidetti C, Usai P, 
Cesari P, Pelli MA, Loperfido S, Volta U, Calabro A, Certo M and Club del Tenue Study Group. 
(2001) Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet. 
358:356-361. 
Cosnes J, Cellier C, Viola S, Colombel JF, Michaud L, Sarles J, Hugot JP, Ginies JL, Dabadie A, 
Mouterde O, Allez M, Nion-Larmurier I and Groupe D'Etude et de Recherche Sur la Maladie 
Coeliaque. (2008) Incidence of autoimmune diseases in celiac disease: protective effect of the 
gluten-free diet. Clin Gastroenterol Hepatol. 6:753-758. 
Damen GM, Boersma B, Wit JM and Heymans HS. (1994) Catch-up growth in 60 children with 
celiac disease. J Pediatr Gastroenterol Nutr. 19:394-400. 
Daum S, Weiss D, Hummel M, Ullrich R, Heise W, Stein H, Riecken EO, Foss HD and Intestinal 
Lymphoma Study Group. (2001) Frequency of clonal intraepithelial T lymphocyte proliferations 
in enteropathy-type intestinal T cell lymphoma, coeliac disease, and refractory sprue. Gut. 
49:804-812. 
de Mascarel A, Belleannee G, Stanislas S, Merlio C, Parrens M, Laharie D, Dubus P and Merlio JP. 
(2008) Mucosal intraepithelial T-lymphocytes in refractory celiac disease: a neoplastic population 
with a variable CD8 phenotype. Am J Surg Pathol. 32:744-751. 
Demirceken FG, Kansu A, Kuloglu Z, Girgin N, Guriz H and Ensari A. (2008) Human tissue 
transglutaminase antibody screening by immunochromatographic line immunoassay for early 
diagnosis of celiac disease in Turkish children. Turk J Gastroenterol. 19:14-21. 
Diamanti A, Basso MS, Pietrobattista A and Nobili V. (2008) Prevalence of celiac disease in children 
with autoimmune hepatitis. Dig Liver Dis. 40:965. 
Dicke WK. (1950) Coeliakie. 
Dickey W, McMillan SA and Callender ME. (1997) High prevalence of celiac sprue among patients 
with primary biliary cirrhosis. J Clin Gastroenterol. 25:328-329. 
78 
 
Dickey W, Hughes DF and McMillan SA. (2000) Disappearance of endomysial antibodies in treated 
celiac disease does not indicate histological recovery. Am J Gastroenterol. 95:712-714. 
Dickey W and Kearney N. (2006) Overweight in celiac disease: prevalence, clinical characteristics, 
and effect of a gluten-free diet. Am J Gastroenterol. 101:2356-2359. 
Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO and Schuppan D. (1997) 
Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med. 3:797-801. 
Dieterich W, Laag E, Schopper H, Volta U, Ferguson A, Gillett H, Riecken EO and Schuppan D. 
(1998) Autoantibodies to tissue transglutaminase as predictors of celiac disease. 
Gastroenterology. 115:1317-1321. 
Dipper C, Maitra S, Thomas R, Lamb C, McLean-Tooke A, Ward R, Smith D, Spickett G and 
Mansfield J. (2009) Anti-tissue transglutaminase antibodies in the follow-up of adult coeliac 
disease. Aliment Pharmacol Ther. 30:236-244. 
Diss TC, Watts M, Pan LX, Burke M, Linch D and Isaacson PG. (1995) The polymerase chain 
reaction in the demonstration of monoclonality in T cell lymphomas. J Clin Pathol. 48:1045-
1050. 
Drago S, El Asmar R, Di Pierro M, Grazia Clemente M, Tripathi A, Sapone A, Thakar M, Iacono G, 
Carroccio A, D'Agate C, Not T, Zampini L, Catassi C and Fasano A. (2006) Gliadin, zonulin and 
gut permeability: Effects on celiac and non-celiac intestinal mucosa and intestinal cell lines. 
Scand J Gastroenterol. 41:408-419. 
Emami MH, Karimi S, Kouhestani S, Hashemi M and Taheri H. (2008) Diagnostic accuracy of IgA 
anti-tissue transglutaminase in patients suspected of having coeliac disease in Iran. J 
Gastrointestin Liver Dis. 17:141-146. 
Esposito C, Paparo F, Caputo I, Rossi M, Maglio M, Sblattero D, Not T, Porta R, Auricchio S, 
Marzari R and Troncone R. (2002) Anti-tissue transglutaminase antibodies from coeliac patients 
inhibit transglutaminase activity both in vitro and in situ. Gut. 51:177-181. 
Fabiani E, Taccari LM, Ratsch IM, Di Giuseppe S, Coppa GV and Catassi C. (2000) Compliance 
with gluten-free diet in adolescents with screening-detected celiac disease: a 5-year follow-up 
study. J Pediatr. 136:841-843. 
Fabiani E, Catassi C and International Working Group. (2001) The serum IgA class anti-tissue 
transglutaminase antibodies in the diagnosis and follow up of coeliac disease. Results of an 
international multi-centre study. International Working Group on Eu-tTG. Eur J Gastroenterol 
Hepatol. 13:659-665. 
Fabiani E, Peruzzi E, Mandolesi A, Garbuglia G, Fanciulli G, D'Appello AR, Gasparin M, Bravi E, 
Bearzi I, Galeazzi R and Catassi C. (2004) Anti-human versus anti-guinea pig tissue 
transglutaminase antibodies as the first-level serological screening test for coeliac disease in the 
general population. Dig Liver Dis. 36:671-676. 
Farre C, Esteve M, Curcoy A, Cabre E, Arranz E, Amat LL and Garcia-Tornel S. (2002) 
Hypertransaminasemia in pediatric celiac disease patients and its prevalence as a diagnostic clue. 
Am J Gastroenterol. 97:3176-3181. 
Farstad IN, Johansen FE, Vlatkovic L, Jahnsen J, Scott H, Fausa O, Bjorneklett A, Brandtzaeg P and 
Halstensen TS. (2002) Heterogeneity of intraepithelial lymphocytes in refractory sprue: potential 
implications of CD30 expression. Gut. 51:372-378. 
Fasano A, Berti I, Gerarduzzi T, Not T, Colletti RB, Drago S, Elitsur Y, Green PH, Guandalini S, 
Hill ID, Pietzak M, Ventura A, Thorpe M, Kryszak D, Fornaroli F, Wasserman SS, Murray JA 
and Horvath K. (2003) Prevalence of celiac disease in at-risk and not-at-risk groups in the United 
States: a large multicenter study. Arch Intern Med. 163:286-292. 
Ferguson A and Murray D. (1971) Quantitation of intraepithelial lymphocytes in human jejunum. 
Gut. 12:988-994. 
Ferguson A, Arranz E and O'Mahony S. (1993) Clinical and pathological spectrum of coeliac 
disease--active, silent, latent, potential. Gut. 34:150-151. 
Ferguson R, Basu MK, Asquith P and Cooke WT. (1976) Jejunal mucosal abnormalities in patients 
with recurrent aphthous ulceration. Br Med J. 1:11-13. 
Ferreira M, Davies SL, Butler M, Scott D, Clark M and Kumar P. (1992) Endomysial antibody: is it 
the best screening test for coeliac disease? Gut. 33:1633-1637. 
Fine KD, Ogunji F, Saloum Y, Beharry S, Crippin J and Weinstein J. (2001) Celiac sprue: another 
autoimmune syndrome associated with hepatitis C. Am J Gastroenterol. 96:138-145. 
Freeman HJ and Chiu BK. (1986) Multifocal small bowel lymphoma and latent celiac sprue. 
Gastroenterology. 90:1992-1997. 
79 
 
Frost AR, Band MM and Conway GS. (2009) Serological screening for coeliac disease in adults with 
Turner's syndrome: prevalence and clinical significance of endomysium antibody positivity. Eur J 
Endocrinol. 160:675-679. 
Frustaci A, Cuoco L, Chimenti C, Pieroni M, Fioravanti G, Gentiloni N, Maseri A and Gasbarrini G. 
(2002) Celiac disease associated with autoimmune myocarditis. Circulation. 105:2611-2618. 
Gabrielli M, Cremonini F, Fiore G, Addolorato G, Padalino C, Candelli M, De Leo ME, Santarelli L, 
Giacovazzo M, Gasbarrini A, Pola P and Gasbarrini A. (2003) Association between migraine and 
Celiac disease: results from a preliminary case-control and therapeutic study. Am J Gastroenterol. 
98:625-629. 
Gale J, Simmonds PD, Mead GM, Sweetenham JW and Wright DH. (2000) Enteropathy-type 
intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin 
Oncol. 18:795-803. 
Gass J, Bethune MT, Siegel M, Spencer A and Khosla C. (2007) Combination enzyme therapy for 
gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology. 133:472-480. 
Gee S. (1888) On the coeliac affection. St Bart Hosp Rep. 24:17-20. 
Gobbi G. (2005) Coeliac disease, epilepsy and cerebral calcifications. Brain Dev. 27:189-200. 
Gobbi G, Bouquet F, Greco L, Lambertini A, Tassinari CA, Ventura A and Zaniboni MG. (1992) 
Coeliac disease, epilepsy, and cerebral calcifications. The Italian Working Group on Coeliac 
Disease and Epilepsy. Lancet. 340:439-443. 
Goldstein NS and Underhill J. (2001) Morphologic features suggestive of gluten sensitivity in 
architecturally normal duodenal biopsy specimens. Am J Clin Pathol. 116:63-71. 
Greco L, Babron MC, Corazza GR, Percopo S, Sica R, Clot F, Fulchignoni-Lataud MC, Zavattari P, 
Momigliano-Richiardi P, Casari G, Gasparini P, Tosi R, Mantovani V, De Virgiliis S, Iacono G, 
D'Alfonso A, Selinger-Leneman H, Lemainque A, Serre JL and Clerget-Darpoux F. (2001) 
Existence of a genetic risk factor on chromosome 5q in Italian coeliac disease families. Ann Hum 
Genet. 65:35-41. 
Greco L, Romino R, Coto I, Di Cosmo N, Percopo S, Maglio M, Paparo F, Gasperi V, Limongelli 
MG, Cotichini R, D'Agate C, Tinto N, Sacchetti L, Tosi R and Stazi MA. (2002) The first large 
population based twin study of coeliac disease. Gut. 50:624-628. 
Green PH and Cellier C. (2007) Celiac disease. N Engl J Med. 357:1731-1743. 
Hadithi M, de Boer H, Meijer JW, Willekens F, Kerckhaert JA, Heijmans R, Pena AS, Stehouwer 
CD and Mulder CJ. (2007) Coeliac disease in Dutch patients with Hashimoto's thyroiditis and 
vice versa. World J Gastroenterol. 13:1715-1722. 
Hadjivassiliou M, Gibson A, Davies-Jones GA, Lobo AJ, Stephenson TJ and Milford-Ward A. 
(1996) Does cryptic gluten sensitivity play a part in neurological illness? Lancet. 347:369-371. 
Hadjivassiliou M, Grunewald RA, Chattopadhyay AK, Davies-Jones GA, Gibson A, Jarratt JA, 
Kandler RH, Lobo A, Powell T and Smith CM. (1998) Clinical, radiological, neurophysiological, 
and neuropathological characteristics of gluten ataxia. Lancet. 352:1582-1585. 
Hadjivassiliou M, Davies-Jones GA, Sanders DS and Grunewald RA. (2003) Dietary treatment of 
gluten ataxia. J Neurol Neurosurg Psychiatry. 74:1221-1224. 
Hadjivassiliou M, Mäki M, Sanders DS, Williamson CA, Grunewald RA, Woodroofe NM and 
Korponay-Szabo IR. (2006) Autoantibody targeting of brain and intestinal transglutaminase in 
gluten ataxia. Neurology. 66:373-377. 
Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N and Aeschlimann D. (2008) 
Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol. 
64:332-343. 
Hakanen M, Luotola K, Salmi J, Laippala P, Kaukinen K and Collin P. (2001) Clinical and 
subclinical autoimmune thyroid disease in adult celiac disease. Dig Dis Sci. 46:2631-2635. 
Hall NJ, Rubin G and Charnock A. (2009) Systematic review: Adherence to a gluten-free diet in 
adult patients with coeliac disease. Aliment Pharmacol Ther. 30:315-30. 
Halstensen TS, Scott H and Brandtzaeg P. (1989) Intraepithelial T cells of the TcR gamma/delta+ 
CD8- and V delta 1/J delta 1+ phenotypes are increased in coeliac disease. Scand J Immunol. 
30:665-672. 
Halttunen T and Mäki M. (1999) Serum immunoglobulin A from patients with celiac disease inhibits 
human T84 intestinal crypt epithelial cell differentiation. Gastroenterology. 116:566-572. 
Hansen D, Brock-Jacobsen B, Lund E, Bjorn C, Hansen LP, Nielsen C, Fenger C, Lillevang ST and 
Husby S. (2006) Clinical benefit of a gluten-free diet in type 1 diabetic children with screening-
detected celiac disease: a population-based screening study with 2 years' follow-up. Diabetes 
Care. 29:2452-2456. 
80 
 
Hardman CM, Garioch JJ, Leonard JN, Thomas HJ, Walker MM, Lortan JE, Lister A and Fry L. 
(1997) Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med. 
337:1884-1887. 
Hervonen K, Vornanen M, Kautiainen H, Collin P and Reunala T. (2005) Lymphoma in patients with 
dermatitis herpetiformis and their first-degree relatives. Br J Dermatol. 152:82-86. 
Heyman M and Menard S. (2009) Pathways of gliadin transport in celiac disease. Ann N Y Acad Sci. 
1165:274-278. 
Hill ID, Dirks MH, Liptak GS, Colletti RB, Fasano A, Guandalini S, Hoffenberg EJ, Horvath K, 
Murray JA, Pivor M, Seidman EG and North American Society for Pediatric Gastroenterology, 
Hepatology and Nutrition. (2005) Guideline for the diagnosis and treatment of celiac disease in 
children: recommendations of the North American Society for Pediatric Gastroenterology, 
Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 40:1-19. 
Hoffenberg EJ, Haas J, Drescher A, Barnhurst R, Osberg I, Bao F and Eisenbarth G. (2000) A trial of 
oats in children with newly diagnosed celiac disease. J Pediatr. 137:361-366. 
Hollen E, Holmgren Peterson K, Sundqvist T, Grodzinsky E, Högberg L, Laurin P, Stenhammar L, 
Falth-Magnusson K and Magnusson KE. (2006) Coeliac children on a gluten-free diet with or 
without oats display equal anti-avenin antibody titres. Scand J Gastroenterol. 41:42-47. 
Holm K, Mäki M, Vuolteenaho N, Mustalahti K, Ashorn M, Ruuska T and Kaukinen K. (2006) Oats 
in the treatment of childhood coeliac disease: a 2-year controlled trial and a long-term clinical 
follow-up study. Aliment Pharmacol Ther. 23:1463-1472. 
Holmes GK, Prior P, Lane MR, Pope D and Allan RN. (1989) Malignancy in coeliac disease--effect 
of a gluten free diet. Gut. 30:333-338. 
Holopainen P, Arvas M, Sistonen P, Mustalahti K, Collin P, Mäki M and Partanen J. (1999) 
CD28/CTLA4 gene region on chromosome 2q33 confers genetic susceptibility to celiac disease. 
A linkage and family-based association study. Tissue Antigens. 53:470-475. 
Holopainen P, Naluai AT, Moodie S, Percopo S, Coto I, Clot F, Ascher H, Sollid L, Ciclitira P, 
Greco L, Clerget-Darpoux F, Partanen J and Members of the European Genetics Cluster on 
Coeliac Disease. (2004) Candidate gene region 2q33 in European families with coeliac disease. 
Tissue Antigens. 63:212-222. 
Hopman EG, von Blomberg ME, Batstra MR, Morreau H, Dekker FW, Koning F, Lamers CB and 
Mearin ML. (2008) Gluten tolerance in adult patients with celiac disease 20 years after diagnosis? 
Eur J Gastroenterol Hepatol. 20:423-429. 
Hopper AD, Cross SS and Sanders DS. (2008) Patchy villous atrophy in adult patients with suspected 
gluten-sensitive enteropathy: is a multiple duodenal biopsy strategy appropriate? Endoscopy. 
40:219-224. 
Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, Verkarre V, Fodil N, Bahram S, 
Cerf-Bensussan N and Caillat-Zucman S. (2004) A direct role for NKG2D/MICA interaction in 
villous atrophy during celiac disease. Immunity. 21:367-377. 
Hällström O. (1989) Comparison of IgA-class reticulin and endomysium antibodies in coeliac 
disease and dermatitis herpetiformis. Gut. 30:1225-1232. 
Högberg L, Grodzinsky E and Stenhammar L. (2003) Better dietary compliance in patients with 
coeliac disease diagnosed in early childhood. Scand J Gastroenterol. 38:751-754. 
Högberg L, Laurin P, Falth-Magnusson K, Grant C, Grodzinsky E, Jansson G, Ascher H, Browaldh 
L, Hammersjo JA, Lindberg E, Myrdal U and Stenhammar L. (2004) Oats to children with newly 
diagnosed coeliac disease: a randomised double blind study. Gut. 53:649-654. 
Iltanen S, Collin P, Korpela M, Holm K, Partanen J, Polvi A and Mäki M. (1999a) Celiac disease and 
markers of celiac disease latency in patients with primary Sjogren's syndrome. Am J 
Gastroenterol. 94:1042-1046. 
Iltanen S, Holm K, Ashorn M, Ruuska T, Laippala P and Mäki M. (1999b) Changing jejunal gamma 
delta T cell receptor (TCR)-bearing intraepithelial lymphocyte density in coeliac disease. Clin 
Exp Immunol. 117:51-55. 
Iltanen S, Holm K, Partanen J, Laippala P and Mäki M. (1999c) Increased density of jejunal 
gammadelta+ T cells in patients having normal mucosa--marker of operative autoimmune 
mechanisms? Autoimmunity. 29:179-187. 
Ivarsson A, Hernell O, Stenlund H and Persson LA. (2002) Breast-feeding protects against celiac 
disease. Am J Clin Nutr. 75:914-921. 
Ivarsson A, Hernell O, Nystrom L and Persson LA. (2003) Children born in the summer have 
increased risk for coeliac disease. J Epidemiol Community Health. 57:36-39. 
81 
 
Jabri B, Kasarda DD and Green PH. (2005) Innate and adaptive immunity: the yin and yang of celiac 
disease. Immunol Rev. 206:219-231. 
Janatuinen EK, Pikkarainen PH, Kemppainen TA, Kosma VM, Järvinen RM, Uusitupa MI and 
Julkunen RJ. (1995) A comparison of diets with and without oats in adults with celiac disease. N 
Engl J Med. 333:1033-1037. 
Janatuinen EK, Kemppainen TA, Pikkarainen PH, Holm KH, Kosma VM, Uusitupa MI, Mäki M and 
Julkunen RJ. (2000) Lack of cellular and humoral immunological responses to oats in adults with 
coeliac disease. Gut. 46:327-331. 
Janatuinen EK, Kemppainen TA, Julkunen RJ, Kosma VM, Mäki M, Heikkinen M and Uusitupa MI. 
(2002) No harm from five year ingestion of oats in coeliac disease. Gut. 50:332-335. 
Järvinen TT, Kaukinen K, Laurila K, Kyrönpalo S, Rasmussen M, Mäki M, Korhonen H, Reunala T 
and Collin P. (2003) Intraepithelial lymphocytes in celiac disease. Am J Gastroenterol. 98:1332-
1337. 
Järvinen TT, Collin P, Rasmussen M, Kyrönpalo S, Mäki M, Partanen J, Reunala T and Kaukinen K. 
(2004) Villous tip intraepithelial lymphocytes as markers of early-stage coeliac disease. Scand J 
Gastroenterol. 39:428-433. 
Jenkins D, Goodall A and Scott BB. (1986) T-lymphocyte populations in normal and coeliac small 
intestinal mucosa defined by monoclonal antibodies. Gut. 27:1330-1337. 
Jos J and Labbe F. (1976) Ultrastructural localization of IgA globulins in normal and coeliac 
intestinal mucosa using immunoenzymatic methods. Biomedicine. 24:425-434. 
Jos J, Labbe F, Geny B and Griscelli C. (1979) Immunoelectron-microscopic localization of 
immunoglobulin A and secretory component in jejunal mucosa from children with coeliac 
disease. Scand J Immunol. 9:441-450. 
Kagnoff MF, Austin RK, Hubert JJ, Bernardin JE and Kasarda DD. (1984) Possible role for a human 
adenovirus in the pathogenesis of celiac disease. J Exp Med. 160:1544-1557. 
Kagnoff MF. (2007) Celiac disease: pathogenesis of a model immunogenetic disease. J Clin Invest. 
117:41-49. 
Karell K, Louka AS, Moodie SJ, Ascher H, Clot F, Greco L, Ciclitira PJ, Sollid LM, Partanen J and 
European Genetics Cluster on Celiac Disease. (2003) HLA types in celiac disease patients not 
carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics 
Cluster on Celiac Disease. Hum Immunol. 64:469-477. 
Karinen H, Kärkkäinen P, Pihlajamäki J, Janatuinen E, Heikkinen M, Julkunen R, Kosma VM, 
Naukkarinen A and Laakso M. (2006) Gene dose effect of the DQB1*0201 allele contributes to 
severity of coeliac disease. Scand J Gastroenterol. 41:191-199. 
Karpati S, Kosnai I, Torok E and Kovacs JB. (1988) Immunoglobulin A deposition in jejunal mucosa 
of children with dermatitis herpetiformis. J Invest Dermatol. 91:336-339. 
Kaukinen K, Collin P, Holm K, Rantala I, Vuolteenaho N, Reunala T and Mäki M. (1999) Wheat 
starch-containing gluten-free flour products in the treatment of coeliac disease and dermatitis 
herpetiformis. A long-term follow-up study. Scand J Gastroenterol. 34:163-169. 
Kaukinen K, Mäki M, Partanen J, Sievänen H and Collin P. (2001) Celiac disease without villous 
atrophy: revision of criteria called for. Dig Dis Sci. 46:879-887. 
Kaukinen K, Halme L, Collin P, Färkkilä M, Mäki M, Vehmanen P, Partanen J and Hockerstedt K. 
(2002a) Celiac disease in patients with severe liver disease: gluten-free diet may reverse hepatic 
failure. Gastroenterology. 122:881-888. 
Kaukinen K, Sulkanen S, Mäki M and Collin P. (2002b) IgA-class transglutaminase antibodies in 
evaluating the efficacy of gluten-free diet in coeliac disease. Eur J Gastroenterol Hepatol. 14:311-
315. 
Kaukinen K, Peräaho M, Collin P, Partanen J, Woolley N, Kaartinen T, Nuutinen T, Halttunen T, 
Mäki M and Korponay-Szabo I. (2005) Small-bowel mucosal transglutaminase 2-specific IgA 
deposits in coeliac disease without villous atrophy: a prospective and randomized clinical study. 
Scand J Gastroenterol. 40:564-572. 
Kaukinen K, Collin P, Laurila K, Kaartinen T, Partanen J and Mäki M. (2007a) Resurrection of 
gliadin antibodies in coeliac disease. Deamidated gliadin peptide antibody test provides additional 
diagnostic benefit. Scand J Gastroenterol. 42:1428-1433. 
Kaukinen K, Peräaho M, Lindfors K, Partanen J, Woolley N, Pikkarainen P, Karvonen AL, Laasanen 
T, Sievänen H, Mäki M and Collin P. (2007b) Persistent small bowel mucosal villous atrophy 
without symptoms in coeliac disease. Aliment Pharmacol Ther. 25:1237-1245. 
82 
 
Kemppainen T, Kroger H, Janatuinen E, Arnala I, Kosma VM, Pikkarainen P, Julkunen R, Jurvelin J, 
Alhava E and Uusitupa M. (1999a) Osteoporosis in adult patients with celiac disease. Bone. 
24:249-255. 
Kemppainen T, Kroger H, Janatuinen E, Arnala I, Lamberg-Allardt C, Kärkkäinen M, Kosma VM, 
Julkunen R, Jurvelin J, Alhava E and Uusitupa M. (1999b) Bone recovery after a gluten-free diet: 
a 5-year follow-up study. Bone. 25:355-360. 
Kilmartin C, Lynch S, Abuzakouk M, Wieser H and Feighery C. (2003) Avenin fails to induce a Th1 
response in coeliac tissue following in vitro culture. Gut. 52:47-52. 
Kiraly R, Vecsei Z, Demenyi T, Korponay-Szabo IR and Fesus L. (2006) Coeliac autoantibodies can 
enhance transamidating and inhibit GTPase activity of tissue transglutaminase: dependence on 
reaction environment and enzyme fitness. J Autoimmun. 26:278-287. 
Kolho KL and Savilahti E. (1997) IgA endomysium antibodies on human umbilical cord: an 
excellent diagnostic tool for celiac disease in childhood. J Pediatr Gastroenterol Nutr. 24:563-
567. 
Kondrashova A, Mustalahti K, Kaukinen K, Viskari H, Volodicheva V, Haapala AM, Ilonen J, Knip 
M, Mäki M, Hyoty H and Epivir Study Group. (2008) Lower economic status and inferior 
hygienic environment may protect against celiac disease. Ann Med. 40:223-231. 
Korponay-Szabo IR, Kovacs JB, Czinner A, Goracz G, Vamos A and Szabo T. (1999) High 
prevalence of silent celiac disease in preschool children screened with IgA/IgG antiendomysium 
antibodies. J Pediatr Gastroenterol Nutr. 28:26-30. 
Korponay-Szabo IR, Sulkanen S, Halttunen T, Maurano F, Rossi M, Mazzarella G, Laurila K, 
Troncone R and Mäki M. (2000) Tissue transglutaminase is the target in both rodent and primate 
tissues for celiac disease-specific autoantibodies. J Pediatr Gastroenterol Nutr. 31:520-527. 
Korponay-Szabo IR, Dahlbom I, Laurila K, Koskinen S, Woolley N, Partanen J, Kovacs JB, Mäki M 
and Hansson T. (2003a) Elevation of IgG antibodies against tissue transglutaminase as a 
diagnostic tool for coeliac disease in selective IgA deficiency. Gut. 52:1567-1571. 
Korponay-Szabo IR, Laurila K, Szondy Z, Halttunen T, Szalai Z, Dahlbom I, Rantala I, Kovacs JB, 
Fesus L and Mäki M. (2003b) Missing endomysial and reticulin binding of coeliac antibodies in 
transglutaminase 2 knockout tissues. Gut. 52:199-204. 
Korponay-Szabo IR, Halttunen T, Szalai Z, Laurila K, Kiraly R, Kovacs JB, Fesus L and Mäki M. 
(2004) In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac 
autoantibodies. Gut. 53:641-648. 
Kotze LM. (2004) Gynecologic and obstetric findings related to nutritional status and adherence to a 
gluten-free diet in Brazilian patients with celiac disease. J Clin Gastroenterol. 38:567-574. 
Kuitunen P, Kosnai I and Savilahti E. (1982) Morphometric study of the jejunal mucosa in various 
childhood enteropathies with special reference to intraepithelial lymphocytes. J Pediatr 
Gastroenterol Nutr. 1:525-531. 
Kurppa K, Koskinen O, Collin P, Mäki M, Reunala T and Kaukinen K. (2008) Changing phenotype 
of celiac disease after long-term gluten exposure. J Pediatr Gastroenterol Nutr. 47:500-503. 
Kurppa K, Collin P, Viljamaa M, Haimila K, Saavalainen P, Partanen J, Laurila K, Huhtala H, 
Paasikivi K, Mäki M and Kaukinen K. (2009) Diagnosing mild enteropathy celiac disease: a 
randomized, controlled clinical study. Gastroenterology. 136:816-823. 
Kutlu T, Brousse N, Rambaud C, Le Deist F, Schmitz J and Cerf-Bensussan N. (1993) Numbers of T 
cell receptor (TCR) alpha beta+ but not of TcR gamma delta+ intraepithelial lymphocytes 
correlate with the grade of villous atrophy in coeliac patients on a long term normal diet. Gut. 
34:208-214. 
Lancaster-Smith M, Packer S, Kumar PJ and Harries JT. (1976) Immunological phenomena in the 
jejunum and serum after reintroduction of dietary gluten in children with treated coeliac disease. J 
Clin Pathol. 29:592-597. 
Lancaster-Smith M, Joyce S and Kumar P. (1977) Immunoglobulins in the jejunal mucosa in adult 
coeliac disease and dermatitis herpetiformis after the reintroduction of dietary gluten. Gut. 
18:887-891. 
Leffler DA, Dennis M, Hyett B, Kelly E, Schuppan D and Kelly CP. (2007) Etiologies and predictors 
of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol. 5:445-450. 
Lepore L, Martelossi S, Pennesi M, Falcini F, Ermini ML, Ferrari R, Perticarari S, Presani G, 
Lucchesi A, Lapini M and Ventura A. (1996) Prevalence of celiac disease in patients with 
juvenile chronic arthritis. J Pediatr. 129:311-313. 
83 
 
Lindberg T, Nilsson LA, Borulf S, Cavell B, Fallstrom SP, Jansson U, Stenhammar L and Stintzing 
G. (1985) Serum IgA and IgG gliadin antibodies and small intestinal mucosal damage in children. 
J Pediatr Gastroenterol Nutr. 4:917-922. 
Liu J, Juo SH, Holopainen P, Terwilliger J, Tong X, Grunn A, Brito M, Green P, Mustalahti K, Mäki 
M, Gilliam TC and Partanen J. (2002) Genomewide linkage analysis of celiac disease in Finnish 
families. Am J Hum Genet. 70:51-59. 
Logan RF, Rifkind EA, Busuttil A, Gilmour HM and Ferguson A. (1986) Prevalence and "incidence" 
of celiac disease in Edinburgh and the Lothian region of Scotland. Gastroenterology. 90:334-342. 
Lohi S, Mustalahti K, Kaukinen K, Laurila K, Collin P, Rissanen H, Lohi O, Bravi E, Gasparin M, 
Reunanen A and Mäki M. (2007) Increasing prevalence of coeliac disease over time. Aliment 
Pharmacol Ther. 26:1217-1225. 
Luft LM, Barr SG, Martin LO, Chan EK and Fritzler MJ. (2003) Autoantibodies to tissue 
transglutaminase in Sjogren's syndrome and related rheumatic diseases. J Rheumatol. 30:2613-
2619. 
Lundin KE, Nilsen EM, Scott HG, Loberg EM, Gjoen A, Bratlie J, Skar V, Mendez E, Lovik A and 
Kett K. (2003) Oats induced villous atrophy in coeliac disease. Gut. 52:1649-1652. 
Luostarinen L, Pirttila T and Collin P. (1999) Coeliac disease presenting with neurological disorders. 
Eur Neurol. 42:132-135. 
Maglio M, Florian F, Vecchiet M, Auricchio R, Paparo F, Spadaro R, Zanzi D, Rapacciuolo L, 
Franzese A, Sblattero D, Marzari R and Troncone R. (2009) The great majority of children with 
type 1 diabetes produce and deposit anti-tissue transglutaminase antibodies in the small intestine. 
Diabetes. 58:1578-1584. 
Maglio M, Tosco A, Paparo F, Auricchio R, Granata V, Colicchio B, Indolfi V, Miele E and 
Troncone R. (2010) Serum and Intestinal Celiac Disease-associated Antibodies in Children With 
Celiac Disease Younger Than 2 Years of Age. J Pediatr Gastroenterol Nutr. 50:43-8. 
Mahadeva S, Wyatt JI and Howdle PD. (2002) Is a raised intraepithelial lymphocyte count with 
normal duodenal villous architecture clinically relevant? J Clin Pathol. 55:424-428. 
Maiuri L, Ciacci C, Vacca L, Ricciardelli I, Auricchio S, Quaratino S and Londei M. (2001) IL-15 
drives the specific migration of CD94+ and TCR-gammadelta+ intraepithelial lymphocytes in 
organ cultures of treated celiac patients. Am J Gastroenterol. 96:150-156. 
Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Auricchio S, Picard J, Osman M, Quaratino S 
and Londei M. (2003) Association between innate response to gliadin and activation of 
pathogenic T cells in coeliac disease. Lancet. 362:30-37. 
Mankai A, Sakly W, Landolsi H, Gueddah L, Sriha B, Ayadi A, Sfar MT, Skandrani K, Harbi A, 
Essoussi AS, Korbi S, Fabien N, Jeddi M and Ghedira I. (2005) Tissue transglutaminase 
antibodies in celiac disease, comparison of an enzyme linked immunosorbent assay and a dot blot 
assay. Pathol Biol (Paris). 53:204-209. 
Mankai A, Ben Hamouda H, Amri F, Ghedira-Besbes L, Harbi A, Tahar Sfar M, Sahloul Essoussi A, 
Jeddi M and Ghedira I. (2007) Screening by anti-endomysium antibodies for celiac disease in 
Tunisian children with type 1 diabetes mellitus. Gastroenterol Clin Biol. 31:462-466. 
Marsh MN. (1992) Gluten, major histocompatibility complex, and the small intestine. A molecular 
and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). 
Gastroenterology. 102:330-354. 
Martinelli P, Troncone R, Paparo F, Torre P, Trapanese E, Fasano C, Lamberti A, Budillon G, 
Nardone G and Greco L. (2000) Coeliac disease and unfavourable outcome of pregnancy. Gut. 
46:332-335. 
Marzari R, Sblattero D, Florian F, Tongiorgi E, Not T, Tommasini A, Ventura A and Bradbury A. 
(2001) Molecular dissection of the tissue transglutaminase autoantibody response in celiac 
disease. J Immunol. 166:4170-4176. 
Matysiak-Budnik T, Malamut G, de Serre NP, Grosdidier E, Seguier S, Brousse N, Caillat-Zucman 
S, Cerf-Bensussan N, Schmitz J and Cellier C. (2007) Long-term follow-up of 61 coeliac patients 
diagnosed in childhood: evolution toward latency is possible on a normal diet. Gut. 56:1379-
1386. 
Mawhinney H and Love AH. (1975) Anti-reticulin antibody in jejunal juice in coeliac disease. Clin 
Exp Immunol. 21:394-398. 
Meloni GF, Tomasi PA, Bertoncelli A, Fanciulli G, Delitala G and Meloni T. (2001) Prevalence of 
silent celiac disease in patients with autoimmune thyroiditis from Northern Sardinia. J Endocrinol 
Invest. 24:298-302. 
84 
 
Memeo L, Jhang J, Hibshoosh H, Green PH, Rotterdam H and Bhagat G. (2005) Duodenal 
intraepithelial lymphocytosis with normal villous architecture: common occurrence in H. pylori 
gastritis. Mod Pathol. 18:1134-1144. 
Mention JJ, Ben Ahmed M, Begue B, Barbe U, Verkarre V, Asnafi V, Colombel JF, Cugnenc PH, 
Ruemmele FM, McIntyre E, Brousse N, Cellier C and Cerf-Bensussan N. (2003) Interleukin 15: a 
key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. 
Gastroenterology. 125:730-745. 
Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, Raulet DH, Lanier LL, Groh 
V, Spies T, Ebert EC, Green PH and Jabri B. (2004) Coordinated induction by IL15 of a TCR-
independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in 
celiac disease. Immunity. 21:357-366. 
Meyer D, Stavropolous S, Diamond B, Shane E and Green PH. (2001) Osteoporosis in a north 
american adult population with celiac disease. Am J Gastroenterol. 96:112-119. 
Molberg O, Mcadam SN, Korner R, Quarsten H, Kristiansen C, Madsen L, Fugger L, Scott H, Noren 
O, Roepstorff P, Lundin KE, Sjostrom H and Sollid LM. (1998) Tissue transglutaminase 
selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. 
Nat Med. 4:713-717. 
Monsuur AJ, de Bakker PI, Alizadeh BZ, Zhernakova A, Bevova MR, Strengman E, Franke L, van't 
Slot R, van Belzen MJ, Lavrijsen IC, Diosdado B, Daly MJ, Mulder CJ, Mearin ML, Meijer JW, 
Meijer GA, van Oort E, Wapenaar MC, Koeleman BP and Wijmenga C. (2005) Myosin IXB 
variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. 
Nat Genet. 37:1341-1344. 
Murray JA, Moore SB, Van Dyke CT, Lahr BD, Dierkhising RA, Zinsmeister AR, Melton LJ,3rd, 
Kroning CM, El-Yousseff M and Czaja AJ. (2007) HLA DQ gene dosage and risk and severity of 
celiac disease. Clin Gastroenterol Hepatol. 5:1406-1412. 
Mustalahti K, Collin P, Sievänen H, Salmi J and Mäki M. (1999) Osteopenia in patients with 
clinically silent coeliac disease warrants screening. Lancet. 354:744-745. 
Mustalahti K, Lohiniemi S, Collin P, Vuolteenaho N, Laippala P and Mäki M. (2002a) Gluten-free 
diet and quality of life in patients with screen-detected celiac disease. Eff Clin Pract. 5:105-113. 
Mustalahti K, Sulkanen S, Holopainen P, Laurila K, Collin P, Partanen J and Mäki M. (2002b) 
Coeliac disease among healthy members of multiple case coeliac disease families. Scand J 
Gastroenterol. 37:161-165. 
Myhre AG, Aarsetoy H, Undlien DE, Hovdenak N, Aksnes L and Husebye ES. (2003) High 
frequency of coeliac disease among patients with autoimmune adrenocortical failure. Scand J 
Gastroenterol. 38:511-515. 
Myleus A, Ivarsson A, Webb C, Danielsson L, Hernell O, Högberg L, Karlsson E, Lagerqvist C, 
Norstrom F, Rosen A, Sandstrom O, Stenhammar L, Stenlund H, Wall S and Carlsson A. (2009) 
Celiac Disease Revealed in 3% of Swedish 12-year-olds Born During an Epidemic. J Pediatr 
Gastroenterol Nutr. 49:170-176. 
Mylotte M, Egan-Mitchell B, McCarthy CF and McNicholl B. (1973) Incidence of coeliac disease in 
the West of Ireland. Br Med J. 1:703-705. 
Myrsky E, Kaukinen K, Syrjänen M, Korponay-Szabo IR, Mäki M and Lindfors K. (2008) Coeliac 
disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis. Clin Exp 
Immunol. 152:111-119. 
Myrsky E, Caja S, Simon-Vecsei Z, Korponay-Szabo IR, Nadalutti C, Collighan R, Mongeot A, 
Griffin M, Mäki M, Kaukinen K and Lindfors K. (2009) Celiac disease IgA modulates vascular 
permeability in vitro through the activity of transglutaminase 2 and RhoA. Cell Mol Life Sci. 
66:3375-3385. 
Mäki M and Collin P. (1997) Coeliac disease. Lancet. 349:1755-1759. 
Mäki M, Hällström O, Huupponen T, Vesikari T and Visakorpi JK. (1984a) Increased prevalence of 
coeliac disease in diabetes. Arch Dis Child. 59:739-742. 
Mäki M, Hällström O, Vesikari T and Visakorpi JK. (1984b) Evaluation of a serum IgA-class 
reticulin antibody test for the detection of childhood celiac disease. J Pediatr. 105:901-905. 
Mäki M, Kallonen K, Lahdeaho ML and Visakorpi JK. (1988) Changing pattern of childhood coeliac 
disease in Finland. Acta Paediatr Scand. 77:408-412. 
Mäki M, Holm K, Collin P and Savilahti E. (1991a) Increase in gamma/delta T cell receptor bearing 
lymphocytes in normal small bowel mucosa in latent coeliac disease. Gut. 32:1412-1414. 
85 
 
Mäki M, Holm K, Lipsanen V, Hällström O, Viander M, Collin P, Savilahti E and Koskimies S. 
(1991b) Serological markers and HLA genes among healthy first-degree relatives of patients with 
coeliac disease. Lancet. 338:1350-1353. 
Mäki M, Mustalahti K, Kokkonen J, Kulmala P, Haapalahti M, Karttunen T, Ilonen J, Laurila K, 
Dahlbom I, Hansson T, Hopfl P and Knip M. (2003) Prevalence of Celiac disease among children 
in Finland. N Engl J Med. 348:2517-2524. 
Nilsen EM, Lundin KE, Krajci P, Scott H, Sollid LM and Brandtzaeg P. (1995) Gluten specific, 
HLA-DQ restricted T cells from coeliac mucosa produce cytokines with Th1 or Th0 profile 
dominated by interferon gamma. Gut. 37:766-776. 
Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fiedler PT and Messias-Reason IT. (2005) 
Celiac disease in children and adolescents with Down syndrome. J Pediatr (Rio J). 81:373-376. 
Nistico L, Fagnani C, Coto I, Percopo S, Cotichini R, Limongelli MG, Paparo F, D'Alfonso S, 
Giordano M, Sferlazzas C, Magazzu G, Momigliano-Richiardi P, Greco L and Stazi MA. (2006) 
Concordance, disease progression, and heritability of coeliac disease in Italian twins. Gut. 
55:803-808. 
Not T, Tommasini A, Tonini G, Buratti E, Pocecco M, Tortul C, Valussi M, Crichiutti G, Berti I, 
Trevisiol C, Azzoni E, Neri E, Torre G, Martelossi S, Soban M, Lenhardt A, Cattin L and 
Ventura A. (2001) Undiagnosed coeliac disease and risk of autoimmune disorders in subjects 
with Type I diabetes mellitus. Diabetologia. 44:151-155. 
O'Leary C, Walsh CH, Wieneke P, O'Regan P, Buckley B, O'Halloran DJ, Ferriss JB, Quigley EM, 
Annis P, Shanahan F and Cronin CC. (2002) Coeliac disease and autoimmune Addison's disease: 
a clinical pitfall. QJM. 95:79-82. 
Oliveira RP, Sdepanian VL, Barreto JA, Cortez AJ, Carvalho FO, Bordin JO, de Camargo Soares 
MA, da Silva Patricio FR, Kawakami E, de Morais MB and Fagundes-Neto U. (2007) High 
prevalence of celiac disease in Brazilian blood donor volunteers based on screening by IgA 
antitissue transglutaminase antibody. Eur J Gastroenterol Hepatol. 19:43-49. 
Olmos M, Antelo M, Vazquez H, Smecuol E, Maurino E and Bai JC. (2008) Systematic review and 
meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Dig Liver 
Dis. 40:46-53. 
O'Mahony S, Vestey JP and Ferguson A. (1990) Similarities in intestinal humoral immunity in 
dermatitis herpetiformis without enteropathy and in coeliac disease. Lancet. 335:1487-1490. 
O'Mahony S, Arranz E, Barton JR and Ferguson A. (1991) Dissociation between systemic and 
mucosal humoral immune responses in coeliac disease. Gut. 32:29-35. 
O'Mahony S, Howdle PD and Losowsky MS. (1996) Review article: management of patients with 
non-responsive coeliac disease. Aliment Pharmacol Ther. 10:671-680. 
O'Shea U, Abuzakouk M, O'Morain C, O'Donoghue D, Sheahan K, Watson P, O'Briain S, Alexander 
D, Catherwood M, Jackson J, Kelly J and Feighery C. (2008) Investigation of molecular markers 
in the diagnosis of refractory coeliac disease in a large patient cohort. J Clin Pathol. 61:1200-
1202. 
Paterson BM, Lammers KM, Arrieta MC, Fasano A and Meddings JB. (2007) The safety, tolerance, 
pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease 
subjects: a proof of concept study. Aliment Pharmacol Ther. 26:757-766. 
Paulley JW. (1954) Observation on the aetiology of idiopathic steatorrhoea; jejunal and lymph-node 
biopsies. Br Med J. 2:1318-1321. 
Peltola M, Kaukinen K, Dastidar P, Haimila K, Partanen J, Haapala AM, Mäki M, Keränen T and 
Peltola J. (2009) Hippocampal sclerosis in refractory temporal lobe epilepsy is associated with 
gluten sensitivity. J Neurol Neurosurg Psychiatry. 80:626-630. 
Pender SL, Tickle SP, Docherty AJ, Howie D, Wathen NC and MacDonald TT. (1997) A major role 
for matrix metalloproteinases in T cell injury in the gut. J Immunol. 158:1582-1590. 
Peräaho M, Kaukinen K, Mustalahti K, Vuolteenaho N, Mäki M, Laippala P and Collin P. (2004) 
Effect of an oats-containing gluten-free diet on symptoms and quality of life in coeliac disease. A 
randomized study. Scand J Gastroenterol. 39:27-31. 
Perkkiö M, Savilahti E and Kuitunen P. (1981) Semi-quantitative analysis of immunoglobulins and 
complement fractions 3 and 4 in the jejunal mucosa in coeliac disease and in food allergy in 
childhood. Immunohistochemical study by light and electron microscopy. Acta Pathol Microbiol 
Scand A. 89:343-350. 
Picarelli A, Maiuri L, Frate A, Greco M, Auricchio S and Londei M. (1996) Production of 
antiendomysial antibodies after in-vitro gliadin challenge of small intestine biopsy samples from 
patients with coeliac disease. Lancet. 348:1065-1067. 
86 
 
Picarelli A, Di Tola M, Sabbatella L, Gabrielli F, Di Cello T, Anania MC, Mastracchio A, Silano M 
and De Vincenzi M. (2001) Immunologic evidence of no harmful effect of oats in celiac disease. 
Am J Clin Nutr. 74:137-140. 
Reeves GE, Squance ML, Duggan AE, Murugasu RR, Wilson RJ, Wong RC, Gibson RA, Steele RH 
and Pollock WK. (2006) Diagnostic accuracy of coeliac serological tests: a prospective study. Eur 
J Gastroenterol Hepatol. 18:493-501. 
Remes-Troche JM, Rios-Vaca A, Ramirez-Iglesias MT, Rubio-Tapia A, Andrade-Zarate V, 
Rodriguez-Vallejo F, Lopez-Maldonado F, Gomez-Perez FJ and Uscanga LF. (2008) High 
prevalence of celiac disease in Mexican Mestizo adults with type 1 diabetes mellitus. J Clin 
Gastroenterol. 42:460-465. 
Ress K, Harro M, Maaroos HI, Harro J, Uibo R and Uibo O. (2007) High prevalence of coeliac 
disease: need for increasing awareness among physicians. Dig Liver Dis. 39:136-139. 
Reunala T, Kosnai I, Karpati S, Kuitunen P, Torok E and Savilahti E. (1984) Dermatitis 
herpetiformis: jejunal findings and skin response to gluten free diet. Arch Dis Child. 59:517-522. 
Reunala T, Collin P, Holm K, Pikkarainen P, Miettinen A, Vuolteenaho N and Mäki M. (1998) 
Tolerance to oats in dermatitis herpetiformis. Gut. 43:490-493. 
Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC and Jabri B. (2001) NKG2D receptors 
induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment. J 
Immunol. 167:5527-5530. 
Roka V, Potamianos SP, Kapsoritakis AN, Yiannaki EE, Koukoulis GN, Stefanidis I, Koukoulis GK 
and Germenis AE. (2007) Prevalence of coeliac disease in the adult population of central Greece. 
Eur J Gastroenterol Hepatol. 19:982-987. 
Rostami K, Kerckhaert J, Tiemessen R, von Blomberg BM, Meijer JW and Mulder CJ. (1999) 
Sensitivity of antiendomysium and antigliadin antibodies in untreated celiac disease: 
disappointing in clinical practice. Am J Gastroenterol. 94:888-894. 
Rubio-Tapia A, Van Dyke CT, Lahr BD, Zinsmeister AR, El-Youssef M, Moore SB, Bowman M, 
Burgart LJ, Melton LJ,3rd and Murray JA. (2008) Predictors of family risk for celiac disease: a 
population-based study. Clin Gastroenterol Hepatol. 6:983-987. 
Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT and Murray JA. (2009a) Clinical staging and 
survival in refractory celiac disease: a single center experience. Gastroenterology. 136:99-107;. 
Rubio-Tapia A, Kyle RA, Kaplan EL, Johnson DR, Page W, Erdtmann F, Brantner TL, Kim WR, 
Phelps TK, Lahr BD, Zinsmeister AR, Melton LJ,3rd and Murray JA. (2009b) Increased 
prevalence and mortality in undiagnosed celiac disease. Gastroenterology. 137:88-93. 
Salmi TT, Collin P, Järvinen O, Haimila K, Partanen J, Laurila K, Korponay-Szabo IR, Huhtala H, 
Reunala T, Mäki M and Kaukinen K. (2006a) Immunoglobulin A autoantibodies against 
transglutaminase 2 in the small intestinal mucosa predict forthcoming coeliac disease. Aliment 
Pharmacol Ther. 24:541-552. 
Salmi TT, Collin P, Korponay-Szabo IR, Laurila K, Partanen J, Huhtala H, Kiraly R, Lorand L, 
Reunala T, Mäki M and Kaukinen K. (2006b) Endomysial antibody-negative coeliac disease: 
clinical characteristics and intestinal autoantibody deposits. Gut. 55:1746-1753. 
Sardy M, Karpati S, Merkl B, Paulsson M and Smyth N. (2002) Epidermal transglutaminase (TGase 
3) is the autoantigen of dermatitis herpetiformis. J Exp Med. 195:747-757. 
Sategna Guidetti C, Solerio E, Scaglione N, Aimo G and Mengozzi G. (2001) Duration of gluten 
exposure in adult coeliac disease does not correlate with the risk for autoimmune disorders. Gut. 
49:502-505. 
Savilahti E. (1972) Intestinal immunoglobulins in children with coeliac disease. Gut. 13:958-964. 
Savilahti E, Arato A and Verkasalo M. (1990) Intestinal gamma/delta receptor-bearing T 
lymphocytes in celiac disease and inflammatory bowel diseases in children. Constant increase in 
celiac disease. Pediatr Res. 28:579-581. 
Savilahti E, Reunala T and Mäki M. (1992) Increase of lymphocytes bearing the gamma/delta T cell 
receptor in the jejunum of patients with dermatitis herpetiformis. Gut. 33:206-211. 
Selby PL, Davies M, Adams JE and Mawer EB. (1999) Bone loss in celiac disease is related to 
secondary hyperparathyroidism. J Bone Miner Res. 14:652-657. 
Selby WS, Janossy G, Bofill M and Jewell DP. (1983) Lymphocyte subpopulations in the human 
small intestine. The findings in normal mucosa and in the mucosa of patients with adult coeliac 
disease. Clin Exp Immunol. 52:219-228. 
Shiner M. (1973) Ultrastructural changes suggestive of immune reactions in the jejunal mucosa of 
coeliac children following gluten challenge. Gut. 14:1-12. 
87 
 
Shiner M and Ballard J. (1972) Antigen-antibody reactions in jejunal mucosa in childhood coeliac 
disease after gluten challenge. Lancet. 1:1202-1205. 
Shmerling DH and Franckx J. (1986) Childhood celiac disease: a long-term analysis of relapses in 91 
patients. J Pediatr Gastroenterol Nutr. 5:565-569. 
Siegel M, Xia J and Khosla C. (2007) Structure-based design of alpha-amido aldehyde containing 
gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg Med Chem. 
15:6253-6261. 
Sigurgeirsson B, Agnarsson BA and Lindelof B. (1994) Risk of lymphoma in patients with dermatitis 
herpetiformis. BMJ. 308:13-15. 
Sollid LM, Markussen G, Ek J, Gjerde H, Vartdal F and Thorsby E. (1989) Evidence for a primary 
association of celiac disease to a particular HLA-DQ alpha/beta heterodimer. J Exp Med. 
169:345-350. 
Sollid LM, Molberg O, McAdam S and Lundin KE. (1997) Autoantibodies in coeliac disease: tissue 
transglutaminase--guilt by association? Gut. 41:851-852. 
Spencer J, Isaacson PG, MacDonald TT, Thomas AJ and Walker-Smith JA. (1991) Gamma/delta T 
cells and the diagnosis of coeliac disease. Clin Exp Immunol. 85:109-113. 
Spurkland A, Ingvarsson G, Falk ES, Knutsen I, Sollid LM and Thorsby E. (1997) Dermatitis 
herpetiformis and celiac disease are both primarily associated with the HLA-DQ (alpha 1*0501, 
beta 1*02) or the HLA-DQ (alpha 1*03, beta 1*0302) heterodimers. Tissue Antigens. 49:29-34. 
Srinivasan U, Leonard N, Jones E, Kasarda DD, Weir DG, O'Farrelly C and Feighery C. (1996) 
Absence of oats toxicity in adult coeliac disease. BMJ. 313:1300-1301. 
Srinivasan U, Jones E, Carolan J and Feighery C. (2006) Immunohistochemical analysis of coeliac 
mucosa following ingestion of oats. Clin Exp Immunol. 144:197-203. 
Stagi S, Giani T, Simonini G and Falcini F. (2005) Thyroid function, autoimmune thyroiditis and 
coeliac disease in juvenile idiopathic arthritis. Rheumatology (Oxford). 44:517-520. 
Stene LC, Honeyman MC, Hoffenberg EJ, Haas JE, Sokol RJ, Emery L, Taki I, Norris JM, Erlich 
HA, Eisenbarth GS and Rewers M. (2006) Rotavirus infection frequency and risk of celiac 
disease autoimmunity in early childhood: a longitudinal study. Am J Gastroenterol. 101:2333-
2340. 
Stenman SM, Lindfors K, Korponay-Szabo IR, Lohi O, Saavalainen P, Partanen J, Haimila K, 
Wieser H, Mäki M and Kaukinen K. (2008) Secretion of celiac disease autoantibodies after in 
vitro gliadin challenge is dependent on small-bowel mucosal transglutaminase 2-specific IgA 
deposits. BMC Immunol. 9:6. 
Stenman SM, Venalainen JI, Lindfors K, Auriola S, Mauriala T, Kaukovirta-Norja A, Jantunen A, 
Laurila K, Qiao SW, Sollid LM, Mannisto PT, Kaukinen K and Mäki M. (2009) Enzymatic 
detoxification of gluten by germinating wheat proteases: implications for new treatment of celiac 
disease. Ann Med. 41:390-400. 
Storsrud S, Hulthen LR and Lenner RA. (2003a) Beneficial effects of oats in the gluten-free diet of 
adults with special reference to nutrient status, symptoms and subjective experiences. Br J Nutr. 
90:101-107. 
Storsrud S, Malmheden Yman I and Lenner RA. (2003b) Gluten contamination in oat products and 
products naturally free from gluten. Eur Food Res Technol. 317:481-485. 
Storsrud S, Olsson M, Arvidsson Lenner R, Nilsson LA, Nilsson O and Kilander A. (2003c) Adult 
coeliac patients do tolerate large amounts of oats. Eur J Clin Nutr. 57:163-169. 
Sulkanen S, Collin P, Laurila K and Mäki M. (1998) IgA- and IgG-class antihuman umbilical cord 
antibody tests in adult coeliac disease. Scand J Gastroenterol. 33:251-254. 
Swinson CM, Slavin G, Coles EC and Booth CC. (1983) Coeliac disease and malignancy. Lancet. 
1:111-115. 
Szodoray P, Barta Z, Lakos G, Szakall S and Zeher M. (2004) Coeliac disease in Sjogren's 
syndrome--a study of 111 Hungarian patients. Rheumatol Int. 24:278-282. 
Teesalu K, Uibo O, Kalkkinen N, Janmey P and Uibo R. (2001) Increased levels of IgA antibodies 
against desmin in children with coeliac disease. Int Arch Allergy Immunol. 126:157-166. 
Tikkakoski S, Savilahti E and Kolho KL. (2007) Undiagnosed coeliac disease and nutritional 
deficiencies in adults screened in primary health care. Scand J Gastroenterol. 42:60-65. 
Tommasini A, Not T, Kiren V, Baldas V, Santon D, Trevisiol C, Berti I, Neri E, Gerarduzzi T, Bruno 
I, Lenhardt A, Zamuner E, Spano A, Crovella S, Martellossi S, Torre G, Sblattero D, Marzari R, 
Bradbury A, Tamburlini G and Ventura A. (2004) Mass screening for coeliac disease using 
antihuman transglutaminase antibody assay. Arch Dis Child. 89:512-515. 
88 
 
Tosco A, Maglio M, Paparo F, Rapacciuolo L, Sannino A, Miele E, Barone MV, Auricchio R and 
Troncone R. (2008) Immunoglobulin A anti-tissue transglutaminase antibody deposits in the 
small intestinal mucosa of children with no villous atrophy. J Pediatr Gastroenterol Nutr. 47:293-
298. 
Troncone R and Ferguson A. (1991) Anti-gliadin antibodies. J Pediatr Gastroenterol Nutr. 12:150-
158. 
Troncone R, Mayer M, Spagnuolo F, Maiuri L and Greco L. (1995) Endomysial antibodies as 
unreliable markers for slight dietary transgressions in adolescents with celiac disease. J Pediatr 
Gastroenterol Nutr. 21:69-72. 
Tursi A and Brandimarte G. (2003) The symptomatic and histologic response to a gluten-free diet in 
patients with borderline enteropathy. J Clin Gastroenterol. 36:13-17. 
Vader LW, Stepniak DT, Bunnik EM, Kooy YM, de Haan W, Drijfhout JW, Van Veelen PA and 
Koning F. (2003a) Characterization of cereal toxicity for celiac disease patients based on protein 
homology in grains. Gastroenterology. 125:1105-1113. 
Vader W, Stepniak D, Kooy Y, Mearin L, Thompson A, van Rood JJ, Spaenij L and Koning F. 
(2003b) The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and 
breadth of gluten-specific T cell responses. Proc Natl Acad Sci U S A. 100:12390-12395. 
Valdimarsson T, Toss G, Ross I, Lofman O and Strom M. (1994) Bone mineral density in coeliac 
disease. Scand J Gastroenterol. 29:457-461. 
Van Belzen MJ, Meijer JW, Sandkuijl LA, Bardoel AF, Mulder CJ, Pearson PL, Houwen RH and 
Wijmenga C. (2003) A major non-HLA locus in celiac disease maps to chromosome 19. 
Gastroenterology. 125:1032-1041. 
van de Kamer JH, Weijers HA and Dicke WK. (1953) Coeliac disease. IV. An investigation into the 
injurious constituents of wheat in connection with their action on patients with coeliac disease. 
Acta Paediatr. 42:223-231. 
Vasquez H, Mazure R, Gonzalez D, Flores D, Pedreira S, Niveloni S, Smecuol E, Maurino E and Bai 
JC. (2000) Risk of fractures in celiac disease patients: a cross-sectional, case-control study. Am J 
Gastroenterol. 95:183-189. 
Vecsei AK, Graf UB and Vogelsang H. (2009) Follow-up of adult celiac patients: which noninvasive 
test reflects mucosal status most reliably? Endoscopy. 41:123-128. 
Ventura A, Magazzu G and Greco L. (1999) Duration of exposure to gluten and risk for autoimmune 
disorders in patients with celiac disease. SIGEP Study Group for Autoimmune Disorders in 
Celiac Disease. Gastroenterology. 117:297-303. 
Verbeek WH, Van De Water JM, Al-Toma A, Oudejans JJ, Mulder CJ and Coupe VM. (2008a) 
Incidence of enteropathy--associated T-cell lymphoma: a nation-wide study of a population-based 
registry in The Netherlands. Scand J Gastroenterol. 43:1322-1328. 
Verbeek WH, von Blomberg BM, Scholten PE, Kuik DJ, Mulder CJ and Schreurs MW. (2008b) The 
presence of small intestinal intraepithelial gamma/delta T-lymphocytes is inversely correlated 
with lymphoma development in refractory celiac disease. Am J Gastroenterol. 103:3152-3158. 
Verkarre V, Asnafi V, Lecomte T, Patey Mariaud-de Serre N, Leborgne M, Grosdidier E, Le Bihan 
C, Macintyre E, Cellier C, Cerf-Bensussan N and Brousse N. (2003) Refractory coeliac sprue is a 
diffuse gastrointestinal disease. Gut. 52:205-211. 
Verkasalo MA, Arato A, Savilahti E and Tainio VM. (1990) Effect of diet and age on jejunal and 
circulating lymphocyte subsets in children with coeliac disease: persistence of CD4-8-
intraepithelial T cells through treatment. Gut. 31:422-425. 
Viljamaa M, Kaukinen K, Huhtala H, Kyrönpalo S, Rasmussen M and Collin P. (2005) Coeliac 
disease, autoimmune diseases and gluten exposure. Scand J Gastroenterol. 40:437-443. 
Villalta D, Girolami D, Bidoli E, Bizzaro N, Tampoia M, Liguori M, Pradella M, Tonutti E and 
Tozzoli R. (2005) High prevalence of celiac disease in autoimmune hepatitis detected by anti-
tissue tranglutaminase autoantibodies. J Clin Lab Anal. 19:6-10. 
Vilppula A, Kaukinen K, Luostarinen L, Krekela I, Patrikainen H, Valve R, Mäki M and Collin P. 
(2009) Increasing prevalence and high incidence of celiac disease in elderly people: a population-
based study. BMC Gastroenterol. 9:49. 
Vogelsang H, Hanel S, Steiner B and Oberhuber G. (2001) Diagnostic duodenal bulb biopsy in celiac 
disease. Endoscopy. 33:336-340. 
Volta U, De Franceschi L, Molinaro N, Cassani F, Muratori L, Lenzi M, Bianchi FB and Czaja AJ. 
(1998) Frequency and significance of anti-gliadin and anti-endomysial antibodies in autoimmune 
hepatitis. Dig Dis Sci. 43:2190-2195. 
89 
 
Volta U, Granito A, De Franceschi L, Petrolini N and Bianchi FB. (2001a) Anti tissue 
transglutaminase antibodies as predictors of silent coeliac disease in patients with 
hypertransaminasaemia of unknown origin. Dig Liver Dis. 33:420-425. 
Volta U, Ravaglia G, Granito A, Forti P, Maioli F, Petrolini N, Zoli M and Bianchi FB. (2001b) 
Coeliac disease in patients with autoimmune thyroiditis. Digestion. 64:61-65. 
Volta U, Rodrigo L, Granito A, Petrolini N, Muratori P, Muratori L, Linares A, Veronesi L, Fuentes 
D, Zauli D and Bianchi FB. (2002) Celiac disease in autoimmune cholestatic liver disorders. Am 
J Gastroenterol. 97:2609-2613. 
Volta U, Granito A, Fiorini E, Parisi C, Piscaglia M, Pappas G, Muratori P and Bianchi FB. (2008) 
Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up. 
Dig Dis Sci. 53:1582-1588. 
Wagner G, Berger G, Sinnreich U, Grylli V, Schober E, Huber WD and Karwautz A. (2008) Quality 
of life in adolescents with treated coeliac disease: influence of compliance and age at diagnosis. J 
Pediatr Gastroenterol Nutr. 47:555-561. 
Wahab PJ, Meijer JW and Mulder CJ. (2002) Histologic follow-up of people with celiac disease on a 
gluten-free diet: slow and incomplete recovery. Am J Clin Pathol. 118:459-463. 
Wahnschaffe U, Ullrich R, Riecken EO and Schulzke JD. (2001) Celiac disease-like abnormalities in 
a subgroup of patients with irritable bowel syndrome. Gastroenterology. 121:1329-1338. 
Walker-Smith JA, Guandalini S, Schmitz J, Schmerling DH and Visakorpi JK. (1990) Revised 
criteria for diagnosis of coeliac disease. Report of Working Group of European Society of 
Paediatric Gastroenterology and Nutrition. Arch Dis Child. 65:909-911. 
Weijers HA and van de Kamer JH. (1965) Some Considerations of Celiac Disease. Am J Clin Nutr. 
17:51-54. 
Weinstein WM. (1974) Latent celiac sprue. Gastroenterology. 66:489-493. 
Weiss B, Skourikhin Y, Modan-Moses D, Broide E, Fradkin A and Bujanover Y. (2008) Is adult 
height of patients with celiac disease influenced by delayed diagnosis? Am J Gastroenterol. 
103:1770-1774. 
West J, Logan RF, Smith CJ, Hubbard RB and Card TR. (2004) Malignancy and mortality in people 
with coeliac disease: population based cohort study. BMJ. 329:716-719. 
Westerlund A, Ankelo M, Simell S, Ilonen J, Knip M, Simell O and Hinkkanen AE. (2007) Affinity 
maturation of immunoglobulin A anti-tissue transglutaminase autoantibodies during development 
of coeliac disease. Clin Exp Immunol. 148:230-240. 
Wolters VM, Verbeek WH, Zhernakova A, Onland-Moret C, Schreurs MW, Monsuur AJ, Verduijn 
W, Wijmenga C and Mulder CJ. (2007) The MYO9B gene is a strong risk factor for developing 
refractory celiac disease. Clin Gastroenterol Hepatol. 5:1399-405, 1405.e1-2. 
Xia J, Bergseng E, Fleckenstein B, Siegel M, Kim CY, Khosla C and Sollid LM. (2007) Cyclic and 
dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. 
Bioorg Med Chem. 15:6565-6573. 
Young WF and Pringle EM. (1971) 110 Children with Coeliac Disease, 1950-1969. Arch Dis Child. 
46:421-436. 
Zanoni G, Navone R, Lunardi C, Tridente G, Bason C, Sivori S, Beri R, Dolcino M, Valletta E, 
Corrocher R and Puccetti A. (2006) In celiac disease, a subset of autoantibodies against 
transglutaminase binds toll-like receptor 4 and induces activation of monocytes. PLoS Med. 
3:e358. 
Zimmer KP, Fischer I, Mothes T, Weissen-Plenz G, Schmitz M, Wieser H, Mendez E, Buening J, 
Lerch MM, Ciclitira PC, Weber P and Naim HY. (2009) Endocytotic Segregation of Gliadin 
Peptide 31-49 in Enterocytes. Gut 59:300-310.  
 
90 
 
APPENDIX  
Colour figures from original articles (II-IV) 
Original article II, figure 2: At baseline, this 13-year old boy had been on a conventional gluten-free diet avoiding wheat, 
rye, barley, and oats for 2 years andevinced normal small-bowel mucosa villous morphology and negative mucosal IgA 
deposits (A). After 6 months’ gluten (wheat, rye, barley,and oats) challenge he still had normal villi, but clear IgA deposits 
were already present (B). The small-bowel mucosa relapsed after12 months with gluten, and strong IgA deposits can be seen 
(C). After adopting an oat-containing gluten-free diet the mucosal IgA deposits slowly disappeared following villous recovery 
(D), after 6 months with oats; (E), after 2 years with oats. IgA is stained in green andtransglutaminase 2 (TG2) in red; yellow 
(arrow) in composite figures indicates colocalization of coeliac-type IgA deposits and TG2. 
 
Original article II, figure 4: A 16-year-old boy developed abdominal 
symptoms immediately after ingestion of oats; small-bowel mucosal 
villous morphology remained normal and densities of CD3þ 
intraepithelial lymphocytes even decreased (from 86 cells/mm to 51 
cells/mm). Mucosal IgA deposits were negative both before (A) and 
immediately after (B) oats challenge. IgA is labelled green, 
transglutaminase 2 in red; IgA deposition or co-localization of IgA and 
TG2 (yellow) was not detected. 
 
 
 
Original article III, figure 2: Small-bowel mucosal immunofluorescence staining of IgA (green) and transglutaminase-2 
(red) from patients having untreated coeliac disease which subsequently responded well to a gluten-free diet (A), refractory 
coeliac disease patient with abnormal immunophenotype of small-bowel mucosal intraepithelial lymphocytes (B), a refractory 
coeliac patient with enteropathy-associated T cell lymphoma (C) and a patient with autoimmune enteropathy (D). 
Colocalization of IgA and TG2 is shown in yellow (arrow).  
Original article IV, figure 2: A–F, Small 
bowel mucosal immunoglobulin (Ig)A deposits 
in a 48-year-old woman having latent coeliac 
disease. The first small bowel mucosal biopsy 
(B) showed normal villous morphology, but (D) 
2 years later when she continued on a normal 
gluten-containing diet villous atrophy with crypt 
hyperplasia developed. Villous morphology (F) 
recovered on a gluten-free diet. Serum celiac 
autoantibodies were negative throughout, but 
(A) strong subepithelial tissue transglutaminase 
(TG2)-targeted IgA autoantibody deposits 
(yellow, arrow) already were present in the 
small bowel mucosa in the first biopsy, and (C) 
also when villous atrophywas detected. The 
deposits disappeared (E) with a gluten-free diet. 
G-L, Mucosal IgA deposits are shown from a 
21-year-old woman with potential coeliac 
disease having (G) normal small bowel mucosal 
architecture and strong subepithelial tissue TG2-
specific IgA deposits. After 1 year on a gluten-
free diet her symptoms recovered and IgA 
deposits disappeared (L). IgA is stained with 
green (H, J), TG2 with red (I,K), and 
colocalization of IgA and TG2 is shown in 
yellow (A,C,G). 
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challenge. # 2009 by European Society for PediatricFurthermore, serum IgA-class TG2 antibodies were measured. Gastroenterology, Hepatology, and N
Results:At baseline, serum TG2 antibodies were negative in all
utrition and North
American Society for Pediatric Gastroenterology,
Hepatology, and NutritionThe only effective treatment for coeliac disease is a
lifelong gluten-free diet that excludes all food products
containing wheat, rye, and barley. However, the necessitytoms after ingestion of oats (2,3), but more recent in vitro
and in vivo studies have questioned its toxicity (4–11).
There is now a large body of evidence to support the safe
consumption of oats in the vast majority of both children
and adults having coeliac disease and dermatitis herpe-
tiformis (4–11). Nonetheless, some concerns persist
regarding recommending oats to all coeliac patients.
The purity of oat products cannot always be guaranteed
and contamination of oats with other gluten-containing
cereals during harvesting and milling is known to occur
(12,13). Furthermore, there would appear to be a small
subset of coeliac patients who experience more abdomi-
nal symptoms while consuming an oat-containing diet as
against the conventional gluten-free diet (14,15). There
are studies showing that the symptoms induced by thenauthorized reproduction of this article is prohibited.
consumption of oats are not associated with small-bowel
mucosal damage (15,16). It was recently demonstrated
that 3 of 9 oat-intolerant patients with coeliac disease had
Copy
INEavenin-reactive T cells in the small-bowel mucosa (17).
Oats have sequence similarities to wheat at the amino
acid level (18), and in in vitro studies oat avenin has been
shown to stimulate gliadin-reactive T cell lines (17,19).
The clinical relevance of these somewhat discrepant
findings remains obscure, and more investigations on
the toxicity and immunogenicity of oats in coeliac dis-
ease are thus called for.
In addition to gluten-induced small-bowel mucosal
inflammatory and morphological changes, humoral
response to transglutaminase-2 (TG2) is highly patho-
gnomic for active coeliac disease. These circulating
coeliac disease-specific autoantibodies disappear during
a gluten-free diet but reappear if gluten is reintroduced
(20). Recent evidence shows that anti-TG2 autoanti-
bodies are produced locally in the small-bowel mucosa
(21,22), where they can be found deposited extracellu-
larly already early in the disease process before manifest
mucosal lesion with villus atrophy has set in and before
autoantibodies are detectable in the circulation (23–25).
Interestingly, in an earlier study by Shiner et al (26) it was
suggested that in treated coeliac disease patients small-
bowel mucosal subepithelial IgA deposits appear rapidly
after gluten challenge—even hours before marked muco-
sal lymphocytosis is detectable. This prompted us to
hypothesize that detection of TG2-targeted IgA-class
autoantibody deposits in the small-bowel mucosa may
offer a useful tool for revealing early gluten-induced
minor mucosal changes in coeliac disease. We used this
method to investigate the toxicity of oats in children with
coeliac disease during a 2-year follow-up.
METHODS
Patients and Study Design
This study is part of a randomized controlled trial, whose
details have been presented elsewhere (27). In brief, 23 consecu-
tive children aged 7 years or older with previously diagnosed
coeliac disease (median age 13 years, range 7–18 years, 7 female)
were enrolled. At the time of diagnosis all evinced positive serum
IgA-class endomysial antibodies and villous atrophy with crypt
hyperplasia in the small-bowel mucosa. After maintaining a
conventional gluten-free diet avoiding wheat, rye, barley, and
oats for at least 2 years all had experienced a good clinical,
serological, and histological response. At the baseline of the
study, 13 children (median age 11 years, range 9–18 years, 6
female) in remission were randomized to undergo open oats
challenge and 10 (median age 13 years, range 7–8 years, 1
female) a gluten challenge allowing the consumption of wheat,
rye, and barley in addition to oats. When clear small-bowel
mucosal relapse was verified during the gluten challenge, patients
reverted to a gluten-free diet, avoiding wheat, rye, and barley but
continuing oat consumption. Small-bowel mucosal biopsies and
serum samples were taken at baseline and after 6 and 24 months
560 KOSKright © 2009 by Lippincott Williams & Wilkins.Un
from the patients ingesting only oats during the entire study
period. In patients undergoing a gluten challenge, the first follow-
up examination was carried out when clinical symptoms
J Pediatr Gastroenterol Nutr, Vol. 48, No. 5, May 2009suggested a relapse or coeliac antibodies seroconverted positive.
After the relapse and commencement of an oat-containing gluten-
free diet, follow-up examinations were carried out in the same
way at 6 and 24 months as in the oats challenge group. During the
2-year trial, oats had no detrimental effect on intestinal mucosal
villous morphology, densities of CD3þ, abþ and gdþ intra-
epithelial lymphocytes (IEL) or HLA DR expression. In contrast,
the gluten challenge group relapsed after 3 to 12 months, but
complete recovery from the diseasewas accomplished in all on an
oat-containing gluten-free diet during the 2-year follow-up (27).
Oat Product and Dietary Assessment
At baseline, children and their parents were given instruc-
tions by a trained dietician on the oat-containing gluten-free diet
and gluten challenge (27). A detailed dietary analysis was
assessed repeatedly by means of interview and 4-day record
of food intake. The rolled, uncontaminated oats (1 single batch;
Melia Ltd, Raisio, Finland; details of the cultivar were not
provided by the manufacturer) were given to the patients free of
charge. During the gluten challenge, patients bought their
wheat-, rye-, barley-, and oats-containing products freely from
grocery stores, and thus no specific cultivar was used. During a
2-year trial, the median daily consumption of oats was 45 g/day
(range 13–81 g/day) in the oats challenge group. In the gluten
challenge group, the median daily intake of gluten in the form
of wheat-, rye-, barley-, and oat-containing normal bread was
14 g (range 7–19 g/day), and after adopting an oat-containing
gluten-free diet the median intake of oats was 41 g/day, range
24 to 59 g/day. One patient in the oats challenge group had
transient dietary lapses at the 6-month time point; all of the rest
adhered to a strict gluten-free diet throughout the study (27).
Small-bowel Mucosal Morphology and
TG2-specific IgA Deposits
All small-bowel intestinal biopsies were obtained by an
adult Watson capsule in X-ray control next to the ligamentum
of Treitz in jejunum. One part of the biopsy specimen was
paraffin embedded and stained with hematoxylin and eosin to
study small-bowel mucosal morphology and to determinate the
villous height–crypt depth ratios (Vh/CrD) (28). From well-
oriented biopsy sections Vh/CrD< 2 was considered charac-
teristic for active coeliac disease.
The other part of the biopsy was snap-frozen and embedded
in optimal cutting temperature compound (OCT, Tissue-Tec,
Miles Inc, Elkhart, IN). In each case, altogether 6 unfixed,
5-mm-thick sections from the frozen small-bowel specimens
were processed, 3 for investigation of IgA deposits and 3 for
double-colour labelling for both IgA and TG2 by direct immuno-
fluorescence. IgAwas detected using fluorescein isothiocyanate-
labelled rabbit antibody against human IgA (Dako AS, Glostrup,
Denmark) at a dilution of 1:40 in phosphate-buffered saline
(PBS), pH 7.4. For the double labelling, sections were stained
for human IgA (as above, green) and for TG2 (red) using
monoclonal mouse antibodies against TG2 (CUB7402, Neo-
Markers, Fremont, CA), followed by rhodamine-conjugated
anti-mouse immunoglobulin antibodies (Dako), both diluted
N ET ALauthorized reproduction of this article is prohibited.
1:200 in PBS. In normal small-intestinal mucosal samples
IgA is detected only inside the plasma and epithelial cells. In
contrast, it has been shown that in active coeliac disease on a
Cop
FIG. 1. Intensity of small-bowel mucosal transglutaminase
2-specific IgA deposits in patients randomized to oats (A) or gluten
challenge (B) groups. Two patients in the oats challenge group (A)
who prematurely withdrew from the study were rebiopsied
immediately after symptoms occurred (within 1 month after oat
challenge was started), and these cases are indicated with open
MUCOSAL AUTOANTIBODY RESPONSE 561gluten-containing diet a clear TG2-targeted subepithelial IgA
deposition can be found below the basement membrane along the
villous and crypt epithelium and around mucosal vessels. In
earlier studies it has been shown that such small-intestinal
mucosal IgA deposition targets against TG2 (23,29). In short,
when this IgA was eluted from the tissues, it targeted purified
TG2 both in enzyme-linked immunosorbent assay (ELISA) and
Western blot (23). In addition, when TG2 binding to fibronectin
was disrupted by chloroacetic acid, disappearance of extracellu-
lar IgA deposits was demonstrated in coeliac small-bowel
samples. Furthermore, we have shown that IgA deposits in the
small bowel of active coeliac disease patients have the ability to
bind external TG2 added to the tissue (29). The method used here
was based on our previous experiments to detect TG2-specific
antibodies in situ in tissue sections by their colocalization with
TG2 when double-labelled by immunofluorescence. In this study
the IgA deposits were graded semiquantitatively according to
their intensity along the basement membrane in the villous-crypt
area as follows: negative (), weak positive (þ), moderate
positive (þþ), and strong positive (þþþ). In cases in which
the intensity of the staining was patchy, the intensity of IgA
deposits was graded from different areas and a mean value of the
staining was given. All evaluations were carried out blindly
without knowledge of disease history or laboratory findings.
In our laboratory inter- and intraobserver variation have both
been 98% in the detection of IgA deposits (29).
Serology
Serum IgA-class antibodies against TG2 were detected by
ELISA using human recombinant TG2 as antigen, with a cutoff
line of 5.0 U/mL (Celikey, Phadia, GmbH, Freiburg, Germany).
Statistics
Quantitative data were expressed as medians and ranges, and
qualitative data as percentage of abnormal values. Statistical
differences were evaluated using the Wilcoxon test, as appro-
priate. Correlations were tested by Spearman correlation test.
All testing was 2-sided, and P values <0.05 were considered
OATS DO NOT INDUCE SYSTEMIC ORyright © 2009 by Lippincott Williams & Wilkins.U
statistically significant. All calculations were performed with
the Statistical Package for Social Sciences version 14.0 (SPSS,
Inc, Chicago, IL).
FIG. 2. At baseline, this 13-year old boy had been on a conventional glu
evinced normal small-bowel mucosa villous morphology and negative mu
and oats) challenge he still had normal villi, but clear IgA deposits we
12 months with gluten, and strong IgA deposits can be seen (C). After ad
slowly disappeared following villous recovery (D), after 6 months with
transglutaminase 2 (TG2) in red; yellow (arrow) in composite figures inEthical Considerations
circles.nauthorized reproduction of this article is prohibited.
The study protocol was approved by the Ethics Committee
of Tampere University Hospital. All children and their parents
gave their written informed consent.
ten-free diet avoiding wheat, rye, barley, and oats for 2 years and
cosal IgA deposits (A). After 6 months’ gluten (wheat, rye, barley,
re already present (B). The small-bowel mucosa relapsed after
opting an oat-containing gluten-free diet the mucosal IgA deposits
oats; (E), after 2 years with oats. IgA is stained in green and
dicates colocalization of coeliac-type IgA deposits and TG2.
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FIG. 3. Correlation between the intensity of small-bowel mucosal
transglutaminase 2-specific IgA deposits and serum IgA-class TG2
antibodies (A), (Spearman correlation coefficient was r¼0.694,
P<0.001), and between small-bowel mucosal IgA deposits and
villous height-crypt depth ratios (B), (Spearman correlation coeffi-
cient was r¼0.550, P<0.001). Dotted line indicates the cutoff
value for positivity in TG2 antibody measurements from serum.
Cases having standard gluten-free diet omitting wheat, rye, barley,
INEN ET ALRESULTS
At baseline, all treated children with coeliac disease
were in clinical remission and had normal villous archi-
tecture at histology (27). Small-bowel mucosal median
Vh/CrD was 4.1 (range 3.0–5.1) in the oat challenge
group and 4.4 (range 3.2–5.9) in the gluten challenge
group. In addition, serum IgA-class anti-TG2 antibodies
were negative in all. When autoantibodies were sought
at the small-bowel mucosal level, weak-to-moderate
TG2-specific IgA deposits were present in 4 of 13
(31%) in the oat challenge group and in 3 of 10 (30%)
in the gluten challenge group (Fig. 1A and B).
In the oat challenge group, there was no significant
change in the intensity of mucosal IgA deposits during
the 2-year trial (Fig. 1A). In contrast, in the gluten
challenge group the intensity of IgA deposits increased
parallel with the development of small-bowel mucosal
villous atrophy with crypt hyperplasia, and at the time of
relapse all had moderate-to-severe IgA depositions pre-
sent in the mucosa (Fig. 1B and 2). During the gluten
challenge, 2 patients were also biopsied before they
developed small-bowel mucosal villous atrophy, and
interestingly, both already evinced clear TG2-specific
IgA deposits even if the villous morphology was still
intact (Fig. 2B). When an oat-containing gluten-free diet
was adopted after relapse of the disease, the intensity
of small-bowel mucosal IgA deposits again decreased
significantly within 6 months, and after 2 years with oats
only 1 of 7 (14%) had minor depositions left in the
mucosa (Fig. 1B and 2). At the end of the 2-year trial
with oats all patients again had negative serum anti-
TG2 antibodies and Vh/CrD was normal in all (median
Vh/CrD 4.2, range 2.9–5.2).
When data from both study groups and all time
points were collated, it was noted that the intensity of
small-bowel mucosal IgA deposits correlated well with
serum TG2-antibody levels (Spearman test r¼ 0.694,
P< 0.001) (Fig. 3A), and the severity of small-bowel
mucosal villous damage (r¼0.550, P< 0.001)
(Fig. 3B).
One patient in the oat challenge group admitted pas-
sing dietary transgressions at 6 months. At that time, his
serum anti-TG2 antibody titre increased from 0.4 to
3.1 U/mL, still, however, remaining below the cutoff
level, and the intensity of small-bowel mucosal IgA
deposits was slightly increased. After continuing with
a strict oat-containing gluten-free diet both serum and
mucosal autoantibodies again decreased (Fig. 1A).
Two children with coeliac disease experienced
abdominal pain and vomiting immediately after intake
of oats, and within 1 month both withdrew prematurely
from the study. The follow-up biopsies were taken upon
562 KOSKright © 2009 by Lippincott Williams & Wilkins.Un
withdrawal immediately after symptoms occurred,
and they showed that the small-bowel mucosa villous
morphology was normal and the densities of IELs were
J Pediatr Gastroenterol Nutr, Vol. 48, No. 5, May 2009even lower than at the beginning of the study (27).
and oats (n¼23) are shown in black circles, cases having gluten
challenge (n¼10) in black squares, cases with oat containing diet
(n¼39) in open circles, and 2 patients in oat group with premature
withdrawals in open squares.authorized reproduction of this article is prohibited.
Furthermore, at follow-up serum anti-TG2 antibodies
and small-bowel mucosal autoantibody deposits remained
negative in both patients (Fig. 4A and B).
Cop
FIG. 4. A 16-year-old boy developed abdominal symptoms imme-
diately after ingestion of oats; small-bowel mucosal villous
morphology remained normal and densities of CD3þ intraepithelial
lymphocytes even decreased (from 86cells/mm to 51cells/mm).
Mucosal IgA deposits were negative both before (A) and imme-
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OATS DO NOT INDUCE SYSTEMIC OR MUCOSAL AUTOANTIBODY RESPONSE 563DISCUSSION
We demonstrated by measuring the intensities of
small-bowel mucosal TG2-specific autoantibody depos-
its that the ingestion of oats during a gluten-free diet for
2 years does not result in humoral immune activation in
children with coeliac disease. In contrast, when wheat,
rye, and barley are consumed in addition to oats, a
marked small-bowel mucosal antibody response occurs
parallel with small-bowel mucosal damage within 3 to
12 months. If oats were disease inducing per se, then the
small-bowel mucosa would not have recovered after the
relapse on a diet excluding wheat, rye, and barley but
containing oats. The present findings are in accord with
those in earlier studies in children (Table 1) and adults
with coeliac disease or dermatitis herpetiformis, showing
that oats have neither toxic nor immunogenic effects on
the small-bowel mucosa and are tolerated by the majority
of patients with coeliac disease (4–8,16).
Although several studies have suggested that oats can
be safely added to the diet of patients with coeliac
disease, reports that some develop more abdominal
symptoms or may even have avenin-reactive T cells in
the small-bowel mucosa while consuming oats raise
some concern (15,17). Furthermore, some studies have
reported somewhat higher withdrawal frequencies from
oats challenge groups when compared with standard
gluten-free diet groups also omitting oats (11,15). Most
patients who dropped out of these studies were not
properly followed up to study whether oat intolerance
was due to relapse of the disease or whether it was related
diately after (B) oats challenge. IgA is labelled green, transgluta-
minase 2 in red; IgA deposition or co-localization of IgA and TG2
(yellow) was not detected.yright © 2009 by Lippincott Williams & Wilkins.Unauthorized reproduction of this article is prohibited.
to something else in oats, for example, high fibre content
(16). In the present study, both children with coeliac
disease who developed dramatic abdominal symptoms R
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INEimmediately after ingesting oats were biopsied, but no
signs of immune activation or relapse of coeliac disease
were found. This notwithstanding, the possibility that
some patients with coeliac disease may be truly oat
intolerant and should thus avoid oats to remain in remis-
sion should be kept in mind.
In our challenge study, small-bowel mucosal TG2-
specific IgA deposits proved to be clearly gluten-sensi-
tive and they were, in fact, present in the mucosa even
before the onset of villous atrophy (Fig. 2). Furthermore,
in 1 case, the intensity of the IgA deposition transiently
increased when the patient had advertent dietary lapses
even if serum anti-TG2 antibody levels remained normal
(Fig. 1A). The specificity for TG2 of IgA deposits have
been shown in earlier studies by ELISA, Western blot,
and in situ (23,29). Gluten sensitivity of mucosal IgA
deposits has been also shown in studies concerning early-
stage coeliac disease; mucosal IgA deposits have been
detected in patients still evincing normal small-bowel
mucosal villous architecture but who subsequently devel-
oped mucosal damage when gluten consumption was
continued (23–25). Interestingly, IgA deposits can also
be detected in the small-bowel mucosa of such patients
with coeliac disease who do not have the autoantibodies
in their serum (23,29). Because the coeliac disease–
specific autoantibodies against TG2 are produced in
the mucosa of the small intestine, it would appear that
after gluten ingestion the autoantibodies are first seques-
tered in the bowel and that only later ‘‘spilling over’’ from
the gut leads to their appearance in the serum.
In conclusion, this study showed that consumption of
oats is safe for the majority of children with coeliac
disease. Lifelong follow-up is recommended for children
wishing to consume a diet containing oats. The detection
of mucosal IgA-deposits is a potent means of monitoring
treatment of coeliac disease, although not needed in
routine surveillance. However, new treatment options
in coeliac disease are under study, meaning that reliable
and sensitive diagnostic tools to detect minor gluten-
induced small-bowel mucosal changes are warranted.
The detection of mucosal IgA deposits could provide
such a tool and be useful also in the follow-up of
clinically problematic cases.
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Abstract  
 
Background and aims: The diagnosis of coeliac disease is problematic in individuals 
not responding to a gluten free diet. Small-bowel villous atrophy occurs in other 
enteropathies and non-responsive patients are often seronegative. We investigated 
whether small-bowel mucosal transglutaminase-2 specific autoantibody deposits 
distinguish non-responsive coeliac disease from other enteropathies.   
Methods: Small bowel mucosal autoantibody deposits were determined in 27 non-
responsive, 28 responsive coeliac patients and ten controls with other enteropathies. Of 
the non-responsive coeliac patients six were adhering poorly and 21 strictly to the diet; 
six of the 21 had enteropathy-associated lymphoma, five refractory coeliac disease and 
ten otherwise persistent villous atrophy. The presence of mucosal autoantibody deposits 
was compared to serology, villous morphology, densities of intraepithelial lymphocytes 
(IELs) and markers of refractory coeliac disease.  
Results: Twenty out of 21 well-adhering, all six poorly adhering non-responsive and all 
28 untreated responsive coeliac patients had small-bowel mucosal autoantibody deposits 
present, while controls with other enteropathies were negative. Small-bowel mucosal 
autoantibody deposits were more accurate in detecting coeliac disease than serology or 
IEL densities. Refractory coeliac markers revealed only cases with the most severe 
condition.  
Conclusions: Small-bowel mucosal autoantibody deposits differentiate coeliac disease 
from other enteropathies, enabling the design of appropriate therapeutic strategies.  
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Introduction 
The basis for the treatment of coeliac disease is life-long adherence to a gluten-free diet 
during which the gluten-induced small-bowel mucosal villous atrophy with crypt 
hyperplasia generally resolves within 1-2 years. In cases with poor histological response 
to diet further investigations are always required. The most common reason for persistent 
villous atrophy is continuous intentional or unintentional gluten consumption [1,2], which 
may be difficult to reveal even with careful dietary assessment. Moreover, as villous 
atrophy sometimes also occurs in conjunction with other enteropathies such as 
autoimmune enteropathy and Crohn’s disease [3], the initial diagnosis has to be 
ascertained especially if coeliac-specific serum endomysial (EmA) and transglutaminase 
2 antibodies (TG2-ab) have been negative at the time of diagnosis. In addition, sustained 
severe mucosal damage might be due to refractory coeliac disease. Refractory coeliac 
disease fortunately affects less than 5% of coeliac patients, but is a serious condition with 
the potential to develop to ulcerative jejunitis and further to enteropathy-associated T-cell 
lymphoma (EATL) [4,5].  A subset of patient suffering from refractory coeliac disease 
(type II) present with an abnormal immunophenotype of small-bowel mucosal 
intraepithelial lymphocytes (IELs) and with clonal proliferation of these cells, both 
regarded as poor prognostic markers of the condition [4-8]. 
As patients suffering from refractory coeliac disease are often seronegative while 
adhering to a gluten-free diet, differential diagnostics between unresponsive coeliac 
disease and other causes of enteropathy can be laborious. It is well known that the serum 
coeliac-specific antibodies normalize fairly rapidly after commencement of a gluten-free 
diet, even before full recovery of the small-bowel mucosal villous morphology [9,10], 
which further limits the usefulness of coeliac serology during the follow-up of the 
disease. Evidence shows that in coeliac disease, the TG2-specific autoantibodies are 
produced at small-bowel mucosal level, where they are also sequestered below the 
basement membrane along the villous and crypt epithelium and around the blood vessels 
[9,11-14]. These autoantibody deposits can be found even in newly diagnosed coeliac 
disease patients having no serum autoantibodies [11], and interestingly these depositions 
seem to disappear slowly during a gluten free diet [15]. As simple immunofluorescent 
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staining can reveal the presence of such TG2-specific coeliac disease type IgA 
autoantibody deposits, we hypothesized that this method could be used in distinguishing 
non-responsive, often seronegative, coeliac disease from other types of enteropathy. We 
addressed this issue by studying altogether 27 non-responsive coeliac disease patients 
evincing persistent villous atrophy despite a gluten-free diet, and ten disease control 
patients suffering from other intestinal disorders. 
 
Methods 
Patients and study design 
Our study cohort comprised altogether 27 consecutive adults having non-responsive 
coeliac disease and referred to the Department of Gastroenterology and Alimentary Tract 
surgery of Tampere University Hospital. Non-responsive coeliac disease was considered 
to be refractory coeliac disease when symptoms due to villous atrophy persisted after 
gluten withdrawal or recurred after a former good response on a gluten free diet [4,7,16]. 
A thorough dietary assessment revealed that six of these patients were adhering poorly to 
a gluten-free diet, whereas the remaining 21 had good adherence (Table 1). Of these latter 
21 coeliac patients, six developed EATL, five had refractory coeliac disease and ten 
persistent villous atrophy despite being apparently asymptomatic. Clinical data on some 
of these patients have been presented in detail in a previous study [17]. 
For comparison, 28 adults with responsive coeliac disease were studied at diagnosis and 
after one year on a gluten-free diet (Table 1). Further, ten patients with enteropathy other 
than coeliac disease served as disease controls. Of these ten, four had autoimmune 
enteropathy with small bowel-mucosal villous atrophy, one had Crohn’s disease with 
patchy, mild villous atrophy, and the remaining five had normal villous architecture (two 
with ulcerative colitis or Crohn’s disease and three with collagenous colitis) (Table 1). 
All disease controls were diagnosed according to published criteria [18-20]. At least six 
small-intestinal mucosal biopsy specimens were taken from the distal duodenum upon 
gastroscopy or enteroscopy. Three of the biopsies were embedded in paraffin and the 
remaining three freshly in optimal cutting temperature compound (OCT; Tissue-Tec, 
Miles Inc, Elkhart, IN), snap-frozen and stored at -70°C until used. Serum coeliac 
antibodies were measured at the time of endoscopy. 
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Small-bowel mucosal transglutaminase 2 (TG2)-specific IgA deposit 
Unfixed small-bowel mucosal frozen sections (5µm) were stained by direct 
immunofluorescence using fluorescein isothiocyanate-labelled rabbit antibody against 
human IgA (Dako AS, Glostrup, Denmark) at a dilution of 1:40 in phosphate-buffered 
saline (PBS). To establish whether there is co-localization of IgA and TG2, sections were 
double-stained with anti-IgA antibody as described above and using monoclonal mouse 
antibodies against TG2 (CUB7402, NeoMarkers, Fremont, CA), followed by rhodamine-
conjugated anti-mouse immunoglobin antibodies (Dako) diluted 1:200 in PBS. In coeliac 
disease subepithelial deposition can be found along the villous and crypt epithelium and 
around vessels, in contrast to that observed in non-coeliac samples, where endogenous 
IgA is found inside plasma cells and epithelial cells [12,21]. It has previously been shown 
that these mucosal IgA deposits are targeted specifically against TG2 [11,12]. The 
occurrence of IgA deposits was graded semi-quantitatively according to their intensity 
along the basement membrane in the villous-crypt area as follows: negative, weak (+), 
moderate (++) and strong positive (+++). In cases where the intensity of the staining was 
patchy, it was graded from different areas and the mean value given. All evaluations were 
carried out in blinded fashion without knowledge of disease history or laboratory 
findings. In our laboratory the inter- and intraobserver variations have both been 0.98 in 
the detection of IgA deposits [11]. 
 
Small-bowel mucosal histology and intraepithelial lymphocytes 
Hematoxylin-eosin staining was carried out on processed paraffin-embedded sections and 
the villous height/ crypt depth ratio (Vh/CrD) determined as previously described [22]. 
Vh/CrD below two was considered abnormal. 
Sections of paraffin-embedded tissue from the duodenum were used for 
immunohistochemistry, applying the standard immunoperoxidase method [5]. The 
following antibodies (all from Lab Vision Corporation, Fremont, CA) were used: anti-
CD3 and anti-CD8 (both at a dilution of 1:30) and anti-CD30 (1:50). Positively stained 
intraepithelial lymphocytes were counted from randomly selected surface epithelium and 
expressed as IELs per 100 epithelial cells. The percentage of CD3+CD8-IELs was 
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determined in patients with high numbers of IELs as previously described and a 
proportion above 52% was considered abnormal [23]. 
In addition, immunohistochemical staining of CD3+ and γδ + IELs was carried out on 
frozen sections. CD3+ IELs were stained with monoclonal antibody Leu-4 (Becton 
Dickinson, San Jose, CA) and γδ+ IELs with T-cell receptor -γ antibody (Endogen, 
Woburn, MA). Positive IELs were counted with a magnification x100 throughout the 
surface epithelium and at least 30 fields were counted; the result was given as IEL density 
cells/mm of epithelium. IEL densities over 37 cells/mm of epithelium for CD3+ IELs and 
4.3 cells /mm of epithelium for γδ + IELs were considered abnormal [24]. 
 
DNA extraction and analysis of T-cell clonality 
DNA was extracted from paraffin-embedded biopsy samples with the Illustra DNA 
extraction nucleon HT kit (GE Healthcare, Buckinghamshire, UK) according to 
manufacturer’s instructions. One hundred nanograms of DNA were used as template in 
two separate polymerase chain reactions (PCR) to detect the clonality of the TCR- γ gene 
as previously described [25]. All PCR reactions were performed in duplicate.  
 
Serum autoantibodies 
EmA was determined by an indirect immunofluorescence method, a serum dilution of 
1:≥5 being considered positive. In addition, serum TG2 antibody titers were measured by 
enzyme-linked immunosorbent assay (ELISA) (Celikey, Pharmacia Diagnostics, GmbH, 
Freiburg, Germany) using human recombinant TG2 as antigen, unit values over 5 being 
considered positive [26]. When either EmA or TG2 antibodies were above the cut-off 
level, the subject was regarded as coeliac autoantibody-positive.  
 
HLA-typing 
HLA DQB1* allele groups were determined using the Olerup SSP DQ low-resolution kit 
(Olerup SSP AB, Saltsjobaden, Sweden). This method determines the HLA DQ2, DQ4, 
DQ5, DQ6, DQ7, DQ8 and DQ9 allele groups. In coeliac disease 90–95% of patients 
carry the HLA DQ2-haplotype and most of the rest HLA DQ8 [27]. 
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Statistical methods 
Quantitative data were expressed as medians and ranges. Statistical differences were 
evaluated using Mann-Whitney test and Wilcoxon’s test as appropriate and all testing 
was two-sided. P- values < 0.005 were considered statically significant. All statistical 
testing was performed using the Statistical Package for Social Sciences version 17.0 
(SPSS Inc., Chicago, IL). 
 
Ethical considerations 
The study protocol was approved by the Ethical Committee of Tampere University 
Hospital. All subjects gave written informed consent. 
 
Results 
Of our study group of 27 non-responsive coeliac disease patients having a manifest small-
intestinal mucosal lesion, all six with poor adherence to gluten-free diet had coeliac 
disease autoantibodies present in both sera and small-bowel mucosa as deposits (Figure 1, 
Table 2). In contrast, of the remaining 21 non-responsive coeliac disease patients with 
good adherence to gluten-free diet, only four (19%) had autoantibodies in the serum 
while twenty (95%) had autoantibodies deposited in the small-bowel mucosa, this 
including the five patients with EATL (Figure 2). All 28 coeliac disease control patients 
who responded to a gluten-free diet had TG2-specific IgA deposits in their small 
intestinal mucosa before treatment, two (7%) of them being however initially 
seronegative. During a gluten-free diet of one year the serum autoantibody levels 
normalized in all, but 21 of the 28 (75%) responsive coeliac disease patients still evinced 
autoantibodies deposited in the small-intestinal mucosa, although their intensity 
significantly declined (Figure 1). In contrast, none of the patients with enteropathies other 
than coeliac disease had autoantibodies in their small-intestinal mucosa or in sera 
(Figures 1 and 2, Table 2). Thus, the sensitivity and specificity of TG2-specific mucosal 
IgA autoantibody deposits in distinguishing non-responsive coeliac disease patients 
adhering to a gluten-free diet from those with other types of enteropathy was 95% and 
100%, respectively. 
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Small-bowel mucosal IgA deposits were found to differentiate non-responsive coeliac 
patients regardless of the strictness of the diet from controls with other enteropathies 
better than the densities of CD3+ or γδ+ IELs (Table 2). Increased densities of both types 
of IELs could also be found in one third of the disease control patients with other 
enteropathies.  
Typical markers of refractory coeliac disease (abnormal CD8/CD3 ratio and TCR γ -gene 
rearrangement) were found only in patients with refractory coeliac disease with or 
without EATL (Table 2). CD30+ IELs were found in six out of 21 non-responsive 
adhering coeliac disease patients, in one non-adhering coeliac patient and in one with 
autoimmune enteropathy. 
 
Discussion 
The major finding in this study was that small-bowel mucosal TG2-specific IgA 
autoantibody deposits can distinguish non-responsive coeliac disease from other non-
coeliac-related enteropathies (e.g. autoimmune enteropathy) better than other markers 
utilized in coeliac disease diagnostics (Figure 1, Table 2). Serum TG2-autoantibodies 
have proved to be highly sensitive and specific in finding untreated coeliac disease 
patients and as they normalize fairly quickly on a gluten-free diet they have been used in 
monitoring dietary response in clinical practice [10,28,29]. A positive serum 
autoantibody test result during a gluten free diet most often points to dietary 
transgressions. However, as also shown in this study, the serum autoantibodies often fail 
to detect non-responsive coeliac disease and ongoing coeliac-type small-bowel mucosal 
damage, as non-responsive coeliac disease patients tend to be seronegative [10,11,17]. 
Often diagnosis of coeliac disease is established years before non-responsiveness is 
perceived, thus initial serum autoantibody results at the time of diagnosis may not be 
available anymore. Consequently, serum TG2-autoantibodies are not applicable in 
differential diagnostics between coeliac-type small-bowel mucosal lesion and other 
causes of enteropathy. Furthermore, although increased densities of CD3+ and γδ+ IELs 
would strongly suggest coeliac disease [24,30], they are not sensitive or specific enough 
to be relied on for a definitive coeliac disease diagnosis in problematic cases (Table 2). 
Moreover, the widely used markers of aberrant phenotype and T cell clonality of IELs in 
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detecting refractory coeliac disease patients [4,5] were able to identify only a subset of 
our non-responsive coeliac disease patients having the most severe condition. In addition, 
immunophenotyping requires access to molecular laboratory facilities. Taken together, 
the value of these refractory markers is limited in the diagnostic workup of seronegative 
small-bowel villous atrophy. As small bowel mucosa does not normalize in all (especially 
in adults) coeliac patients in whom clinical remission is achieved [31] the differential 
diagnostics between histologically unresponsive celiac disease and other enteropathies 
remains a challenge in clinical practice. 
An intriguing question is why non-responsive patients adhering strictly to a gluten-free 
diet evince TG2-specific IgA deposits in their small-bowel mucosa even after long-term 
dietary treatment. Since coeliac disease autoantibodies are produced in the small-bowel 
mucosa [32], one explanation could lie in minor gluten contaminations in gluten-free 
products [33,34], these possibly sustaining a local immunoresponse in the small intestine. 
Furthermore, it has been shown that during the progression of coeliac disease the in vitro 
avidity of the autoantibodies increases [35]. Similarly, in an earlier study of the target 
specificity of the deposited autoantibodies in the small-intestine we found that the coeliac 
autoantibodies were bound to intestinal TG2 in situ with considerably high avidity [11]. 
Such high avidity in antigen-antibody binding might prevent the spilling over of the 
autoantibodies from the gut mucosa into the circulation and thus result in seronegativity 
[11].  
Patients with IgA deficiency often tend have coeliac disease [36], and in this group 
determining small-bowel mucosal IgA deposits can not be used; deposits must be 
determined in other Ig-class autoantibodies (IgG or IgM) instead [12,37]. HLA DQ2 or 
DQ8 haplotypes are present in up to 40% in the general population, therefore the 
presence of these HLA-types does not necessarily confirm the diagnosis of coeliac 
disease but their absence speaks in favour of other disease entities [38]. 
In our earlier paper [9] our control group consisted of 78 nonceliac subjects who 
underwent endoscopy because of indigestion or suspicion of celiac disease, the condition 
being excluded by normal small-bowel mucosal villous architecture. Of these, 18% had at 
most weak, often patchy deposits. However, as these controls were patients suffering 
from indigestion or suspected but excluded for celiac disease, it remains to be seen 
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whether the subjects with minor IgA deposits but normal mucosal architecture have 
early-stage celiac disease and will develop villous atrophy later in life while continuing 
consumption of gluten. In our current study we wanted to have disease controls suffering 
from other enteropathies than celiac disease to obtain certainty whether the determination 
of intestinal IgA deposits is reliable in differential diagnostics between celiac disease and 
other enteropathies. Furthermore, it is important to note that the majority of the 
nonresponsive celiac disease patient in the current study evinced moderate or strong IgA 
deposits which clearly differs from the week and patchy deposits of the control subjects 
in the previous study [9]. 
Although the investigation of intestinal IgA deposits is fairly simple and easy to perform, 
it is a special method requiring frozen small-bowel biopsy specimens and the 
interpretation of results requires practice. The method is thus probably not appropriate in 
routine coeliac disease diagnostics and surveillance but in a certain subset of patients it 
can help the diagnostic work-up. As the diagnostic workup of problematic cases often 
requires repeated endoscopies and multiple biopsies, it might be advisable to take a few 
extra biopsies for the determination of small-bowel mucosal TG2-specific IgA deposits. 
In conclusion, small-bowel mucosal TG2-specific IgA autoantibody deposits offer a 
valuable tool in the differential diagnostics of seronegative enteropathies, enabling the 
design of appropriate therapeutic strategies.  
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FIGURE LEGENDS 
 
Figure 1 Intensity of transglutaminase-2 specific small-bowel mucosal IgA deposits in 
different study groups. Patients with refractory coeliac disease (CD) are marked with 
open squares, and enteropathy associated T cell lymphoma patients have been marked 
with black squares. A p value less than 0.05 was considered significant.  
 
Figure 2 Small-bowel mucosal immunofluorescence staining of IgA (green) and 
transglutaminase-2 (red) from patients having untreated coeliac disease which 
subsequently responded well to a gluten-free diet (A), refractory coeliac disease patient 
with abnormal immunophenotype of small-bowel mucosal intraepithelial lymphocytes 
(B), a refractory coeliac patient with enteropathy-associated T cell lymphoma (C) and a 
patient with autoimmune enteropathy (D). Colocalization of IgA and TG2 is shown in 
yellow (arrow). 
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Patients and Methods: All together 48 subjects suspected of
coeliac disease but having normal small bowel mucosal villi
were enrolled; 28 of them had latent coeliac disease. The
remaining 20 having positive intestinal IgA deposits adopted
a gluten-free diet before villous atrophy had developed. For
comparison, 13 patients with overt coeliac disease and 42
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436Results: Intestinal IgA deposits were seen in all but 1 of the
patients with latent coeliac disease, when the morphology was
still intact; the intensity of these deposits increased as villous
atrophy developed and decreased again on a gluten-free diet. In
20 patients with intestinal IgA deposits in normal villi, the
intensity of the deposits decreased with the diet similarly to that
seen in patients with overt coeliac disease. Mucosal IgA
deposits were seen initially only in 5% of noncoeliac
controls and in 8% after extended gluten consumption.
Conclusions: The response of small bowel mucosal
transglutaminase-2–specific IgA deposits for dietary
intervention was similar in overt and mild enteropathy
coeliac disease. Detection of such IgA deposits thus offers a
good diagnostic tool to uncover early-stage coeliac disease.
JPGN 47:436–442, 2008. Key Words: Latent coeliac
disease—Immunoglobulin A deposit—Gluten dependency. #transglutaminase-2–specific autoantibodies were compared 2008 by European Society for Pediat
with villous morphology, intraepithelial lymphocyte densities,
ric Gastroenterology,
Hepatology, and Nutrition and North American Society for
Pediatric Gastroenterology, Hepatology, and NutritionThe current diagnostic criteria for coeliac disease are elongation of crypts and finally to overt villous atrophy
(2,3), the atrophy thus covering only the end stage of the
disease. Evidence suggests that coeliac patients may
suffer from gluten-sensitive symptoms and signs even
before villous atrophy has developed (4–7). Minor small
bowel mucosal morphological and inflammatory changes
such as increased densities of CD3þ and gdþ intrae-
pithelial lymphocytes (IELs) are unspecific and subject
to false diagnosis (8–11), and new reliable tools to detect
mild enteropathy coeliac disease are therefore warranted.
A specific test also should encompass proof of gluten
dependency when patients are placed on gluten-freehorized reproduction of this article is prohibited.
dietary treatment.
Apart from mucosal changes, a typical feature
of untreated coeliac disease is the presence of serum
TABLE 1. Demographic data on study patients
Latent coeliac
disease, n¼28
Potential coeliac
disease, n¼20
Overt coeliac
disease, n¼13
Noncoeliac
controls, n¼42
Female, % 75 80 77 71
Median age (range), y 37 (2–69) 46 (21–74) 47 (28–68) 41 (17–68)
Children, n (%) 10 (36) 0 0 0
Main indication for biopsy, n (%)
Abdominal complaints

17 (61) 17 (85) 7 (54) 30 (71)
Malabsorbtiony 2 (7) 1 (5) 1 (8) 7 (17)
Atypical symptomsz 5 (18) 2 (10) 2 (15) 3 (7)
Screening of risk groups§ 4 (14) 0 (0) 3 (23) 2 (5)
Family history of coeliac disease, n (%) 11 (41) 4 (20) 7 (54) 5 (12)

Abdominal pain, flatulence, diarrhoea.
atopic
se, Sjo¨
MUCOSAL IGA DEPOSITS IN COELIAC DISEASE 437immunoglobulin (Ig)A–class autoantibodies against
transglutaminase-2 (TG2) (12,13), which offer high
sensitivity and specificity (14,15). In fact, positive auto-
antibodies in patients having normal small bowel muco-
sal villous morphology do not necessarily constitute a
false positive finding because they may be a predictive
sign of forthcoming mucosal villous atrophy and coeliac
disease (9,16–18). These autoantibodies are produced in
the small intestinal mucosa (19,20), where they may be
present even when there are no measurable levels in the
sera (5,21,22). Intestinal TG2-specific IgA deposits may
offer a diagnostic tool for detecting early-stage coeliac
disease without villous atrophy (9). These intestinal
antibodies (with absence in serum) also have been found
in patients with diabetes mellitus and in first-degree
relatives of coeliac patients, without full certainty as
to whether these antibodies are gluten induced or related
to coeliac disease (23–25). The demonstration of gluten
dependency in intestinal TG2-specific IgA deposits
would further enhance the specificity of the test.
Our aim was to evaluate the gluten dependency and
diagnostic value of small bowel mucosal TG2-specific
IgA autoantibody deposits in overt and mild enteropathy
coeliac disease. Our series included children and adults
with latent coeliac disease, who initially showed normal
small bowel mucosal villous architecture but sub-
sequently developed mucosal villous atrophy and celiac
disease while continuing on a normal gluten-containing
diet. In addition, we found individuals evincing small
bowel mucosal TG2-specific IgA autoantibody deposits
in intact villi who were directly placed on an experimen-
tal gluten-free diet to find evidence of gluten sensitivity.
The data were compared with those from patients with
overt coeliac disease and noncoeliac controls.
PATIENTS AND METHODS
yWeight loss, anaemia.
zAphthous stomatitis, growth retardation, epilepsy, polyneuropathy,
§ Type 1 diabetes mellitus, family history, autoimmune thyroid diseaCopyright © Lippincott Williams & Wilkins. Unau
The study group comprised 48 patients suspected of coeliac
disease but found to have normal small bowel mucosal villousarchitecture. Of these, 28 had latent coeliac disease because
they developed mucosal villous atrophy during the follow-up
when continuing on a gluten-containing diet (Table 1). In these
patients, the median follow-up time from normal small bowel
mucosal architecture to villous atrophy was 1.7 years
(range 0.2–7.4 years). After the mucosal deterioration, the
patients were placed on a gluten-free diet, the median duration
of the diet being 1.4 years (range 0.8–5.9 years). The remaining
20 patients in the study group were found to have small bowel
mucosal IgA deposits in intact villi (defined in this study as
potential coeliac disease) (Table 1); to find evidence for their
gluten dependency, these individuals were placed on an exper-
imental gluten-free diet even if they did not fullfil the current
diagnostic criteria for coeliac disease. After 1 year, the response
to the dietary treatment was evaluated.
The controls comprised 13 subjects with overt coeliac
disease with small bowel mucosal villous atrophy and crypt
hyperplasia and 42 patients with suspicion of coeliac disease but
no evidence of villous atrophy in 2 successive biopsy samples
on a gluten-containing diet with a median interval of 6.0 years
(range 0.8–10.0 years) (Table 1). The study protocol was
approved by the Ethical Committee of Tampere University
Hospital. All of the subjects gave written informed consent.
Small Bowel Mucosal Morphology and
Intraepithelial Lymphocytes
Small bowel mucosal biopsies were taken upon upper
gastrointestinal endoscopy and in small children with a Watson
capsule. For morphometrical analysis, the samples were paraf-
fin embedded, processed, and stained with hematoxylin-eosin.
The villous height–crypt depth ratio was counted in well-
oriented biopsy samples as previously described (26) and a
ratio <2.0 was considered compatible with coeliac disease.
One piece of capsule biopsy or 2 forceps biopsy specimens
were freshly embedded in optimal cutting temperature com-
pound (OTC, Tissue-Tec, Miles, Elkhart, IN), frozen in liquid
nitrogen, and stored at 708C. Immunohistochemical studies
were carried out on 5-mm-thick frozen sections. CD3þ IELs
dermatitis, arthralgia.
grens syndrome, osteoporosis.thorized reproduction of this article is prohibited.
were stained with monoclonal antibody Leu-4 (Becton Dick-
inson, San Jose, CA) and gdþ IELs with T-cell receptor bearing
cell g antibody (T Cell Diagnostics, Woburn, MA). Positive
J Pediatr Gastroenterol Nutr, Vol. 47, No. 4, October 2008
CINENIELs were counted from immunohistochemically stained speci-
mens with a 100 light microscope objective as described
elsewhere (27). The reference value for CD3þ IELs was set
at 37 cells per millimeter of epithelium and for gdþ cells at 4.3
cells per millimeter of epithelium (27).
Small bowel Mucosa TG2-specific IgA Deposits
Small bowel mucosal TG2-specific IgA deposits were inves-
tigated in unfixed, 5-mm-thick, frozen sections of small bowel
specimens by direct immunofluorescence using fluorescein
isothiocyanate–labelled rabbit antibody against human IgA
(Dako, Glostrup, Denmark) at a dilution of 1:40 in phos-
phate-buffered saline, pH 7.4. In coeliac disease a clear sub-
epithelial IgA deposition can be found below the basement
membrane along the villous and crypt epithelium and around
mucosal vessels; this is in contrast to normal small bowel
samples, in which IgA is detected only inside the plasma
and epithelial cells (21). The IgA deposits were graded semi-
quantitatively from 0 to 3 according to their intensity along the
basement membrane in the villous crypt area, as previously
described (5). It has been shown that these mucosal IgA deposits
are specifically targeted against TG2 (21,22). For double label-
ling, sections were stained for human IgA (green, as above, this
paragraph), and for TG2 (red) using monoclonal mouse anti-
bodies against TG2 (CUB7402, NeoMarkers, Fremont, CA),
followed by rhodamine-conjugated anti-mouse immunoglobu-
lin antibodies (Dako), both diluted 1:200 in phosphate-buffered
saline. In our laboratory, intraobserver and interobserver agree-
ment in the detection of present or absent TG2-specific IgA
deposits has been 98% among 5 investigators. All of the
evaluations were carried out blindly without knowledge of
disease history or laboratory findings.
Serology
Serum IgA-class reticulin (ARA) or endomysial antibodies
were determined by an indirect immunofluorescence method as
described earlier (14). A positive staining pattern seen in a
serum dilution of 1:5 or more was considered positive in both
tests. During the study period, endomysial antibodies replaced
ARA in clinical practice. If the endomysial antibodies result
438 KOSKopyright © Lippincott Williams & Wilkins. Unaut
was not available, then the ARA result was used instead. These
2 coeliac autoantibody tests have proved in our laboratory to be
almost identical (28), and both have been shown to be directed
TABLE 2. Abnormal findings and HLA DQ2 or DQ8 haploty
Laten
dis
Small bowel mucosal TG2-specific IgA deposits present, n (%) 25/2
Small bowel mucosal CD3þ IELs, density increased, n (%) 13/2
Small bowel mucosal gdþ IELs density increased, n (%) 15/2
Serum IgA class coeliac autoantibodies (ARA or EmA)
present, n (%)
19/2
HLA DQ2 or DQ8 haplotype present, n (%) 12/1
TG2¼ transglutaminase-2; IgA¼ immunoglobulin A; IEL¼ intraepithelial
By definition in this study.
yAll 4 antibody-positive (all ARAþ, see methods) noncoeliac controls we
deposits.
J Pediatr Gastroenterol Nutr, Vol. 47, No. 4, October 2008against TG2 (13). In this study, these antibodies are indicated as
serum coeliac autoantibodies. In retrospect, it was impossible
here to determine serum TG2-antibodies by enzyme-linked
immunosorbent assay in all of the patients and controls.
HLA Typing
HLA typing was based on polymerase chain reaction with
allele-specific primers identifying HLA DQ2 and DQ8, and
performed with a Dynal DQ low-resolution SSp kit (Dynal,
Oslo, Norway). In coeliac disease, 90% to 95% of patients
carry the HLA DQ2-haplotype and most of the rest carry HLA
DQ8 (29).
Statistics
Quantitative data are expressed as medians and ranges and
qualitative data as percent of abnormal values. Statistical
differences were evaluated using the Mann-Whitney U, Wil-
coxon, and McNemar tests, as appropriate. All of the testing
was 2-sided, and P< 0.05 were considered statistically signifi-
cant. All of the calculations were performed with the Statistical
Package for Social Sciences version 14.0 (SPSS, Chicago, IL).
RESULTS
Small bowel mucosal TG2-specific IgA deposits
already were seen in the first biopsy in all but 1 of the
patients with latent coeliac disease, when mucosal villous
architecture was still intact (Table 2, Fig. 1). When the
patients continued on a normal gluten-containing diet,
small bowel mucosal villous atrophy and crypt hyper-
plasia developed; in parallel, the intensity of mucosal IgA
deposits increased, and the deposits were present in all of
the patients at the time of the diagnosis of coeliac disease
(Figs. 1 and 2). The intensity of mucosal IgA deposits
again decreased significantly when the patients were
placed on a gluten-free diet, albeit minor depositions
still were seen in many. A total of 7 patients in the latent
coeliac disease group were initially serum autoantibody
ET AL.horized reproduction of this article is prohibited.
negative; 6 of them still had positive small bowel mucosa
IgA deposits, 2 had family history for coeliac disease, and
all 6 cases tested had coeliac-type HLA. Sixteen of the
pes in different patient groups at the time of first biopsy
t coeliac
ease
Potential
coeliac disease
Overt coeliac
disease
Noncoeliac
controls
6 (96) 20/20 (100)

13/13 (100) 1/22y (5)
1 (62) 15/20 (75) 9/13 (69) 18/42 (43)
1 (71) 18/20 (90) 11/13 (85) 20/42 (48)
6 (73) 14/19 (74) 11/13 (85) 4/41y (10)
2 (100) 16/16 (100) 12/12 (100) 18/42 (43)
lymphocyte; ARA¼ reticulin antibody; EmA¼ endomysial antibody.
re HLA DQ2 and DQ8 negative; 1 of them had positive mucosal IgA
-2 (TG
in pa
n-con
MUCOSAL IGA DEPOSITS IN COELIAC DISEASE 43920 patients having TG2-specific small bowel mucosal
IgA deposits in intact villi (potential coeliac disease)
agreed to a follow-up biopsy after 1 year on a gluten-free
diet. The intensity of the deposits decreased in 15 (94%)
of the 16 on a gluten-free diet (Figs. 1 and 2). Parallel to
FIG. 1. Changes in small bowel mucosal tissue transglutaminase
depth ratios, and densities of CD3þ intraepithelial lymphocytes
noncoeliac controls at different time points. Gluten¼normal gluteCopyright © Lippincott Williams & Wilkins. Unau
these changes, abdominal symptoms and signs of malab-
sorption resolved in 13 (65%) and improved in 5 (25%) of
the patients whilst on the gluten-free diet (Table 3). TG2-specific small bowel mucosal IgA deposits were present
in all of the patients with untreated overt coeliac disease,
and the intensity of the deposits decreased with the diet.
In noncoeliac controls the deposits were seen initially in
1 of 22 (5%) and in 3 of 38 (8%) patients on a gluten-
2)–specific immunoglobulin (Ig)A deposits, villous height–crypt
tients having latent, potential, and overt coeliac disease and in
taining diet; GFD¼gluten-free diet.thorized reproduction of this article is prohibited.
containing diet in the follow-up biopsies (Fig. 1); these
deposit-positive cases did not present with any particular
clinical sign and had no family history of coeliac disease.
J Pediatr Gastroenterol Nutr, Vol. 47, No. 4, October 2008
CFIG. 2. A–F, Small bowel mucosal immunoglobulin (Ig)A deposits in a 48-year-old woman having latent coeliac disease. The first small
bowel mucosal biopsy (B) showed normal villous morphology, but (D) 2 years later when she continued on a normal gluten-containing diet
villous atrophy with crypt hyperplasia developed. Villous morphology (F) recovered on a gluten-free diet. Serum celiac autoantibodies were
negative throughout, but (A) strong subepithelial tissue transglutaminase (TG2)-targeted IgA autoantibody deposits (yellow, arrow) already
were present in the small bowel mucosa in the first biopsy, and (C) also when villous atrophy was detected. The deposits disappeared (E) with
a gluten-free diet. G-L, Mucosal IgA deposits are shown from a 21-year-old woman with potential coeliac disease having (G) normal small
specifi
n (H,
440 KOSKINEN ET AL.The histological, serological, and HLA DQ findings are
set out in Table 2 and Figure 1. At the first biopsy in the
noncoeliac control group, densities of CD3þ IELs were
increased in 41% and gdþ IELs in 48%, and during
the study the cell densities decreased significantly with
time without any dietary intervention (Table 3, Fig. 1). At
the outset, 4 (10%) of the noncoeliac controls were
coeliac autoantibody positive, but all of them serocon-
verted negatively during the study (Table 2).
DISCUSSION
bowel mucosal architecture and strong subepithelial tissue TG2-
recovered and IgA deposits disappeared (L). IgA is stained with gree
yellow (A,C,G).opyright © Lippincott Williams & Wilkins. Unaut
The present study confirms earlier data indicating that
the borders of coeliac disease clearly extend beyond
J Pediatr Gastroenterol Nutr, Vol. 47, No. 4, October 2008small bowel mucosal villous atrophy (30). The current
diagnostic criteria have been applied for many years and
small intestinal mucosal atrophy has been sine qua non
for the diagnosis (1). To revise the criteria of coeliac
disease beyond villous atrophy requires the demon-
stration of gluten dependency of the symptoms and
histology in genetically susceptible individuals. We have
shown in this article that by careful examination we are
able to find coeliac disease in patients with normal
villous structure. Once the criteria have been revised,
the inevitable consequence is that these patients should
c IgA deposits. After 1 year on a gluten-free diet her symptoms
J), TG2 with red (I,K), and colocalization of IgA and TG2 is shown inhorized reproduction of this article is prohibited.
be treated with a gluten-free diet. In this study, mucosal
TG2-specific IgA deposits were accurate markers for
gluten sensitivity; they were detected early on in the
TABLE 3. Findings and subjective symptoms in 20 patients having potential coeliac disease before and after GFD
Sex,
age (y)
HLA DQ2
or DQ8
Family history of
coeliac disease
Positive serum autoantibodies Symptoms and signs
Before GFD After GFD Before GFD After GFD
F46 þ/  þ þy Abdominal pain Resolved
M54 þ/þ  þ  Abdominal pain Resolved
F47 þ/þ  þ  Loose stools, anaemia Resolved
F43 þ/ þ þ  Abdominal pain Resolved
F48 þ/  þ  Diarrhoea, flatulence, anaemia Resolved
F72 þ/    Diarrhoea Resolved
F28 þ/ þ   Abdominal pain, flatulence Resolved
F37 þ/  þ  Loose stools, flatulence Resolved
F59 ND  þ  Abdominal pain Resolved
F59 þ/  þ  Loose stools, flatulence Resolved
F58 þ/  þ  Abdominal pain, flatulence, Resolved
F33 þ/    Diarrhoea Resolved
M52 þ/ þ þ  Weight loss, anaemia Resolved
F44 þ/  þ  Abdominal pain Improved
F21 þ/  þ  Dyspepsia Improved
F59 þ/    Diarrhoea, arthralgia Improved
F41 ND  ND ND Abdominal pain Improved
F39 ND  þ ND Diarrhoea Improved
M36 þ/ þ   Arthritis No change
M51 þ/  þ  Refractory epilepsy No change
no da
e rest
MUCOSAL IGA DEPOSITS IN COELIAC DISEASE 441disease process, their intensity increased as enteropathy
progressed on a gluten-containing diet, and their intensity
decreased along with mucosal recovery on a gluten-free
diet. These intestinal coeliac autoantibody deposits
proved to be better initial markers for gluten sensitivity
than small bowel mucosal IEL densities, and they also
were able to detect serum coeliac autoantibody-negative
cases having mild enteropathy coeliac disease (Table 2).
This was demonstrated in patients with latent coeliac
disease for whom the development of villous atrophy had
been confirmed by follow-up on a gluten-containing diet.
Furthermore, in patients with TG2-specific IgA deposits
but no evidence of progression to overt coeliac disease,
the deposits were shown to be gluten dependent (Fig. 1).
The process was akin to that of overt coeliac disease and
latent coeliac disease. In this study, the majority of
patients with latent coeliac disease had experienced
gluten-dependent symptoms before subsequent diagnos-
tic enteropathy had developed (Table 1).
Furthermore, 18 (90%) of the 20 patients found to have
small bowel mucosal TG2-specific IgA deposits, but
considered in view of normal small bowel histology
not to have celiac disease, benefited from gluten-free
dietary treatment (Table 3). Similar cases have been
reported in the literature (6,31,32); some subjects have
even been diagnosed as having osteopenia or osteoporo-
sis (4,7,33). Of note, in this study group the nonrespon-
þ, positive finding; , negative finding; GFD, gluten-free diet; ND,
At the baseline Marsh 0-type small bowel mucosal lesion; all of th
yAutoantibody titre decreased.Copyright © Lippincott Williams & Wilkins. Unau
sive symptoms were refractory epilepsy and arthritis,
indicating that these extraintestinal manifestations were
not gluten dependent. Assuming that the diagnosticcriteria for the disease should indeed be widened to
cover mild enteropathy coeliac disease, some issues
should be stressed to avoid overdiagnosis of the disorder.
Marsh 1-type small bowel mucosal lymphocytosis is an
unspecific finding (8–10), as also seen in the present
study; the densities of CD3þ and gdþ IELs also
decreased with time in noncoeliac controls without any
dietary intervention (Fig. 1). Some noncoeliac patients
evinced negative seroconversion during the follow-up;
these cases were ARA positive without HLA DQ2 or DQ8.
Furthermore, 8% of these controls had minor small
bowel mucosal IgA deposits without any signs of gluten
sensitivity in the follow-up biopsy. Long-term follow-up
is needed to show whether these subjects will eventually
develop overt coeliac disease (7,34,35). To conclude, no
single test alone can reliably detect early-stage coeliac
disease without villous atrophy, but gluten-dependent
TG2-specific IgA deposits offer a good diagnostic tool.
Based on the findings in this study, we suggest that
the deposits should be investigated when coeliac disease
is suspected but the small bowel mucosal villous
morphology is equivocal. In symptomatic patients
(as was the case in the present series) having signs of
minor enteropathy coeliac disease without villous atro-
phy, gluten-free dietary treatment should be considered.
In asymptomatic cases, the benefits of early treatment are
more ambiguous and subject to further studies. In the
ta.
had Marsh 1 lesion.thorized reproduction of this article is prohibited.
meantime, follow-up with a normal gluten-containing
diet is recommended. In coeliac disease, however,
gluten-induced symptoms may occur outside the
J Pediatr Gastroenterol Nutr, Vol. 47, No. 4, October 2008
CINENintestine (30), and during the follow-up the wide clinical
spectrum of the disease should be kept in mind.
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